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Developing oral insulin formulations for the treatment of diabetes can 
greatly improve the quality of life of the patients. Many different approaches have 
been investigated to address the problems associated with oral insulin delivery, 
but the bioavailability of oral insulin is still low, even in some of the most 
successful formulations. Insulin is rapidly degraded by the enzymes in the GI 
tract and is not transported across the epithelial barrier easily. The oral insulin 
formulation developed in this work makes use of complexation hydrogels for oral 
delivery of insulin bioconjugates. The insulin bioconjugates synthesized in this 
work consist of insulin bound to transferrin molecule which can be uptaken by the 
epithelial cells. These conjugates can increase the permeability of insulin across 
the epithelial barrier by receptor-mediated transcytosis. The transferrin in the 
conjugate is also shown to stabilize insulin in the presence of intestinal enzymes. 
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Use of complexation hydrogels for delivery of insulin-transferrin conjugate may 
greatly increase the bioavailability of oral insulin. This is because, the 
complexation hydrogels are known to exhibit characteristics that make them ideal 
candidates for oral protein delivery. For example, it is shown in this work that the 
hydrogels can increase the retention of the therapeutic protein in the small 
intestine. They can also inhibit the degradation of insulin in the GI tract. Thus, 
combination of these two approaches provides an innovative platform for oral 
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Increasing number of therapeutic agents emerging from the rapid growth 
of biotechnological research component of pharmaceutical drug discovery are 
macromolecules such as proteins. However, difficulties encountered in 
administration of these proteins limit their clinical applicability. Currently the most 
common way of administering therapeutic proteins is through injections. This 
route of administration is typically painful, and suffers from low patient 
compliance for the treatment. Thus, new and improved methods of administration 
are being constantly developed.  
Insulin therapy is at the heart of protein delivery research. Insulin is a 
protein of immense importance because of its role in the treatment of diabetes, 
which is growing into epidemic proportions in many developing countries. The 
options currently available for administration of insulin are mostly limited to 
insulin injections through needles. Hence other routes of administration such as 
pulmonary, dermal, buccal, and oral are currently being investigated. Oral route 
remains the preferred mode of administration because of the ease and cost 
effectiveness of oral dosage formulations. Oral administration is also linked to 
increase in patient compliance and overall increase in the efficacy of treatment.  
 However, the enzymatic instability of insulin in the GI tract and its inability 
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to traverse the intestinal barrier severely reduce the fraction of orally 
administered insulin that reaches the blood stream (bioavailability).  
In this work we have developed an oral insulin formulation based on 
complexation hydrogels used as delivery vehicles for insulin-bioconjugates. The 
complexation hydrogels developed in our laboratory are shown to be promising 
candidates for oral insulin administration. These hydrogels come under the class 
of environment-sensitive hydrogels, and specifically, they show pH-dependent 
swelling behavior. The hydrogel is synthesized by UV-initiated free radical 
polymerization of methacrylic acid (MAA) and methoxy-terminated poly(ethylene 
glycol) monomethacrylate PEGMA and consists of crosslinked PMAA grafted 
with PEG chains, henceforth designated as P(MAA-g-EG). The success of this 
delivery system for insulin is due to the ability of the carriers to protect the protein 
from degradation in the harsh conditions encountered in the GI tract. These 
hydrogels also exhibit potential to stick to the intestinal mucus and increase the 
residence time of the drug in the GI tract.   
The objectives of this work are given in Chapter 3. Experimental 
investigation of gastrointestinal distribution and retention of the microparticles 
was performed here. The ability of microparticles to protect insulin degradation in 
the GI tract was also studied. These studies are presented in Chapter 6 and 
Chapter 7. The ability of the microparticles to change the permeability of model 
intestinal epithelium was also investigated in this work. This study is given in 
Chapter 4. One important factor that limits the bioavailability of orally 
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administered insulin is its inability to efficiently traverse the intestinal epithelium. 
Thus, understanding of mechanisms of insulin transport across the cellular 
barrier is important for development of effective delivery systems. In vitro 
evaluation of transport mechanism was carried out using confocal microscopy 
and the results are presented in Chapter 5. Chapters 8 through Chapter 10 deal 
with the development of oral formulation based on complexation hydrogels used 
as oral delivery vehicle for insulin-transferrin conjugates. The synthesis and 
characterization of insulin-transferrin conjugate is discussed in Chapter 8. 
Optimization of the polymer carriers for delivery of the conjugates is presented in 
Chapter 9. These conjugates are shown to improve the permeability of insulin 
across in vitro model of intestinal epithelium. These cellular studies are 
discussed in Chapter 10. In Chapter 1 an overview of diabetes treatment and 




















Major innovations in the drug delivery field have surfaced in recent years. 
Oral administration of therapeutic agents is the preferred means of delivering 
drugs because of ease of administration, low cost and high patient compliance. 
However, formulating a drug for oral delivery is a complicated process. Poor 
intrinsic protein permeability as a result of large molecular weight, degradation by 
proteolytic enzymes in the stomach and in the small intestine, and chemical 
instability are some of the major hurdles for developing effective formulations for 
delivery of peptides and proteins. Although there are several success stories in 
the development and commercialization of oral dosage forms for small 
molecules, very few oral delivery systems have been developed for proteins and 
peptides. The oral formulation of cyclosporin [1] is one of the very few examples 
of successful development of oral formulations for peptide drugs.   
 In this chapter we will discuss novel methods for administration of insulin 
for the treatment of diabetes. Since its initial administration to humans in 1922, 
insulin has been the cornerstone of type 1 diabetes. Conventionally, insulin is 
administered by subcutaneous injections which mimic, as close as possible, 
secretion of insulin by healthy pancreas.  However, due to compliance-related 
issues and other complications, more acceptable delivery systems are highly 
desirable. An overview of diabetes mellitus and novel ways of treating this 
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disease are included here. Special attention is given to oral insulin delivery which 
is the focus of this work.    
 
2.1 Diabetes Mellitus 
 
Diabetes is characterized by the body’s inability to produce or properly use 
insulin. Diabetes mellitus is a metabolic disorder of multiple aetiology 
characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat 
and protein metabolism resulting from defects in insulin secretion, insulin action, 
or both [2]. There are 18.2 million people in the United States, or 6.3% of the 
population, who have diabetes [3]. Diabetes mellitus is occurring in epidemic 
proportions in many developing and newly industrialized countries [4]. Globally, it 
is now one of the most common non-communicable diseases and is the fourth or 
fifth leading cause of death in most developed countries [5]. The global burden of 
diabetes is estimated to rise from about 118 million in 1995 to 220 million in 2010 
and 300 million in 2025 [6, 7].  
 The aetiological types of diabetes are designated as type 1, type 2 
diabetes and other specific types of diabetes resulting from genetic defects of β-
cell function, genetic defects in insulin action, endocrinopathies (resulting from 
over secretion of insulin antagonizing hormones), infections and drug- or 
chemically induced diabetes [2]. Further, in nearly 3 to 5 % of all pregnancies, 
women develop gestational diabetes [8]. 
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 Type 1 diabetes can be classified as autoimmune diabetes mellitus or 
idiopathic Type 1 diabetes. Autoimmune diabetes mellitus is characterized by the 
autoimmune mediated destruction of the insulin secreting pancreatic β-cells [2]. 
Individuals suffering from this form of Type 1 diabetes typically become 
dependent on insulin for survival and are at a risk of ketoacidosis, a condition 
resulting from extremely high levels of blood glucose (over 249 mg/dl) wherein 
the body begins to burn fat and muscle for energy which causes release of 
ketone bodies in the bloodstream. Idiopathic Type 1 diabetes is a diabetes of 
unknown origin. Some of the patients suffering from this disease have permanent 
insulin deficiency and are prone to ketoacidosis, but this form of diabetes shows 
no evidence of autoimmunity [2, 3].   
 Type 2 is the most common form of diabetes and is characterized by 
disorders of insulin action and insulin secretion, either of which may be the 
predominant feature [2]. Individuals suffering from this form of diabetes are 
typically resistant to the action of insulin [2, 9]. According to the American 
Diabetes Association (ADA), nearly 16 million individuals in the United States 
have type 2 diabetes while about one-third of those people are not aware that 
they have the disease [3]. This is primarily because the hyperglycemia is often 
not severe enough to be symptomatic. Ketoacidosis is relatively infrequent in this 
type of diabetes. Nevertheless individuals suffering from this form of diabetes are 
at increased risk of developing macrovascular and microvascular complications. 
If untreated, type 2 diabetes can cause serious complications, including kidney 
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failure, blindness, heart attack, lower-limb amputation [10]. Fortunately, in many 
cases, type 2 diabetes can be adequately controlled through a combination of 
proper nutrition and exercise. However, some people with type 2 diabetes do 
require oral medications or insulin injections.  
To determine if a patient is normal, pre-diabetic or diabetic, health care 
providers conduct a fasting plasma glucose test (FPG) or an oral glucose 
tolerance test (OGTT) [11]. Either test can be used to diagnose pre-diabetes or 
diabetes. Pre-diabetes, characterized by a glucose level between that of a 
healthy individual and a diabetic patient, is also called impaired glucose tolerance 
(IGT) or impaired fasting glucose (IFG) [12].  
The FPG test is easier, faster, and less expensive to perform. With the 
FPG test, a fasting blood glucose level between 100 and 125 mg/dl indicates pre-
diabetes. A person with a fasting blood glucose level of 126 mg/dl or higher is 
considered diabetic [2, 11]. 
In the OGTT test, a person's blood glucose level is measured after a fast 
and two hours after drinking a glucose-rich beverage (2h-PG value). Two-hour 
blood glucose level of 140-199 mg/dl signals pre-diabetes, whereas the two-hour 
blood glucose level of >200 mg/dl, signals diabetes [2, 11]. Although the OGTT 
(which consists of an FPG and 2-h PG value) is recognized as a valid way to 
diagnose diabetes, the use of the test for diagnostic purposes in clinical practice 
is limited because of its inconvenience, less reproducibility, greater cost  [11, 13]. 
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The most common form of type 1 diabetes treatment is insulin therapy 
which is described in the next section. Some of the important areas of 
therapeutic treatment of diabetes that are currently being explored are discussed 
here.   
Curative therapy for diabetes mellitus mainly implies replacement of 
functional insulin-producing pancreatic beta cells, with pancreas or islet-cell 
transplants. This is the only replacement therapy that can improve metabolic 
control other than conventional and intensive insulin therapy [14]. Transplantation 
can be performed either by implantation of the pancreatic organ or by 
implantation of only the pancreatic islets of Langerhans. Until recently, pancreas 
transplantation was considered to be the only viable procedure for autonomous 
regulation of glucose level [14, 15]. However, to avoid pancreatic graft rejection, 
transplantation has to be coupled with lifelong immunosuppression which itself 
can cause severe side effect as increased susceptibility to viral, fungal, and 
bacterial infections, and increased risk for the development of malignancies [14, 
16, 17].  
Islet transplants are beneficial compared to implantation of pancreatic 
organ since they avoid the need for major surgical procedures. A small mass of 
islet cells can be delivered to the liver through intraportal infusion. The procedure 
for islet cell transplantation was initially successful in small animal models, but 
was not effective in humans [18, 19]. However, Shapiro et al. [20] recently 
developed a new immunosuppressive regimen and reported a 100% success 
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rate in achieving insulin independence through islet transplantation in 7 long term 
diabetic patients. Unfortunately, like pancreatic graft transplants, islet 
transplantation also suffers from the necessity of lifelong immunosuppression. 
Another limitation of islet cell transplantation procedures is the need for adequate 
supply of donor islet cells. One solution to this problem that is currently an area 
of active research is differentiation of embryonic stem cells into the insulin 
secreting islet cells by manipulating the culture conditions [18, 21]. However, the 
precise factors and conditions that convert progenitor stem cells into the desired 
mature β-cells are not yet fully understood [22]. 
Researchers have sought to circumvent the need for immunosuppressant 
regimen in islet transplantation by encapsulation of the islet cells by 
semipermeable membrane that protects the grafts from the host immune system 
[23, 24]. In addition to being immunoprotective, these membranes also have to 
be mechanically stable, biocompatible and sufficiently permeable to insulin and 
should also allow oxygenation of the encapsulated cells.   
 
2.2 Insulin and Insulin Therapy 
 
In 1889, von Mehring and Minkowski showed that ligation of the pancreas 
in dog caused diabetes [25]. This lead to an intensive search for the active 
component that the pancreas was producing that was involved in preventing the 
development of diabetes. In 1922 Banting and Best successfully extracted 
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insulin. For more than a decade following its discovery, insulin was used in the 
form of crude extracts of the pancreas of cow, pig or sheep for diabetes 
treatment [26]. Insulin was first purified by crystallization in the presence of zinc 
in 1936 [27].  
Sanger in 1955 elucidated the primary structure of insulin [28]. Although 
the amino acid sequence of insulin varies among different species, certain 
sequences are highly conserved [29]. The sequences porcine insulin and human 
insulin are almost identical, differing by only one amino acid whereas bovine 
insulin differs by three amino acids from the human analog. However, none of the 
variations in the amino acid sequence are at sites crucial for the activity and 
function of insulin [29].  
When insulin is synthesized by the beta cells of the pancreas, it is 
produced as a large preproharmone. This preproharmone has a molecular 
weight of about 11,500. It is cleaved within the cisternae of the endoplasmic 
reticulum of the β-cells to form proinsulin which has a molecular weight of about 
9,000. This molecule then splits into two pieces: insulin, with a molecular weight 
of 5,808 in humans, and C-peptide, before being secreted outside the cells 
through the secretory granules. The secreted insulin has 31 amino acid long B 
chain and the 20 amino acid long A chain which are locked in their relative 
conformation by two disulfide bonds. The cleaved and secreted insulin is 51 
amino acids long and has a hydrodynamic radius of about 20 Å [30].  
  11
 The plasma glucose level is maintained within a very narrow range of 3.5-
7.0 mmol/L  in spite of wide fluctuations introduced by food intake, exercise, 
other physiological and physiological disturbances [31]. This glucose 
homeostasis is achieved by regulating release and inhibition of glucagons and 
insulin, both secreted by the pancreatic cells.  
Increase in blood glucose triggers secretion of insulin from the pancreas. 
Insulin secreted from the pancreas is infused via the portal vein to the liver, 
where it leads to an increase in the storage of glucose with a concomitant 
decrease in hepatic glucose release to the circulation [32]. Insulin circulates in 
the blood with plasma half life of about 6 minutes, so that it is almost entirely 
cleared from the circulation within 10-15 minutes. The freely circulating insulin 
then acts on several peripheral tissues including muscle, liver and fat tissue by 
binding to the specific insulin receptors on cells.  
An Insulin receptor is a hetero-tetramer with a molecular weight of about 
300,000. The two alpha subunits lie entirely outside of the cell membrane and the 
two beta subunits penetrate through the cell membrane. Insulin binding to the 
alpha subunits on the outside of the cell triggers autophosphorylation of the beta 
subunits on several tyrosine residues protruding into the cytoplasm.  
The activated beta subunits then phosphorylate and activate IRS-1. IRS-1 
is an enzyme and a key mediator of insulin’s biological activity. Following this, 
various intracellular regulators are recruited to IRS-1 and this initiates a 
regulatory cascade of signals with each molecule binding to IRS-1 activating its 
  12
own complex cascade [33]. This finally leads to increase in the permeability of 
cell membranes to glucose and glucose uptake increases. This increased uptake 
of glucose due to insulin binding occurs in the muscle cells, adipose cells, and 
other types of cells in the body constituting about 80 percent of all the cells.  
 In addition to its role in uptake of glucose, insulin also stimulates 
conversion of carbohydrate or proteins to fat (lipogenesis), and increases amino 
acid transport into cells. It also stimulates growth, DNA synthesis, and cell 
replication. 
In the absence of curative therapy for the treatment of diabetes, insulin 
replacement therapy is required for all people with type 1 diabetes [34]. Benefits 
of insulin therapy in patients with type 2 diabetes are also well recognized now 
[35-37]. Intensive glucose control delays the onset and retards the progression of 
microvascular and macrovascular diseases in patients with type 2 diabetes [38]. 
Insulin therapy is, therefore, central to management of patients with diabetes. 
With the development and approval of recombinant technologies for insulin 
production, human insulin could be made biosynthetically which became the 
preferred method of insulin production.  This also led to the development of 
mutant insulin analogues having improved pharmacokinetic properties for 
subcutaneous administration [39-41]. However, for over 80 years injection or 
infusion of insulin into the subcutaneous (s.c.) tissue has been the only route of 
insulin delivery used in clinical practice. This mimics, as close as possible, 
secretion of insulin by healthy pancreas.  
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Recent developments of improved injection devices, such as insulin pens, 
and very sharp needles, have reduced the pain associated with the injection 
therapy to a considerable extent. But even with these developments, injection 
therapy still requires the handling of a device and is associated with pain. This 
often results in low patience compliance to the therapy. Clinical studies have 
shown that because of the non-compliance related issues, even on insulin 
treatment, a significant percentage of patients fail to attain lasting glycemic 
control [32].Further, this route of insulin administration has associated side 
effects, such as hyperinsulinemia and localized deposition of insulin that lead to 
local hypertrophy and fat deposits at injection sites [42].  
Thus there is great interest today in developing formulations that deliver 
insulin through other routes of administration. These alternative routes of insulin 
administration are discussed in the following section.  
 
2.3 Alternative Routes of Insulin Administration 
 
 The current recommended intensive insulin therapy regimens involve 
multiple subcutaneous insulin injections everyday. These increases compliance 
constrains on patients to a great extent and reduce the overall efficacy of 
treatment. Hence, as discussed above, non-invasive insulin formulations that 
mimic physiological secretion of insulin as a means of maintaining the glucose 
homeostasis are highly desirable. Recent advances in alternative routes of 
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administration as an approach to improve insulin therapy are discussed here. 
Investigated delivery systems for insulin therapy mainly include transdermal, 
nasal, buccal, pulmonary and oral delivery systems.  
 
2.3.1 Transdermal delivery 
Large, hydrophilic macromolecules such as insulin cannot efficiently 
permeate the skin. This skin impermeability is mainly due to the intercellular lipid 
layer of the stratum corneum [43]. Thus, the delivery approaches targeted at 
improving the transdermal delivery of drugs involve breaking down or removing 
the lipid barrier by chemical, electrical or physical methods [44]. Iontophoresis, 
low-frequency ultrasound, or chemical agents acting as vesicles are some of the 
methodologies investigated. In Iontophoresis, low-level electric current is used to 
enhance the permeability of the drug across the stratum corneum and the 
permeability of insulin depends on the net charge of the insulin molecule [45, 46]. 
However the potential of this methodology has only been demonstrated in animal 
studies and the amount of insulin transferred across the skin was barely enough 
to meet basal insulin requirement [44].  
Low-frequency ultrasound (20-150 kHz) has been shown to be more 
effective by causing several-fold increase in macromolecular permeability [47]. 
However, even with this technique, insulin delivery rates may not be sufficient for 
physiological replacement of insulin [48]. Combined use of iontophoresis and 
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ultrasound has been proposed as an approach for increasing macromolecular 
transfer across the skin barrier [49].  
Another approach involves incorporating insulin into vesicles made of 
soybean phosphatidylcholine, called transfersomes. Transfersomes are highly 
deformable and as a result are able to pass through pores smaller than their size 
with permeability similar to water [50].  It was observed that transformers 
transport insulin with 50% bioefficiency compared to subcutaneous injection. 
However, more recent studies have been unable to reproduce these findings 
[44]. Despite a number of techniques that have been investigated, so far, dermal 
insulin methodologies have not resulted in reproducible and acceptable transfer 
of insulin across the highly efficient skin barrier [44].   
 
2.3.2 Intranasal Delivery  
The nasal mucosa is characterized by large surface area for drug 
absorption (about 150 cm2), high coverage density of the epithelium by microvilli, 
and a rich, vascularized subepithelium [51]. The drugs entering through this route 
directly enter the systemic circulation, thus avoiding hepatic first-pass 
metabolism. Nasal absorption also provides for rapid attainment of therapeutic 
blood levels, and quicker onset of pharmacological activity [52]. The main 
barriers to absorption include the very active mucociliary clearance, enzyme 
activity, low permeability and low pH of the nasal epithelium. In addition, little 
information is available on the influence of nasal pathology on the efficacy of 
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insulin administration [51, 53]. Small molecular weight molecules such as 
oxytocin (MW 1,007) and calcitonin (MW3,431) have been successfully delivered 
via the nasal route [54], but reproducible and reliable intranasal delivery 
methodology for insulin has not been developed.  
 The observed low bioavailability of insulin administered via the intranasal 
route often necessitates use of absorption enhancers. However many of these 
enhancers have been known to cause damage to the nasal mucosa. Use of 
lecithin, bile salts or laureth-9 as absorption enhancers for nasal absorption 
enhancement caused nasal irritation in patients [48, 55, 56]. Even with the use of 
absorption enhancers, reproducible and reliable insulin delivery has not been 
achieved.  
Intranasal insulin administration with a medium-chain phospholipid 
(didecanoyl-L-alpha-phosphatidylcholine) as an absorption enhancer was 
observed to cause rapid increase in the serum insulin concentration in healthy 
individuals, reaching glucose reducing peak in 20-45 min [57, 58]. 
Pharmacological bioavailability, corrected for the endogenously produced insulin 
for the nasal formulation, was 8.3% relative to an intravenous bolus injection [58]. 
Administered insulin also exhibited a faster time-course of absorption when 
compared to subcutaneous injection. This makes intranasal administration a 
particularly attractive option for prandial insulin replacement.  
However, subsequent studies failed to confirm these initial positive results 
[59]. Potential damage to the nasal mucosa and nasal irritation, especially in the 
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long-term treatment regimen and high rates of treatment failure are the main 
obstacles in clinical application of intranasal insulin delivery [44, 48].  
 
2.3.3 Buccal Delivery 
Buccal mucosa offers an interesting portal of administration for both 
systemic and local delivery of therapeutic agents. The oral mucosa consists of a 
non-keratinized area (sublingual, and buccal mucosa) and the keratinized area 
(the gum or gingiva, the palatal mucosa, and the inner side of the lips). The non-
keratinized regions are generally more permeable as compared to the keratinized 
areas [60]. The oral cavity has a large surface area for absorption (100– 200 
cm2), is richly vascularized and has little proteolytic activity. It has fewer 
proteolytic enzymes than the oral, nasal, vaginal and rectal administration areas 
[61]. The predominant peptidases found in the buccal mucosa are 
aminopeptidases. The proteolytic enzymes such as trypsin, chymotrypsin and 
pepsin, which are present in the gastric and intestinal fluids, are largely absent 
[60, 62]. The factors limiting insulin absorption via the buccal route are the 
relatively thick multi-layered buccal barrier, the high rate of mucus turnover and 
the proteolytic degradation. Strategies investigated to improve absorption of 
insulin include use of absorption enhancers, bioadhesive systems and enzyme 
inhibitors [60, 63, 64].   
Recently, Generex (Toronto, Canada) demonstrated efficacy of a buccal 
insulin delivery system based on an oral insulin spray which administers insulin in 
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the form of a high-velocity, fine particle aerosol directly into the patient’s mouth. 
The particles consist of mixed micelles made from absorption enhancers that 
encapsulate insulin [65]. The fast moving, fine particles are able to penetrate a 
thin membrane that guards the surface area in direct contact with the blob 
circulation. Combined with the effect of absorption enhancers, the penetrating 
particles cause a rapid increase in the uptake of insulin into the systemic 
circulation [66]. The administered insulin appears in the circulation within 10 
minutes of application. Bioavailability of 7 to 8% was determined in a proof-of-
concept study involving type 2 diabetic patients and the insulin peak was reached 
in about 30 min after application. The subcutaneously injected insulin reached 
the absorption peak in about 60 minutes [65]. More clinical and toxicological data 
is required to establish the efficacy of this system.  
 
2.3.4 Pulmonary Delivery 
The respiratory tract offers a high area for drug absorption, a thin epithelial 
membrane and a rich vasculature. It also lacks effective mucociliary clearance 
and is highly immunotolerant. In addition, this route of administration also 
eliminates the first-pass hepatic metabolism [59]. This makes the lungs an 
attractive option for drug delivery [51, 67]. Inhalers are typically used for 
pulmonary insulin delivery, which enables the drug to reach the deep-lung, from 
where it can be quickly absorbed into the circulation. The factors that need to be 
controlled for optimizing insulin delivery include the type of propellant used, the 
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air flow speed, the losses within the device, the particle size and drug deposition 
into the throat and bronchial tubes [48]. Particle size and velocity greatly 
influence the deep-lung deposition of the inhaled protein [67]. Several pulmonary 
insulin delivery systems including Exubera, being jointly developed by Nektar 
Therapeutics, Pfizer and Aventis, the AERx, developed by Aradigm Corporation 
and Novo Nordisk and AIR developed by Alkermes and Eli Lilly, are in 
development and in phase III testing [42-Cefalu]. Two of these devices, Exubera 
and AERx are in phase III testing and show efficacy comparable to subcutaneous 
insulin [48, 68, 69]. In some studies however, it was observed that patients 
treated with inhaled insulin had increased insulin antibody levels, but these levels 
thus far have not been related to any significant clinical change [48, 70]. Adverse 
effects of the treatment on pulmonary function are also a cause of concern [71]. 
Safety and tolerability issues need to be addressed for this treatment to be 
clinically applicable.  
 
 Of all the routes of delivering drugs, the oral route is the most desirable. 
This route of administration results in higher patient compliance than any other 
route of administration. If successful, this delivery system will solve the current 
non-compliance related problems associated with insulin injections. The 
attractiveness of this delivery system has led to several attempts to develop oral 
insulin formulations [59]. Another great advantage of this route of administration 
is that insulin delivered via the oral route mimics more closely the endogenous 
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secretion of insulin. Insulin absorbed from the intestinal epithelium reaches the 
liver through the portal vein and can have a direct effect on the hepatic glucose 
production. This mode of distribution is highly appropriate, since the liver plays 
an important role in maintaining glucose homeostasis in the bloodstream, taking 
up and storing the energy in carbohydrates in the form of glycogen. Parenterally 
administered insulin mainly targets the peripheral tissue rather than the liver with 
pharmacokinetics that do not replicate the normal dynamics of endogenous 
insulin release [32]. A detailed description of the challenges associated with oral 
administration of proteins, and attempted solutions are included in section 2.4.  
 
2.4 Oral Delivery of Proteins 
 
Oral delivery formulation for insulin is highly desirable from a patient 
compliance point of view and other considerations discussed above. However, 
only a small portion of insulin administered orally reaches the blood stream, 
mainly due to extensive degradation of the protein in the gastrointestinal tract. 
Further, large size and hydrophilicity of the molecule greatly limits its transport 
across the intestinal epithelium. No specific transport mechanism is present for 
the passage of insulin cross the intestinal cell monolayer. Insulin molecules that 
are unable to cross the intestinal barrier thus get further exposed to the intestinal 
proteolytic activity, this in turn reduces the bioavailability of the protein. Owing to 
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these factors, less than 0.5% of the orally administered insulin typically reaches 
the systemic circulation.    
For many years researchers have tried to find a solution to these problems 
and in effect increase the oral bioavailability of insulin. The investigated 
approaches include use of permeation enhancers, protease inhibitors [72-74], or 
concomitant administration of permeation enhancers and protease inhibitors, 
chitosan coatings to stabilize the protein and improve cellular permeability [75], 
entrapment of insulin within microparticles [76], and protein modification to make 
it resistant to proteolytic attack and more permeable across the epithelium [77, 
78]. Some of these promising approaches are discussed in detail in Section 
2.4.2. The physiology of the GI tract in relation to oral protein delivery is 
discussed in the Section 2.4.1. 
 
2.4.1 Physiology of the Gastrointestinal Tract 
To maintain a constant state of homeostasis, the body needs to constantly 
replace nutrient molecules, and replenish water and electrolytes that are lost 
through urine, sweat and other means. The digestive system helps achieve this 
by continually supplying the body with energy-rich nutrients, water and 
electrolytes from the external environment. In most cases, the digestive tract 
itself does not directly regulate the uptake and transfer of these components 
based on the body’s requirement, but optimizes the digestion and absorption of 
the ingested food. This is achieved by the movement of the ingested food 
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through the GI tract, digestion of the ingested food by secretion of the digestive 
juices, absorption of the digested components, water and electrolytes, and 
movement of absorbed components away from the digestive tract by blood 
circulation.  
The process of digestion converts complex food matter into simpler and 
smaller fragments that can be absorbed by the cells lining the GI tract to be 
utilized for various bodily functions. The digestive juices are emptied into the 
lumen of the digestive tract by the exocrine glands via the tubular channels 
formed by the duct cells. Specific enzymes in these secretions digest the energy-
rich foodstuff which can be primarily classified into carbohydrates, fats and 
proteins. Proteins of therapeutic value, such as insulin, are broken down into 
smaller peptide fragments and finally into individual amino acids rendering them 
biologically inactive. The specific physiology of the stomach and intestine in 
relation to oral protein delivery as discussed below.  
 
2.4.1.1 Gastric and Intestinal Environment 
 Degradation of proteins during their transit from mouth, the pharynx and 
the esophagus is minimal. The secretions of the salivary glands contain mucus, 
amylase and lysozyme. Digestion in the mouth is limited to initiation of 
polysaccharides hydrolysis into disaccharides by amylase. No absorption of food 
material occurs in the mouth. The secretions of esophagus are entirely mucoid in 
character and maintain a well lubricated esophageal lumen. Mucus secreted by 
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the esophagus protects the esophageal wall from damage due to food. The 
entire movement of food through the pharynx and esophagus takes between 6-
10 seconds.  
 After traveling through the esophagus the food reaches the stomach 
where it is stored and digestion of the ingested food begins. Based on anatomical 
and histological characteristics, the stomach is divided into the fundus (part of 
stomach that lies above the esophageal opening), the body (middle portion) and 
the antrum (lowermost part of the stomach characterized by thick muscles). The 
three regions coordinate and control the motility function of stomach. The 
digestive juices of the stomach are mainly secreted by gastric (or oxyntic) glands. 
These glands are responsible for secretion of hydrochloric acid and pepsinogen 
and mucus along with other components.  
Other exocrine glands present in the gastric mucosa are the pyloric 
glands. These mainly secrete mucus and some pepsinogen. The oxyntic glands 
are mainly present in on the inside surface of the body on the fundus (oxyntic 
mucosa) whereas the pyloric glands are present in the pyloric gland area lining 
the antral surface. Pepsinogen, the inactive precursor of pepsin, is converted into 
pepsin by the HCl secreted by the oxyntic glands. This then leads to autocatalytic 
conversion of pepsinogen into pepsin, which is the main digestive enzyme of the 
stomach. Pepsin is active at low pH but is rapidly inactivated above pH 5.0. 
Pepsin acts at specific amide bonds within protein molecules and convert them 
into smaller peptide fragments.  
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It is most efficient in cleaving amino acid linkages involving the aromatic amino 
acids, phenylalanine, tryptophan, and tyrosine.  
 No absorption of foodstuff takes place through the stomach. Food 
components digested in the stomach are still large fragments and hence cannot 
get absorbed through the gastric mucosa. Most of the digestion and absorption 
occurs in the small intestine. The small intestine is divided into three sections: the 
duodenum, the jejunum and the ileum  [79]. The small intestine secretions 
themselves do not contribute significantly to the process of digestion. Although 
the intestinal cells do secrete digestive enzymes (such as aminopeptidase), they 
mainly act in the brush border of the epithelial cells. The exocrine glands in the 
small intestine mainly secrete mucus that lines the inside of the intestinal wall. 
Protein digestion activity of the small intestine mainly comes from the pancreatic 
secretions.   
The gastric contents, on emptying into the upper portion of the small 
intestine (duodenum), mix with the juices in the small intestine and also with the 
secretions of the pancreas. The secretions of the pancreas come from the 
exocrine pancreatic acinar cells. These cells form sac-like structures with the 
duct cells forming channels leading to the pancreatic duct. The secretions of the 
pancreas mix with the bile duct coming from the liver before mixing into the 
intestinal contents.  
The acinar cells are responsible for the secretion of proteolytic enzymes 
(protein digestion), pancreatic amylase (carbohydrate digestion), and pancreatic 
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lipase (fat digestion). The duct cells secrete large amounts of sodium bicarbonate 
(NaHCO3) that neutralizes the acidity of the contents emptied by the stomach. 
The proteolytic enzyme secretions from the pancreas contain trypsinogen, 
chymotrypsinogen and procarboxypeptidase. Trypsinogen is converted by an 
autocatalytic reaction to its active form, trypsin, by an enzyme called 
enterokinase present in the wall of the duodenum. Trypsin then converts 
chymotrypsin and procarboxypeptidase into their active analogues. Trypsin is the 
most abundant of the three enzymes.  
Each of these enzymes acts on specific amino acid linkages and convert 
the peptide fragments (formed by pepsin digestion) into small peptides and 
amino acids. Trypsin cleaves the peptide bonds where the carboxyl group comes 
from arginine or lysine residue, whereas chymotrypsin specifically breaks the 
peptide bonds where the carboxyl group is donated by tyrosine, phenylalanine, 
tryptophan, methionine, or leucine. Due to the high specificity of trypsin for amino 
acid linkages, it is commonly used as a reagent in unambiguous cleavage of 
proteins.   
 
2.4.1.2 The Intestinal Epithelial Cell Barrier 
The epithelial tissue consists of cells specialized in exchange of materials 
between the external environment and the internal host milieu. Since these cells 
form the boundary between the external and the internal environment, the 
transport across these cells is highly regulated and passage of only selective 
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components is allowed. Most of the absorption of nutrients is completed in the 
duodenum and the jejunum. The small intestinal absorptive epithelium is 
remarkably well adapted for absorption of nutrients from the lumen.  The inner 
surface of the intestine forms macroscopic circular folds, called valvulae 
conniventes that increase the surface area for absorption threefold. Each of 
these folds has microscopic fingerlike projections called villi that result in a 10-
fold increase in the surface area. The villus surface is covered by the absorptive 
epithelial cells along with some mucous cells. The epithelial cells form hairlike 
projections on the luminal side called the microvilli that further increase the 
absorptive area 20-fold. Enzymatic secretions of the small intestine are active 
within these brush borders. Thus these macroscopic and microscopic projections 
together increase the surface area nearly 600-folds compared to a hollow 
cylinder of similar dimensions or about 250 m2.  
Nutrients, such as amino acids and sugars, enter the circulation by 
crossing the epithelium covering the villi. Each villus contains a blunt-ended 
lymphatic capillary bed and a blunt-ended lymphatic vessel called the central 
lacteal. It also has a network of capillaries which absorb the molecules 
transported across the epithelial cells. The intestinal capillaries converge into 
venules and the hepatic portal vein that take the absorbed molecules to the liver. 
Fats, instead of being transported into the capillaries, are absorbed into the 
lymphatic vessels that rapidly flow into the blood via the thoracic duct.  
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The small intestinal epithelium is highly differentiated and consists of six 
distinct cell types: the enterocytes or absorptive cells, mucin producing goblet 
cells, endocrine cells, paneth cells, M cells and tuft and cup cells [80]. Epithelial 
cells are the most common type of cells in the intestinal cell monolayer. The 
epithelial cells are organized as polarized monolayer, which provides a 
permeability barrier between two distinct environments. Disruption of this highly 
regulated polarized cell barrier can cause passage of toxic luminal contents to 
the systemic circulation.  
The epithelial cells are circumferentially tied to one another by intercellular 
junctional complexes. These include the tight junctions or zonula occludens, 
zonula adherens, and desmosomes [81, 82]. The tight junctions, which appear as 
a series of fusion points involving the outer leaflets of the plasma membranes, 
attach the adjacent cells to one another at the apical region of the cells. A 
century ago, these complexes were thought to be absolute and unregulated 
barriers in the paracellular space [82]. Physiological studies of the past several 
decades have shown the tight junctions to be dynamic structures, able to respond 
to extracellular environmental changes. They are composed of the 
transmembrane proteins occludin and claudin, and cytoplasmic plaque proteins 
zonula occludens (ZO)-1, ZO-2, ZO-3, cingulin, and 7H6 [82].  
Next to the tight junction lies the adherens junction, in which cadherins act 
as adhesion receptors. The cadherins are a group of functionally related 
glycoproteins responsible for the calcium-dependent cell-to-cell adhesion.  
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The transcellular pathway is limited to those molecules which have 
specific mechanisms of active or facilitated transport, such as receptors-
mediated endocytosis, wherein the molecules recognize specific receptors 
presented on the cell surface and get endocytosed in the form of endocytotic 
vesicles. The absorption of large and hydrophilic macromolecules is almost 
exclusively limited to the paracellular pathway, which consists of aqueous pores 
created by the cellular tight junctions [80].  However, under normal conditions, 
this pathway is restricted to molecules with molecular radii less than 11 Å  [83].  
The development of efficacious delivery systems based on well-regulated 
modulation of the tight junctions by absorption enhancers has not been very 
successful, mainly due to lack of comprehensive understanding of the function of 
the tight junctions. Some drug delivery approaches based on this approach are 
discussed in section 2.4.2.2 
 
2.4.2 Strategies for Enhancing the Protein Oral Bioavailability 
The strategies for enhancing the oral bioavailability of proteins can mainly 
be categorized into two subsets. The first subset includes approaches that aim at 
reversibly changing the intestinal environment so as to make it more favorable for 
the stability and transport of the protein molecule across the intestinal epithelium. 
The term ‘intestinal environment’ is used here to include the lumen of the 
stomach and the intestine, and the intestinal epithelium. The second subset 
includes those approaches where the protein molecule is modified, typically by 
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covalent modifications, so that it can better resist the proteolytic degradation and 
can permeate the intestinal epithelium effectively. Some specific examples each 
of these approaches are discussed below.  
 
2.4.2.1 Changing the Intestinal Milieu for Improved Absorption 
 As pointed out earlier, the reduced bioavailability of proteins from the oral 
route is mainly due to their extensive degradation in the gastric and intestinal 
fluids and to some extent, in the brush border of the epithelial cells, and also due 
to their limited permeability across the intestinal epithelial barrier. Thus, inhibition 
of the degradative functions of the proteolytic enzymes or an overall increase in 
the paracellular or transcellular permeability of the epithelium may result in 
significant increase in the bioavailability of orally administered proteins. Some 
approaches based on this methodology are highlighted here. 
 
1. Permeation Enhancers, Protease Inhibitors and the Zonula Occludens Toxin 
Permeation enhancers and protease inhibitors have been extensively 
studied to overcome the barriers to oral protein and peptide delivery. Penetration 
enhancers act on the intestinal epithelium and increase the permeability of the 
membrane by either the paracellular or the transcellular pathway. Representative 
examples of this class of compounds include substances like surfactants, fatty 
acids, bile salts, and chelators such as ethylene diamine tetra acetate (EDTA). 
Many gel-forming polymers such as polycarbophil, also act as permeation 
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enhancers by binding the extracellular Ca2+. Fatty acids, bile salts and 
surfactants mostly increase the fluidity of the lipid bilayer of the cell membranes 
thus making them more permeable. Local toxicity to the epithelium in the 
gastrointestinal tract is a major concern in using these systems in pharmaceutical 
products.  
Intracellular Ca2+ plays an important role in regulating the tight junctional 
permeability [84]. Thus, compounds, such as EDTA, that can bind the 
extracellular Ca2+ thus lowering the intracellular Ca2+ concentration, can act as 
permeation enhancers by rendering the paracellular pathway more permeable. 
Some of these enhancers, however, can locally damage the intestinal mucosa 
and even enter the systemic circulation, leading to systemic toxic effects. Thus, 
damage to the epithelium and changes in the intestinal morphology, especially in 
the long term multi-dosing regimen, as would be required in diabetes treatment, 
are major concerns in clinical use of these agents. Another disadvantage of 
these compounds is their non-specificity in permeation enhancement. Increased 
permeability of the epithelium may also allow toxins and biological pathogens in 
the intestinal lumen to pass into the systemic circulation.  
Aprotinin, soybean trypsin inhibitors and polycarbophil are representative 
examples of protease inhibitors. By forming reversible stoichiometric enzyme 
inhibitor-complexes, aprotinin acts as an inhibitor of human trypsin and 
chymotrypsin. Concomitant administration of insulin with aprotinin and soybean 
trypsin inhibitors has been shown to induce hypoglycemic effect [73, 74]. 
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Polyacrylates such as Carbopol 934P and polycarbophil, which are typically used 
as bioadhesives, are also known to inhibit the activity of trypsin and chymotrypsin 
in a calcium-dependent manner [85, 86]. Bai et al. [87] showed that in-situ 
absorption of insulin was improved by carbomer polymers and also induced a 
significant decline in blood glucose levels. 
However, these enzyme inhibitors have a toxic potential caused by the 
inhibition of digestive enzymes, which can further cause incomplete digestion of 
the nutritive proteins. In addition, the inhibitory action can cause increased 
secretion of these enzymes by a feed-back regulation [73, 88]. Studies have 
shown that this feed-back regulation leads to both hypertrophy and hyperplasia 
of the pancreas. Prolonged administration of soybean trypsin inhibitor can lead to 
invasive carcinoma [73].  
One of the recent additions to the class of absorption enhancers is zonla 
occludens toxin (Zot), a protein secreted by Vibrio cholerae [89].  This toxin 
induces modifications of cytoskeletal organization, specifically at the actin 
filament of the zonula occludens which leads to opening of the tight junctions 
causing increased permeability. This permeability increase is reversible, time- 
and dose-dependent and is restricted to jejunal and ileal sections of the small 
intestine owing to the presence of receptors for the protein in those sections [72]. 
Studies with diabetic animals have shown that insulin administered with 5 µg Zot 
and NaHCO3 to neutralize the gastric acidity, induced a hypoglycemic effect 
comparable to that caused by subcutaneously administered insulin. This is a 
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promising approach to improving oral bioavailability of insulin, but it suffers from 
the same safety and specificity issues that limit the use of other permeation 
enhancers discussed above.  
 Thus, attempts to increase the oral bioavailability of proteins using 
permeation enhancers and protease inhibitors have not resulted in an acceptable 
delivery system. Potential side effect of this methodology has limited its clinical 
applicability [90]. 
 
2. Complexation Hydrogels in Protein and Peptide Delivery 
Much attention has been focused on developing stimuli-sensitive hydrogels 
that exhibit dramatic changes in network structure or swelling behavior in 
response to change in pH, temperature, electric field, and ionic strength [91-93]. 
Most of these systems rely on the sensitive nature of specific interpolymeric 
complexation within the hydrogels. By exploiting the sensitive nature of these 
hydrogels, external (magnetic field, laser) or internal triggers (pH, ionic strength 
changes) can be used for temporally and/or spatially targeted delivery of 
biomolecules within the body. Delivery systems can also be designed to release 
macromolecules in response to increased concentration of a specific compound 
[94, 95], or changes in the surrounding environment.  
We have developed hydrogen bonding, copolymer networks of 
poly(methacrylic acid) grafted with poly(ethylene glycol) (P(MAA-g-EG)) as oral 
delivery systems for peptides and proteins. The polymer complexes are prepared 
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by free radical solution polymerization [85] or dispersion polymerization [96] of 
methacrylic acid and methoxy-terminated poly(ethylene glycol) 
monomethacrylate with tetra(ethylene glycol) dimethacrylate added to provide 
crosslinks in the network structure.  
These materials exhibit pH-dependent swelling behavior due to the 
formation/dissociation of interpolymer complexes [97, 98]. In acidic media, 
interpolymer complexes form due to hydrogen bonding between the graft PEG 
chains and the methacrylic acid units. These complexes serve as temporary, 
physical crosslinks and cause the gels to be in the collapsed conformation. The 
pKa of PMAA is about 4.8; thus at neutral pH the MAA groups in the network are 
almost entirely deprotonated. The hydrogen bonds present at low pH dissociate 
at near neutral pH resulting in swelling of the network structure. The equilibrium 
swelling characteristics of the polymer network depend on the composition of the 
polymer.  
Lowman and Peppas [98] studied the effects of copolymer composition and 
the pH of the surrounding medium on the network structure and the drug release 
characteristics. Hydrogels comprising MAA and EG in equimolar amounts exhibit 
maximum change in the mesh size or the correlation length of the network due to 
the pH shift. With an increase in the amount of MAA in the network, the average 
mesh size in the acidic media increases owing to the absence of physical 
crosslinks arising from MAA-EG interactions. Depending on the pH of the 
surrounding medium, the average mesh size in a network with MAA: EG ratio of 
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1:1 changes by a factor of 3 between deswollen to swollen states, which 
corresponds to a 10-fold change in the effective area for diffusion of the drug. 
This results in a change in the diffusion coefficient of the drug by two orders of 
magnitude [99]. Thus these hydrogels are ideal for the oral delivery of peptides 
and proteins due to the large change in network structure over a small pH range. 
  In the acidic environment of the stomach, the drugs would be trapped in 
the collapsed gel and protected from degradation by digestive enzymes in the 
stomach. However, in the near-neutral environment in the intestine where the 
drugs could be absorbed, the peptides and proteins can be readily released. In 
addition, the macromolecular polymer structure and the polymer composition can 
be altered by changing parameters such as the nature of the crosslinker, the 
crosslinking density, and relative amounts of monomers added, to achieve 
diffusion-controlled delivery of proteins and peptides of therapeutic interests. 
These complexation hydrogels can also inhibit the activity of Ca2+ dependent 
proteolytic enzymes [85]. As discussed in chapter 8, these hydrogels can also 
protect the entrapped protein in gastric fluid. Further, the bioactive agent 
released from the polymer formulations in intestinal fluid is significantly protected 
from the proteolytic attack. These polymer networks also exhibit mucoadhesive 
characteristics due to the PEG chains which interact with the mucus layer lining 
the epithelial cells. This mucoadhesive behavior is advantageous since it results 
in release of the drug at the site of absorption and also increases the residence 
time of the drug in the small intestine.   
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The aforementioned characteristics make these copolymers ideal carriers for 
oral delivery of proteins and peptides. We have successfully demonstrated 
application of this system in oral delivery of insulin in the diabetic rat models. 
Insulin can be incorporated into the polymer microparticles by partitioning from a 
concentrated solution followed by acidification to collapse the microparticles. 
 Upon exposure to acidic environment, most of the entrapped insulin remains 
trapped inside and less than 10% of insulin is released from the microparticles. 
But when the pH of the surrounding medium rises to the physiological pH in the 
small intestine, insulin trapped inside the network is released rapidly [100]. In 
addition to exhibiting a pH-responsive behavior, these polymer matrices also 
serve to stabilize the entrapped insulin [101]. The PEG chains present in the 
network serve to maintain the biological activity of the insulin by stabilizing the 
drug and preventing binding to ionizable MAA backbone [99, 101].  
The effectiveness of this system in delivering insulin was evident from the 
observed hypoglycemic effect upon oral administration in the diabetic rat studies 
[102]. The blood glucose levels in diabetic rats were lowered by up to 40% for 
more than 8h. Transport studies using Caco-2 cells, a widely used in vitro model 
for intestinal absorption of drugs [103], have also proven the efficacy of the 
polymeric system [104]. The particles induced Ca2+ concentration-dependent 
lowering on the transepithelial electrical resistance (TEER) due to the reversible 
opening of the tight junctions [96, 104], resulting in an increase in the 
permeability coefficient of insulin across the cell monolayer. Whether or not a 
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similar permeation enhancing effect is responsible for the improved oral 
bioavailability of insulin in animals is not clear.  
 
2.4.2.2 Drug Modification Strategies 
As mentioned previously, some of the approaches for improving the oral 
bioavailability of therapeutic proteins and peptides by transiently modulating the 
tight junctions between the cells suffer from possibility of side effects such as 
systemic toxicity and damage to the epithelium. The potentially invasive nature of 
this approach combined with the lack of precise control over the tight junction 
permeability limits its clinical applicability. A promising alternative to this 
approach are the drug modification strategies. The distinguishing feature of these 
approaches is that instead of altering the physiological conditions for improved 
stability and epithelial transport of protein molecule, the protein itself is modified 
to increase bioavailability. As a specific example, a novel methodology, which 
utilizes receptor-mediated transcytosis of extracellular proteins, is discussed 
here.  
Receptor-mediated endocytosis for improved oral delivery: 
Receptor-mediated endocytosis of proteins is being investigated as a 
specific, non-invasive alternative to facilitate intestinal absorption of drugs [105]. 
Receptor-mediated endocytosis is a pathway for selective and efficient cellular 
uptake of specific macromolecules required for various cell processes from the 
extracellular milieu. During this process, the binding of receptor to a ligand 
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triggers intracellular signaling pathways which lead to endocytosis of the 
receptor-ligand complex in membrane-derived vesicles. After endocytosis, the 
receptor-ligand complex encounters the acidic pH in the early endosomal 
compartments [106], which may lead to (i) uncoupling of the ligand-receptor 
complex due to changes in the conformation of receptor proteins followed by 
recycling of the receptor to the cell membrane, or (ii) degradation of the receptor 
in lysosomes. The endocytosed ligands that dissociate from their receptors in the 
early endosomes are usually degraded in the lysosomes. Some ligands, 
however, remain bound to the receptors and hence share the fate of their bound 
receptors.  
Depending on the specific type of the receptor proteins, the receptors 
along with the bound ligand may be recycled to the same plasma membrane 
domain from which they came, get degraded in the lysosomes, or get transported 
to a different domain of the membrane, as in the polarized epithelial and 
endothelial cells. The last process is called transcytosis and is of particular 
interest from drug delivery standpoint. By coupling therapeutic proteins to the 
ligand molecules that can recognize specific receptors on the epithelial cell 
monolayers, transcellular delivery of these macromolecular biopharmaceuticals 
may be achieved. Since only those molecules that are conjugated to the ligands 
are transcytosed, this process eliminates the potential side effects associated to 
the unspecific transport by the paracellular pathway. Transferrin and lectin 
receptor mediated protein delivery systems are discussed here.    
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1. Transferrin-mediated drug delivery 
Transferrin is a single-chain protein with molecular weight of 
approximately ~80 kDa [107]. Serum transferrin is involved in uptake of iron by 
the cells and tissues. Transferrin receptors (TfRs) have been widely explored for 
receptor-mediated delivery of anticancer agents [107, 108], in enhancing the 
transport of drugs across the blood brain barrier [109, 110], and more recently, 
across the epithelial cells of the intestine [77].  
TfR is a homodimer expressed by many cell types including the human 
intestinal cells. TfR binds iron-bound transferrin (holo-transferrin) on the cell 
surface. This binding is sensed by the cells which results in an uptake of the Tf-
TfR complex. Triggered by the change in the endosomal pH, the ligand-bound 
transferrin then looses its bound iron and the complex is recycled to the cell 
surface where iron-free transferrin (apo-transferrin) is released. In polarized cells 
such as the epithelial and endothelial cells, transferrin can be transcytosed from 
the apical to the basolateral membrane [111]. This mechanism is exploited in 
TfR-mediated drug delivery across the blood brain barrier as well as the epithelial 
barrier of the small intestine.  
Transferrin receptors are present at high densities in human GI epithelium 
[112], and transferrin can resist tryptic and chymotryptic degradation [113]. Shen 
and co-workers [114] were the first to utilize the potential of TfR-mediated 
transport in improving oral delivery of therapeutic agents. They conjugated 
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transferrin to insulin via disulfide linkages and demonstrated that the conjugation 
resulted in 5- to 15-fold increase in insulin transport across Caco-2 cell 
monolayer [115]. As pointed out earlier, since this enhancement is specific for the 
conjugated protein, viz. insulin, and takes place without causing the tight 
junctions to open even momentarily, this approach is most desirable in terms of 
toxicity and damage to the epithelium.   
Following successful in vitro studies, Shen and co-workers [77] 
demonstrated that insulin-transferrin conjugate, when administered orally to 
diabetic rats, caused slow but prolonged hypoglycemic effect. In-Tf conjugate 
after oral administration as well as after subcutaneous injection caused a delayed 
but prolonged glucose reducing activity as compared to native insulin after 
subcutaneous injection. Subcutaneously administered In-Tf conjugate maintained 
low blood glucose levels for at least 4 times longer than unconjugated insulin. 
While this might be beneficial in terms of the frequency of dosage, the reasons 
behind this behavior is not fully understood.  
The authors have also presented data suggesting that the disulfide linkage 
between the two proteins can be reduced in the liver following its absorption into 
the portal vein. The approach thus makes use of transferrin for overcoming the 
transport barrier of the small intestine after which free insulin can be released to 
perform its physiological system.  
The observation that the intact conjugate is able to reach the systemic 
circulation intact, suggests that the insulin conjugated to transferrin is able to 
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overcome proteolytic attack during transit in the GI tract and across the epithelial 
cells. In vitro studies with simulated gastric and intestinal fluids can shed light on 
the conjugates ability to shield insulin from proteolytic attack.  
 
2. Lectin-mediated drug delivery  
Lectins are a class of structurally diverse proteins of non-immune origin 
that are characterized by their ability to specifically bind carbohydrates [116]. 
They are primarily found in seeds, but are also present in animals, plants and 
microorganisms. Lectins have been studied widely for oral delivery applications 
because of their relatively good resistance to the acidic pH and enzymatic 
degradation and presence of binding sites in the gastrointestinal tract [117, 118]. 
While some lectins such as phaseolus vulgaris agglutinin (PHA) from raw kidney 
beans have been known to cause dietary toxicity [119, 120] and are unsuitable 
for drug delivery applications, variety of other lectins such as wheat germ 
agglutinin (WGA) Triticum vulgare [117] and tomato lectin (TL) from 
Lycopersicum esculentum [121] are natural component of our diet and bind to 
intestinal mucosa without any obvious deleterious effects.  
Use of lectins in improving the residence time of the drug carrier 
particulate systems has been the subject of a number of excellent reviews  [122-
125]. Recent work on the use of WGA-protein conjugates for improving the 
uptake and transcytosis of proteins across the epithelial cell barrier of the gut is 
discussed here.  
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WGA is a dimeric protein with two subunits containing two or four 
carbohydrate-combining sites [126]. It specifically binds N-acetylglucosamine and 
sialic acid residues. Wheat germ contains approximately 300 mg WGA/kg and 
hence the peroral toxicity that can result from long term oral administration of 
WGA may be negligible [127]. Further the lectin can resist degradation due to 
proteolytic attack upon exposure to the gastrointestinal enzymes [117]. These 
characteristics and the presence of N-acetylglucosamine containing 
oligosaccharides in the glycocalyx of the intestinal mucosa make WGA a 
promising candidate for enhancing oral bioavailability of drug candidates.  
Binding studies of WGA using Caco-2 cells, mucus producing HT-29 cells 
and HT-8 cells have revealed that it exhibits low nonspecific proteinaceous 
binding to the cell surfaces and high affinity for oligosaccharides present on the 
cell surfaces [128]. In an interesting study, Gabor and co-workers examined 
whether WGA can improve the binding and uptake of a model fluorescently 
labeled BSA (F-BSA), by the Caco-2 cells [127]. They observed that WGA in the 
conjugated form was able to bind specifically to the oligosaccharides on the cell 
surface and the conjugate was uptaken by the cells by an energy dependent 
mechanism.  
This is an important result since it demonstrates the potential of lectin 
mediated delivery in improving the transcellular transport of proteins across the 
epithelium. However, there are concerns about the cellular fate of the uptaken 
conjugate. The conjugate accumulated within lysosomal compartment where it 
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was degraded. The degraded products diffused into the cytosol and finally 
appeared in the extracellular medium. Thus, even though lectins can resist 
degradation due to proteolytic attack, the conjugated protein drug is still 
susceptible to degradation by the enzymes in the lysosomes. In addition, the 
stability of such conjugates in the gastrointestinal environment is an unaddressed 
issue.  
One important consideration here is the size of the protein under 
consideration that is conjugated to the lectin. WGA is 147 kDa, whereas BSA is 
68 kDa protein. Since BSA is a large molecule, the lectin may not be able to 
protect bound protein by creating a steric hindrance to the proteolytic attack. But 
if a smaller protein such as insulin (5.8 kDa with hydrodynamic radius of 
approximately 20 Å) is conjugated to WGA, the lectin might shield the bound 
protein from proteolytic attack and hence improve its stability during transit in the 




A variety of approaches have emerged in the recent past for designing 
oral delivery systems for therapeutic proteins and peptides, although a clinically 
viable solution to this long standing problem still alludes the scientific community. 
These approaches come from such diverse research disciplines as biomaterials, 
conjugation chemistry, nanotechnology, cell biology, and employ different 
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methodologies for solving the same problem. Some of these strategies have 
distinguishing beneficial characteristics that make them good candidates for oral 
protein delivery. Interfacing different strategies to combine the benefits of novel 
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 Development of oral delivery formulations for therapeutic proteins and 
peptides is of great interest to the pharmaceutical industry. Successful oral  
delivery of therapeutic proteins such as insulin, can greatly improve the efficacy 
of treatment of diseases, and improve the quality of life of patients. However, the 
challenges in developing oral protein formulations largely remain unaddressed 
and a universally acceptable solution to those challenges still eludes the scientific 
community. Some significant advances have been made in the recent past, that 
have led to better ways of addressing the challenges of oral protein delivery.  
Use of complexation hydrogels developed in our laboratory has been 
proposed as a promising alternative for oral insulin delivery. Hydrogels-based 
delivery systems effectively address some of the key challenges in protein 
delivery. However, better understanding of how the hydrogel-based oral 
formulations function is desired for developing better ways to enhance oral 
bioavailability of proteins. As discussed in Chapter 2, some of the other 
investigated strategies, such as the use of transferrin specific receptor-mediated 
transcytotic pathway, address the issue of low protein bioavailability through 
other specific means.  
The overall goal of this work was to evaluate the effectiveness 
complexation hydrogels in addressing some key problems in oral protein delivery 
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and to design a system based on integrating the hydrogels with other effective 
strategies for oral protein delivery. The specific goals of this research are outlined 
below: 
(1) Evaluation of the synergistic effect of complexation hydrogels and 
permeation enhancers on the permeability of in vitro cell culture models 
of the intestinal epithelium. 
(2) Investigation of the mechanisms of transport of insulin across the model 
intestinal cell monolayers. 
(3) Evaluation of the contribution of PEG chains in the P(MAA-g-EG) 
particles  towards increased retention of the polymer particles in the GI 
tract.  
(4) Investigation of the ability of the microparticles to protect insulin from 
degradation in the gastric and intestinal environment. 
(5) Investigation and optimization of the synthesis conditions and 
characterization of insulin-transferrin conjugates. 
(6) Optimization of the P(MAA-g-EG) microparticle carriers for delivery of 
the insulin-transferrin conjugates. 
(7) Cellular evaluation of the formulations based on complexation hydrogels 








SYNERGISTIC EFFECT OF PERMEATION ENHANCERS AND 





           
Transport of a drug across the intestinal epithelium is greatly influenced by 
its physiochemical characteristics. Typically, peptides that have molecular weight 
greater than 500, are charged at the intestinal pH, and tend to hydrogen bond, 
diffuse poorly across the epithelial barrier via the transcellular passive diffusion 
pathway [1]. Paracellular transport, as described previously, is size dependent 
and hence the paracellular diffusion of structurally complex proteins, such as 
insulin is negligible [2]. Thus, any enhancement in the paracellular transport of a 
protein will require improved control over the opening of the tight junctions.  
 Various methods based on this rationale have been explored to improve 
the transport of therapeutic proteins across the intestinal epithelium. A common 
method has been the use of permeation enhancers, like detergents, fatty acids or 
bile salts, which open the intercellular tight junctions and hence increase the 
transport of insulin across the intestinal membrane [3]. However, potential for 
damage to the epithelia and toxicity is a major concern since the approach is not 
selective towards the drug molecule of interest and undesirable luminal contents 
can also be transported into the blood stream[4-6].  
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This potential disadvantage of the methodology may be addressed by 
achieving a tight control over permeability of the tight junctions. A delivery system 
which can reversibly open the tight junctions only for a short period of time so 
that only the drug can be transported across the intestinal epithelium is highly 
desirable. Thus, the end goal of these approaches is an oral delivery formulation, 
which, after reaching the upper small intestine, will precisely control opening and 
closing of the tight junctions so that only the protein of interest can cross the 
intestinal barrier to reach the blood stream. By inducing rapid reversibility of the 
tight junction opening, any non-specific transport of undesirable components may 
be greatly restricted, thus avoiding the toxicity associated with this approach.  
 Various permeation enhancers have been investigated for their ability to 
increase the transport of large molecules across the intestinal cell monolayer. 
Most of these enhancers act by opening the tight junctions between the cells [7, 
29]. However, precise control over opening and closing of the tight junctions has 
not been achieved yet.  
It has been shown that P(MAA-g-EG) based complexation hydrogels can 
reversibly open the tight junctions between Caco-2 cells. This property of the 
hydrogels is believed to be associated with their ability to bind free Ca2+ when 
placed in contact with Caco-2 cells. Reduction in extracellular Ca2+ concentration 
is believed to cause opening of the tight junctions. Thus, the complexation 
hydrogels reversibly open the tight junctions between the cells by reducing free 
Ca2+ concentrations and any improvement in the ability of the hydrogels to 
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control opening and closing of the tight junctions may greatly increase the oral 
bioavailability of insulin released from the hydrogel formulation. It was the focus 
of this work to investigate if complexation hydrogels used in conjunction with a 
model paracellular enhancer exhibit better control over the tight junction 
permeability.   
One absorption enhancer that is relatively well-studied and used clinically 
Japan with no reports of side effects is sodium caprate [7-9]. It is the sodium salt 
of capric acid, a 10-carbon saturated fatty acid, that constitutes 2-3% of the fatty 
acids in dairy products [10]. Sodium caprate facilitates transport via the 
transcellular route through membrane perturbation and via the paracellular route 
through the opening of the tight junctions, which are mediated by the contraction 
of calmodulin-dependent actin microfilaments, causing by elevation of 
intracellular calcium ion levels [8, 9]. Ultrastructural studies of Caco-2 
monolayers after exposure to sodium caprate showed dilatations in the tight 
junctions in rat and hamster small intestine [11, 12].  
Tomita et al. [13] showed that sodium caprate induced increase in 
paracellular permeability via a calcium-mediated contraction of the perijunctional 
actin microfilaments. Sakai et al. [14] examined the changes in intracellular 
calcium ion level and histomorphology of actin filaments in Caco-2 cell monolayer 
in the presence of sodium caprate. Sodium caprate induced changes in the 
intracellular calcium concentration and significantly changed the actin filament 
structure in a reversible manner. It was postulated that the paracellular 
  66
permeability enhancing effect of sodium caprate was due the alteration in the 
cytoskeletal actin filaments which are provoked by changes in the intracellular 
calcium ion levels [14]. Further, sodium caprate is non-toxic when used in 
concentrations below 13 mM [15].  
Hence, sodium caprate was used as a model paracellular enhancer for 
these studies. The objective was to investigate if the combination of the 
complexation hydrogels and the specific enhancing agent results into a better 
delivery system. The synergistic effect of sodium caprate and P(MAA-g-EG) 
microparticles on the permeability of the Caco-2 cell monolayer was investigated. 
The permeability of the cell monolayer was measured in terms of the 
transepithelial electric resistance (TEER) value of the monolayer[16, 17]. 
Concentrations of sodium caprate used for this work have been shown to 
reversibly reduce the TEER values of the Caco-2 cell monolayer [18]. 
 
4.2 Materials and Methods 
 
Preparation of Polymer Microparticles: P(MAA-g-EG) hydrogels were prepared 
by free radical solution UV-polymerization of methacrylic acid (MAA) and 
poly(ethylene glycol) ether monomethacrylate (PEGMA). The monomers were 
mixed in the molar ratio of 1:1 (MAA:EG). The MAA (Aldrich Chemical Company, 
Milwaukee, WI) was vacuum distilled at 47°C/25 mmHg to remove the inhibitor 
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hydroquinone monomethyl ethere.  PEGMA (Polysciences, Inc. Warrington, PA) 
was used as received.   
 PEGMA with PEG molecular weight of 1000 was used in this synthesis.  
Tetra(ethylene glycol) dimethacrylate (TEGDMA) (Polysciences, Inc. Warrington, 
PA) was used as the crosslinking agent and was added in the amount of 0.75 % 
moles of the total amount of monomers. The photoinitiator, Irgacure-184 (Ciba-
Geigy Co. Hawthorne, NY) was added in the amount of 0.1wt % of the total 
amount of monomers.  To inhibit autoacceleration in the polymerization reaction, 
monomer mixture was diluted with a mixture of 50 % v/v ethanol and deionized 
water (Milli-Q Plus system, Millipore). Nitrogen was bubbled through the well-
mixed solution for 15 minutes to remove dissolved oxygen, which acts as a free 
radical scavenger.  The mixture was then carefully poured between microscope 
slides (75 x 50 x 1 mm) (Fisher, Pittsburgh PA) separated by Teflon spacers with 
a thickness of 0.9 mm.  The glass slides were then placed in a nitrogen 
atmosphere under a UV light source of 16 mW/cm2 at 365 nm for 30 minutes.  
After the completion of the reaction, the polymer films were washed in deionized 
water for approximately 7 days in order to remove unreacted monomers, 
crosslinking agent, initiator and sol fraction. After washing the polymer films were 
dried at room temperature for a day and then placed in a vacuum oven at 27 °C 
for 2 days.  The dry polymer films were then crushed by using a mortar and 
pestle and then sieved to 150-212 µm by using the corresponding.  All the 
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particles were stored in a closed 5 mL glass vials inside a desiccator until further 
use.  
Preparation of Caco-2 cell monolayer: Caco-2 cell cultures were grown in 6-well 
Transwell plates (4.71 cm2/well) (Costar, Corning Incorp., Corning NY) with 
DMEM culture media for 21 to 24 days until they achieved a constant TEER 
value, which indicated that the tight junctions had formed in the monolayer 
[26,27]. The media was changed every other day. The electrical resistance was 
monitored using a voltmeter with a chopstick electrode (World Precision 
Instrument, Sarasota, FL). The culturing cell density was 2.35 x 105 cells/well.  
Each well consisted of two chambers: the apical (top) and the basolateral 
(bottom), which were separated by membrane with 0.45 µm pore size.   
TEER Measurement Studies: The medium used for these studies was Hanks’ 
balanced salt solution, HBSS containing Ca2+.  Before the measurements, the 
cell membranes were allowed to equilibrate for one hour with the experimental 
medium, HBSS containing Ca2+. After this period, the cell monolayer achieved a 
constant electrical resistance after the change of medium. The electrical 
resistance was monitored using a voltmeter with a chopstick electrode. 
 After the equilibration period, the apical chamber media was removed and 
replaced by fresh HBSS containing the sodium caprate with or without pre-
swollen microparticles. The microparticles were used in concentration of 5 mg/ml 
and sodium caprate was used in two different concentrations of 1 mg/ml and 0.5 
mg/ml. Both these concentrations were used with or without the microparticles. 
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The TEER, of the cell monolayer was measured at different time intervals. The 
temperature was kept constant at 37 0C during the entire course of the 
experiment.  While measuring TEER, the experimental plates were placed on a 
heated mat (Barnstead Thermolyne, size 6 x15 in, model LAB1611003, 
Duburque, Iowa) with a voltage controller (Glass-Col®, Terre Haute, IN) in a 
laminar flow hood. After incubation for 90 minutes, the HBSS containing sodium 
caprate and/or microparticles was removed, the cells were gently washed with 
HBSS and fresh HBSS was introduced on both apical and the basolateral sides. 
TEER readings were taken for 3 hours to study the reversible effect on tight 
junctions. 
 
4. 3 Results and Discussion 
 
 Changes in the tight junction permeability in the presence of sodium 
caprate and P(MAA-g-EG) microparticles was studied by monitoring the TEER 
values of the cell monolayer. The TEER value is a quantitative measure of 
resistance to ion transport across the epithelium and hence the permeability of 
the tight junctions. Reversibility in opening of the tight junctions is a desired 
characteristic for designing a delivery system. P(MAA-g-EG) microparticles have 
been shown to reversibly reduce the TEER value of the Caco-2 cell monolayer 
[18]. Sodium caprate has also been shown to reversibly reduce the TEER values 
of Caco-2 cell monolayer in the concentration range of 0-1mg/ml [33]. Hence, 
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reduction in TEER values in the presence of both the microparticles and sodium 
caprate was studied here.  
 
Percentage TEER value was calculated as  
 
                                    
( )









                          (4.1) 
Here, Rt is the measured electrical resistance at any time, Rw/o is the electrical 
resistance in absence of cell monolayer, Ro is the initial resistance value.  
 Fig 4.1 shows the effect of microparticles and sodium caprate on the 
TEER values of Caco-2 cell monolayer. First 90 minutes show the effect of 
polymer solution and sodium caprate. Fresh HBSS was introduced after 90 
minutes to study the reversible effect on TEER values.  
Controls (cell monolayer without any microparticles or sodium caprate) 
showed some drop in TEER after introduction of fresh HBSS at 90 minutes and 
took longer time than expected to reach the initial value of TEER. As expected, 
both polymer and sodium caprate induced reversible decrease in TEER of the 
cell monolayer. However, when the microparticles and sodium caprate were 
placed together in the epical side, the synergistic effect of the two caused a 
sudden, irreversible decrease in TEER values. The pattern was almost identical 
for both 1 mg/ml and 0.5 mg/ml solutions of sodium caprate. In most cases, the 
combination of microparticles and sodium caprate caused detachment of the cell 
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monolayer from the pore membrane at around 85-90 minutes. This indicated that 
P(MAA-g-EG) microparticles and sodium caprate did not act independently. One 
affected the functioning of the other. Possible interaction between the 
microparticles and sodium caprate could have precipitated the sodium caprate on 
the cell monolayer creating high local concentrations of the salt. High 
concentrations of sodium caprate can open the tight junctions irreversibly [33]. 
This seems to be the most likely cause of the observed irreversible reduction in 




The combination of the enhancing agent and the microparticles did not 
result in an effective delivery system for protein molecules. Sodium caprate and 
P(MAA-g-EG) microparticles caused irreversible damage to the epithelium. Thus 
a formulation which contains permeation enhancers and the microparticles, if 
administered orally, can cause severe damage to the epithelia. Hence this line of 
investigation was abandoned and we turned our attention to the other, non-
invasive mechanism of improving the transport of proteins across the epithelium. 
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Fig. 4.1. Transepithelial electrical resistance (TEER) plotted against time. Combined 
effect of sodium caprate and P(MAA-g-EG) particles on transepithelial electrical 
resistance of Caco-2 cell monolayer. Polymer particles with initial feed ratio MAA:EG of 
1:1 and PEG molecular  weight of 1000 were used in the experiment. (▲)control, (♦) 
polymer(5mg/ml), (∆) sodium caprate(0.5mg/ml), (•)sodium caprate(1mg/ml), 
( )polymer (5mg/ml) and sodium caprate (0.5mg/ml) and (■)polymer (5mg/ml) and 
sodium caprate (1mg/ml). Solutions were replaced by fresh HBSS at 90 min. The 
experiments were carried out at a constant temperature of 370C. Error bars represent 




























EXPERIMENTAL INVESTIGATION OF TRANSPORT MECHANISMS OF 






          As described in Section 2.4.1, the transport of therapeutic agents such as 
proteins across the intestinal gut wall may take place via various pathways [1]. 
The transport can occur primarily through the cell membrane of the enterocytes 
(transcellular transport) or via the tight junctions between the cells (paracellular 
transport). The transcellular passive diffusion pathway is mostly limited to drugs 
that are non-polar, and are lipid soluble, are not charged at the physiological pH 
of the small intestinal lumen. The octanol-water system is typically used as a 
reference system for biological partitioning in drug design work. Drug lipophilicity 
is estimated by determining the drug’s octanol-water partition coefficient [2]. 
Insulin has low lipophilicity with an octanol-water partition coefficient of about 
0.0215 [3]. Further, the iso-electric point of insulin is around 5 and hence insulin 
is negatively charged at the neutral pH of the small intestine. Thus, entry into the 
cell membrane is unfavorable. The primary pathway available for transport of 
insulin across the epithelium is the aqueous paracellular pathway.  
One additional pathway available for the transcellular transport of proteins 
is the receptor mediated endocytosis, wherein, the protein molecules bind 
specific receptors presented on the cell surface. The ligand-receptor complex is 
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then endocytosed into the cells by the process of receptor mediated endocytosis. 
The transport of molecules via this pathway is considerably faster than the 
passive diffusion pathway.  
Insulin receptors have been identified in the basolateral membranes of 
dog intestinal mucosa, in the mouse intestinal cells and in the membrane of 
Caco-2 cells [4-6]. The precise role of these receptors in the GI tract remains 
unclear. Kendzierski et al. [7, 8] analyzed the ability of the gut to make insulin. It 
was suggested that the insulin receptors might be involved in an autocrine or 
paracrine role of the insulin made in the gut. Intracellular immunoreactivity 
towards insulin was found in glandular cells in the stomach and colon but no 
immunoreactivity was found in the small intestine [7]. In addition, the 
preproinsulin mRNA was detected in similar cells in the stomach and colon. 
Insulin produced in the gut may function in controlling cell division, secretion of 
other peptides, or motility and absorption.  
Importantly, insulin has been reported to be absorbed into the rat ileal 
epithelium in the presence of permeation enhancers and protease inhibitors [9-
11]. By applying protein A-gold immunocytochemical technique, Bendayan et al. 
[9] showed that insulin was uptaken into endocytotic vesicles and was routed to 
the basolateral side of the ileal membrane via the trans-side of the Golgi-
apparatus. A similar pathway of the insulin uptake and transport was also 
observed in normal and diabetic rats [12]. In addition to this, an insulin-degrading 
enzyme (IDE), a thiol metalloprotease, has been identified in the cytosol of the 
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rat intestinal enterocytes constituting upto 92% of total insulin-degrading activity 
[13]. These results indicate that the ligand-specific receptor-mediated 
transcellular pathway may be functional in protein transport across the intestinal 
epithelium.  
Thus both the paracellular and transcellular pathways could be functional 
in insulin transport across the intestinal epithelium. However, because of the 
endosomal degradation and the degradation due to the IDE, the contribution of 
the transcellular pathway to the insulin flux across the intestinal mucosa would be 
negligible [13].  
 The precise mechanism of insulin transport across the epithelium when 
delivered using the P(MAA-g-EG) microparticles is not clear. The polymeric 
microparticles have been shown to reversibly reduce the transepithelial electrical 
resistance (TEER) of the Caco-2 cell monolayer [14], which is a measure of the 
integrity of the tight junctions between the cells. This opening of the tight 
junctions by P(MAA-g-PEG) microparticles has been attributed to their ability to 
bind free calcium. Any significant decrease in calcium concentration of the 
medium surrounding the epithelial cells opens the tight junctions [15, 16]. This 
suggests that the microparticles facilitate the paracellular transport of insulin. It is, 
however, unclear whether this is the only mechanism by which insulin can be 
transported across the epithelium. Understanding the precise mechanism of 
enhancement in insulin transport in the presence polymeric microparticles is 
critical to improving the oral bioavailability of the protein.  
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In this study, the transport mechanism of fluorescein isothiocynate insulin 
(FITC-insulin) (Sigma, St. Louis, MO) across the Caco-2 cell monolayer in the 
presence of P(MAA-g-EG) microparticles was investigated by using confocal 
laser scanning microscopy. In order to distinguish between intracellular and 
paracellular insulin, the cells were labeled using Nile Red dye (Sigma, St. Louis, 
Mo), a lipophilic dye used to label the cell membranes. 
 
5.2 Materials and Methods 
 
Preparation of Polymer Microparticles: P(MAA-g-EG) hydrogels were prepared 
by free radical solution UV-polymerization of methacrylic acid (MAA) and 
poly(ethylene glycol) ether monomethacrylate (PEGMA). The monomers were 
mixed in the molar ratio of 1:1 (MAA:EG). The MAA (Aldrich Chemical Company, 
Milwaukee, WI) was vacuum distilled at 47°C/25 mmHg to remove the inhibitor 
hydroquinone monomethyl ethere.  PEGMA (Polysciences, Inc. Warrington, PA) 
was used as received.   
 PEGMA with PEG molecular weight of 1000 was used in this synthesis.  
Tetra(ethylene glycol) dimethacrylate (TEGDMA) (Polysciences, Inc. Warrington, 
PA) was used as the crosslinking agent and was added in the amount of 0.75 % 
moles of the total amount of monomers. The photoinitiator, 1-hydroxy-cyclohexl-
phenylketone, (Irgacure-184) (Ciba-Geigy Co. Hawthorne, NY) was added in the 
amount of 0.1 wt % of the total amount of monomers.  To inhibit autoacceleration 
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in the polymerization reaction, the monomer mixture was diluted with a mixture of 
50 % v/v ethanol and deionized water (Milli-Q Plus system, Millipore). Nitrogen 
was bubbled through the well-mixed solution for 15 minutes to remove dissolved 
oxygen, which acts as a free radical scavenger.  The mixture was then carefully 
poured between microscope slides (75 x 50 x 1 mm) (Fisher, Pittsburgh PA) 
separated by Teflon spacers with a thickness of 0.9 mm.  The glass slides were 
then placed in a nitrogen atmosphere under a UV light source of 16 mW/cm2 at 
365 nm for 30 minutes.   
After the completion of the reaction, the polymer films were washed in 
deionized water for approximately 7 days in order to remove unreacted 
monomers, crosslinking agent, initiator and sol fraction. After washing, the 
polymer films were dried at room temperature for a day and then placed in a 
vacuum oven at 27 °C for 2 days.  The dry polymer films were then crushed by 
using a mortar and pestle and sieved to 150-212 µm.  All the particles were 
stored in a closed 5 mL glass vials inside a desiccator until further use.  
Development of Caco-2 cell monolayer: The cells were cultured in 75 cm2 
culturing flasks (VWR Scientific, West Chester, PA) with 10 mL of Dulbecco’s 
Modified MEM, culture media, DMEM (Bio Fluids, Biosource International). The 
seeding density for cultivation was 2.5x105 cells/flask. Cells were maintained in 
an incubator at 37 °C temperature, 95 % relative humidity, and 5 % CO2. The 
culture medium was replaced with fresh medium every other day for about 6 or 7 
days, until the cells reached 70-80% confluency. A passage operation was 
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performed after the cells reached 60-80% confluency. In the passage operation, 
the cells were detached from the culturing flask by trypsinization, counted and 
transferred with the desired seeding density to a new culturing flask or 
experimental wells. In these cells studies, cells with passage numbers between 
60 and 65 were used. 
 For transport studies, Caco-2 cells were grown in 6-well Transwell® plates 
(4.71 cm2/well) (Costar, Corning Incorp., Corning NY).  The culturing cell density 
was 2.35 x 105 cells/well. The cells were grown in a DMEM culture media 
containing fetal bovine serum (FBS) for 21 to 24 days until they achieved a 
constant transepithelial electrical resistance, which indicated that the tight 
junctions had formed in the monolayer [17, 18]. The medium was changed every 
other day and the electrical resistance was monitored using a voltmeter with a 
chopstick electrode (World Precision Instrument, Sarasota, FL). The 
experimental setup is shown in Figure 5.1. Each well consisted of two chambers:  
the apical (top) and the basolateral (bottom), which were separated by 
membrane with 3.0 µm pore size. The medium used for these studies was 
Hanks’ balanced salt solution, HBSS containing Ca2+.  
Confocal Microscopy Analysis of FITC-insulin Transport: Cell membranes were 
allowed to equilibrate for one hour with the experimental medium, HBSS with 
Ca2+, prior to the initiation of the experiment. HBSS containing Ca2+ was used 
since the absence of Ca2+ from the medium itself can cause opening of the tight 
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junctions. After this period, the cell monolayer achieved a constant electrical 
resistance after the change of the medium. 
The culturing medium from the wells was removed and substituted by 
HBSS-containing FITC-insulin with or without pre-swollen microspheres. The 
wells were then incubated for 120 min and Nile Red dye (Sigma, St. Louis, MO) 
was applied on the apical and the basolateral sides of each well. The final 
concentration of Nile Red dye was 5 µL/ml. The cells were incubated for 5 
minutes for labeling the membranes. The experimental medium was then 
removed and the membranes were gently rinsed with fresh media. The cells 
were fixed by incubation with 3.7% formaldehyde in Dulbecco’s modified 
Phospshate Buffer Saline, DPBS modified (VWR Scientific, West Chester, PA) 
for 10 minutes. After fixation, the formaldehyde solution was removed and cells 
were gently washed with HBSS. The membrane was removed from the plastic 
insert by cutting it with a scalpel. It was then placed on a microscope slide, 
covered with a cover slip and placed under the microscope. The equipment 
consisted of a MRC 1024 with a Nikkon Diaphot 300 (BioRAd, Hercules,CA).  
 
5. 3 Results and Discussion 
 
Confocal laser scanning microscopy experiments were performed to 
visualize the transport of FITC-insulin across Caco-2 cell monolayer in the 
presence or in the absence of P(MAA-g-EG) microparticles. Nile Red dye was 
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used to label the membrane in order to clearly distinguish between paracellular 
and transcellular insulin in the images.  
Figures 5.2 to 5.3 illustrate the results obtained from confocal laser 
scanning microscope.  Each figure is presents two X-Y images, the first one 
showing FITC-insulin (green) and Nile Red dye (red) and the second one 
showing the transmission image. Figure 5.2 shows a control Caco-2 cell 
monolayer (not incubated with FITC-insulin) labeled with the Nile Red dye. The 
dye successfully labeled the cell membranes, although some dye diffused inside 
the cells. The images are not very clear, primarily because high concentration of 
the labeling solution was used and the washing process after the labeling was 
not efficient in removing the excess dye. Based on this observation, lower 
concentration of the labeling solution was used to label the cells in the 
subsequent experiments. This experiment established the ability of Nile Red dye 
to stain the cell membrane of Caco-2 cells in a confluent monolayer.  
Figure 5.3 shows confocal laser scanning microscope images of FITC-
insulin placed on the basolateral side of cell membrane without any 
microparticles. Some important conclusions can be drawn from these images. 
The examination of images indicated that FITC-insulin present in the inter-cellular 
spaces can itself be used to visualize the cell membranes. Hence, the need for a 
lipophilic dye such as the Nile Dye in order to distinguish between the 
paracellular and transcellular insulin was eliminated. The images also revealed 
that some FITC-insulin was present inside the cells.  
  84
This insulin can be seen in the form of green dots localized in the 
intracellular spaces. Such green dots were seen predominantly in the X-Y 
sections near the apical and the basolateral sides of cell monolayer. As 
discussed in section 5.1, the insulin receptors present on the cells could be 
functional in absorbing the labeled insulin into the cells. However, no insulin was 
seen in the transcellular spaces in the optical sections near the basolateral 
membrane. This indicates that the insulin that entered the cells via the 
paracellular route was not able to reach the basolateral side. This could be either 
because of the degradation of protein in the endosomal vesicles or due to the 
degradation by the insulin degrading enzyme. Hence the transcellular component 
of the insulin transport is either extremely low or entirely absent.  
Figure 5.4 shows images of FITC-insulin placed on the basolateral side of 
the cell membrane with microparticles. The FITC-insulin was again located in the 
paracellular spaces. The intensity of fluorescence was only slightly higher as 
compared to the membrane incubated with FITC-insulin without any 
microparticles. Probable cause of this increase in the intensity is enhancement in 
the paracellular transport of insulin because of the presence of the 
microparticles. Interestingly, the green dots indicating transcellular insulin were 
not so prominent in these monolayers compared to the monolayer incubated with 
FITC-insulin only. The reasons behind the absence of FITC-insulin localized in 
the transcellular were not clear. This could be because clear images were not 
obtained with microparticles for focal planes near the apical side since emission 
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due to excess concentration of Nile Dye was picked up in the channel for FITC-
insulin. This made it difficult to analyze the optical planes near the apical region 
for the signal from transcellular FITC-insulin. This excess emission, also called 
bleed over, can also be noticed in Figure 5.4  
    
5.4 Conclusions 
 
Confocal microscopy studies were performed to evaluate the transport 
mechanisms of insulin across the Caco-2 cell monolayers. It was shown that the 
paracellular pathway was the predominant route of insulin transport across the 
monolayers in the presence or absence of the microparticles. The transcellular 
component for insulin transport was almost entirely absent even though uptake of 
insulin by the cells was observed. This is an important consideration in employing 
strategies to increase the flux of insulin across the Caco-2 cell monolayers and 
across the intestinal epithelium. It is suggested that insulin-degrading enzyme 
inhibitors such as N-ethylmaleimide, 1,10-phenanthroline, and EDTA may be 
used to achieve improved insulin absorption in the intestine [13]. However, such 
inhibitors may have adverse effect on the functioning of the intestinal enzymes 
and may also cause permanent damage to the epithelium. Based on the 
observations from the confocal microscopy investigations presented here, we 
targeted transcellular pathway for improving insulin permeability. The details of 
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Figure 5.1 Experimental setup for transport studies using Caco-2 cell monolayers. 
The cells were seeded on the Transwell plates and grown for 21 days to form fully 

























Fig. 5.2 Confocal laser scanning microscopy images of cells incubated with Nile Red
dye. The combination of images (X-Y sections) illustrates (a) Nile Red dye (red) 
labeling the cells, (b) transmission image. The Nile Red dye is seen labeling the 



























Fig. 5.3 Confocal laser scanning microscopy images cell monolayers with FITC-insulin. 
The cells were incubated with FITC-insulin without microsphere suspension. The cell 
monolayer was labeled with Nile Red dye. The combination of images (X-Y sections) 
illustrates (a) Nile Red dye (red) and FITC-insulin (green) co-labeling the cells, (b) 
transmission image. The enclosed spaces indicate insulin entering the paracellular 





































Fig. 5.4 Confocal laser scanning microscopy images cell monolayers with FITC-
insulin and microparticles. The cells were incubated with FITC-insulin with 
microsphere suspension and labeled with Nile Red dye. The combination of 
images (X-Y sections) illustrates (a) Nile Red dye (red) and FITC-insulin (green) 













 One of the most important attributes of the complexation hydrogels used 
as vehicles for oral delivery is their ability to prolong the residence time of the 
drug at the site of absorption, e.g., the upper small intestine. The polymer 
particles can interact favorably with the mucosal layer lining the gut wall and 
delay direct clearance of the formulation through the GI tract. If the drug is 
protected from proteolytic digestion in the small intestine, the increase in 
residence time can significantly enhance the bioavailability of the drug. The 
objective of this work was to evaluate the mucoadhesive properties of the 
complexation hydrogels in animal model and to study the GI transit of the 
polymeric carriers.  
 Bioadhesion is an interfacial phenomenon in which two materials, at least 
one of which is biological, are held together by means of interfacial forces [1, 2].  
The term ‘mucoadhesion’ refers to the property of bioadhesion exhibited by 
certain polymers which become adhesive on hydration and hence can be used 
for targeting a drug to a particular region of the body for extended periods of time 
[1-3]. Thus, the goal of mucoadhesive drug delivery systems is to increase the 
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residence time of therapeutic molecules at the specific sites within the GI tract, 
for absorption of the drug into the circulation [4, 5].  
There is a great interest in developing artificial carriers than can enhance 
the residence time of drug molecules at particular section of the GI tract. In the 
last few years, a large number of mucoadhesive systems have been developed 
including superporous hydrogel composite-based systems [6], lipid-based  
nanocarriers [7], thiolated poly(methacrylic acid)-starch compositions [8], 
chitosan-based carriers [9-11].  
Complexation hydrogels developed in our laboratory are one of the most 
promising mucoadhesive systems for targeted oral delivery of therapeutic 
proteins [5]. It is believed that in these systems, PEG tethers attached to the 
polymer network act as adhesion promoters to enhance the mucoadhesive 
behavior of the carriers. 
 The use of adhesion promoters to achieve improved bioadhesion was first 
proposed by Peppas and co-workers [12-17]. Favorable interactions of the 
pendent PEG chains in the P(MAA-g-EG) polymer networks with the intestinal 
mucosa can increase the residence time of the carriers in the GI tract. However, 
the mucoadhesive characteristics of the hydrogels in the GI tract have not been 
studied in vivo. Understanding how the polymeric carriers travel through the GI 
tract and interact with the gastrointestinal mucosa is critical to developing 
approaches that will further increase the bioavailability of therapeutic proteins 
delivered orally by the complexation hydrogels. Hence, the objective of this study 
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was to evaluate the effect of PEG chains on the GI transit profile and retention 
properties of the complexation hydrogels. 
Primarily, two techniques are employed for studying the GI transit profiles 
of drug carriers, including gamma scintigraphy [18], and radiolabeling of the drug 
carriers [9]. In this work, we developed a fluorescence spectroscopy-based 
method for evaluating the GI transit profiles of P(MAA-g-EG) microparticles.   
 
6.2 Materials and Methods 
 
Synthesis and characterization of fluorescently labeled polymer microparticles: 
Fluorescently labeled microparticles were prepared by incorporating PolyFluor® 
407 (Polysciences, Inc. Warrington, PA), a fluorescent monomer (9-
Anthracenylmethyl methacrylate; excitation wavelength 362nm, emission 
wavelength 407nm), into the polymer network during the polymerization reaction.  
Polymer films were prepared by UV-initiated free radical solution 
polymerization of methacrylic acid (MAA) (Aldrich Chemical Company, 
Milwaukee, WI) and poly(ethylene glycol) ether monomethacrylate (PEGMA) 
(Polysciences, Inc. Warrington, PA). PEGMA was used as received whereas 
MAA was vacuum distilled at 47°C/25 mmHg to remove the inhibitor 
hydroquinone monomethyl ether.  
 The monomers were mixed in the molar ratio of 1:1 or 1:0 (MAA:EG). 
PEGMA with PEG molecular weight of 1000 was used in this synthesis.  The 
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fluorescent monomer was added in 0.1 mol% of the total monomer 
Tetra(ethylene glycol) dimethacrylate (TEGDMA) (Polysciences, Inc. Warrington, 
PA) was used as the crosslinking agent and was added in the amount of 0.75 % 
moles of the total amount of monomers. The photoinitiator, Irgacure-184 (Ciba-
Geigy Co. Hawthorne, NY) was added in the amount of 0.1wt % of the total 
amount of monomers.   
To inhibit autoacceleration in the polymerization reaction, monomer 
mixture was diluted with a mixture of 50 % v/v ethanol and deionized water (Milli-
Q Plus system, Millipore). Oxygen dissolved in the monomer mixture, which acts 
as free radical scavenger was removed by bubbling the monomer solution with 
nitrogen for 25 minutes. The mixture was then pipetted into glass plates (75 x 50 
x 1 mm) (Fisher, Pittsburgh PA) separated by Teflon spacers with a thickness of 
0.9 mm. The polymerization was carried out by exposing the glass plates 
containing the monomer mixture to a UV light (16 mW/cm2 at 365 nm) under 
nitrogen environment for 30 minutes.  After the completion of the reaction, the 
polymer films were washed in deionized water for approximately 7 days in order 
to remove unreacted monomers, crosslinking agent, initiator and sol fraction. The 
polymer films were protected from light during the washing step. After washing 
the polymer films were dried at room temperature for a day and then placed in a 
vacuum oven at 27 °C for 2 days.  The dry polymer films were then crushed by 
using a mortar and pestle and then sieved to <53 µm. All the particles were 
stored in dark in closed 5 ml glass vials inside a desiccator until further use. 
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 The labeled microparticles were compared with the control microparticles 
(no fluorescent monomer), by fluorescent microscopy. Both the control and the 
labeled microparticles were analyzed with a fluorescent microscope (Eclipse 600, 
Nikon Corporation, Tokyo, Japan) with a 5 x objective. The exposure time was 
100 msec for the labeled particles and 1000 msec for the control particles. Figure 
6.2 shows the comparison of the control and labeled particles.  
Distribution of the labeled microparticles in the GI tract: Male Wistar rats (180-
200 g) were fasted for 48 hours before the experiment with free access to water. 
During the experimental period, the rats were housed in cages and given water 
ad libitum. The rats were restrained in a supine position during administration 
without anesthesia. 50 mg of the labeled microparticles suspended in 2 mL 
phosphate-buffered saline (PBS, pH=7.4) were administered orally using a sonde 
needle. The rats were sacrificed by sodium pentobarbital overdose at 10 min, 
0.5, 1, 2, 4, and 8 h after the administration of the microparticles and the 
abdomen was cut open along the median line. The stomach, small intestine and 
colon were excised and the small intestine was further divided into five equal 
segments. Each segment was opened lengthwise and the mucus was collected. 
The collected samples were added to 0.01 wt% sodium deoxycholate solution in 
PBS to dissolve the mucus. Fluorescence associated with the samples due to the 
hydrogels was measured by a fluorescence spectrophotometer at excitation 
wavelength of 355 nm and emission wavelength of 410 nm. 
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GI Retention of the polymer microparticles: The mucoadhesion of the fluorescent 
microparticles was evaluated by in situ loop method. The mucoadhesion was 
measured in stomach and the duodenum.  Male Wistar rats (180-200 g) were 
fasted for 24 hours before the experiment. The rats were anaesthetised by 
intraperitoneal administration of 50 mg/kg sodium pentobarbital and rested in 
supine position. The particle suspension as prepared by adding the 
microparticles to PBS solution. The abdomen was opened along the median line 
and the stomach and the duodenum (10 cm intestinal segment from the pylorus), 
were ligated after insertion of tubings for administration of the particle 
suspension. After 5 min, the stomach was perfused with HCl-KCl buffer and the 
duodenum was perfused with PBS buffer at approximately 1 ml/min for 10 min. 
The buffers used for perfusion were prewarmed at 37 oC. The fluorescence in the 
perfusate was measured as described above. The percent of particles retained 
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6.3 Results and Discussion 
 
In this work, the GI retention properties of the complexation hydrogels 
were characterized. Specifically, the effect of PEG chains on the GI transit profile 
and the retention of the the polymeric carriers was studied. The property of the 
PEG containing polymer networks to adhere to the mucus has been extensively 
studied in our laboratory. De Ascentiis et al. [13] showed that the mucoadhesive 
properties of poly(2-hydroxyethyl methacrylate) (PHEMA) was significantly 
increased due to the incorporation of poly(ethylene oxide) into the network. In 
this work, the adhesion of the PHEMA microspheres to the jejunal section of 
Sprague-Dawley rats was shown to double due to the incorporation of the PEO 
chains in the microspheres. The increased adhesion was attributed to a 
significant increase of the PEO chains penetrating across the mucosal tissue.  
Huang et al. [16] compared the work of adhesion for P(MAA-g-EG) 
polymer gel containing 1:1 molar ratio of MAA:EG and gelled bovine submaxillary 
gland mucin. The work of adhesion was significantly higher at pH 7.4 compared 
to pH3.2. It was concluded that the increased adhesion of the polymer gel was 
primarily due to the interaction between the PEG chains and the mucus and not 
due to the hydrogen bonding by the carboxyl groups.  
In this work, we analyzed the GI transit profiles of PMMA microparticles 
with the P(MAA-g-EG) microparticles containing 1:1 molar ratio of MAA:EG. The 
GI retention of these formulations was also evaluated by in situ closed loop 
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method. To visualize the transit of microparticles through the GI tract in animal 
model, the particles were labeled using a fluorescent monomer (Figure 6.1). 
Figure 6.2 shows the comparison of labeled and control microparticles. As seen 
from these images, the fluorescent monomer was uniformly distributed in the 
polymer particles enabling quantitative determination of the microparticles.  
Figure 6.3 and 6.4 show GI transit profiles of the microparticles containing 
1:1 and 1:0 ratio of MAA/EG microparticles. The results are summarized in Table 
6.1. The crosslinked PMAA hydrogel microparticles (1:0 ratio of MAA:EG) 
immediately passed through the stomach and reached the distal small intestine. 
In contrast, the P(MAA-g-EG) microparticles containing (1:1 ratio of MAA:EG) 
remained in the stomach for extended period and transited slowly to the distal 
part of the small intestine. The gastric emptying rate following administration of 
P(MAA-g-EG)(1:1 MAA:EG) hydrogel microparticles was lower than that of 
PMAA microparticles. These results indicated that the molar ratio of P(MAA-g-
EG) affected the GI transit profile.  
To further understand the reasons behind the increased transit time of the 
particles containing 1:1 molar ratio of MAA:EG particles in the gastric 
environment, we evaluated the retention of the particles  by in situ closed loop 
technique. In this technique, a specific section of the GI tract is isolated and the 
experiments are performed in that segment. Labeled microparticles were directly 
administered into the isolated stomach and the duodenum segments, and after 5 
minutes the non-adherent microparticles were removed by perfusion with buffer 
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solutions. The retention of the particles, Rm, defined here as the percentage of 
the microparticles adhering to the GI segment after perfusion, was calculated for 
1:1 and 1:0 MAA:EG microparticles. These results are shown in Figure 6.5. The 
polymer microparticles containing 1:1 molar ratio of MAA:EG had higher value of 
Rm compared to the crosslinked PMMA microparticles. Interestingly this increase 
in the mucoadhesiveness due to the presence of the PEG chains was seen in 
both stomach and in the small intestine.  
The exact reasons for this enhanced retention are unclear. One of the 
reasons could be that in these studies, the microparticles were administered as a 
suspension in a 2 ml PBS buffer. Although the time between addition of the 
microparticles to the buffer and the administration of the suspension was minimal 
(2-5 min), some of the particles in the suspension may have been pre-swollen. 
The PEG chains in these pre-swollen microparticles could interact with the 
gastric mucosa, thus increasing the retention of the microparticles. This seems to 
be the most probable reason for the enhancement in mucoadhesiveness due to 
the presence of the PEG chains.  
The observed phenomenon may also be explained from the analysis of 
the complexation behavior of the 1:1 MAA:EG hydrogels under low pH 
conditions. The degree of complexation (β) in these hydrogels was defined by 
Lowman and Peppas [19] as the number repeating units of the graft chain 
participating in the complexes divided by the total number of backbone units in 
the material. The number of backbone units in the materials is the number of 
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methacrylic acid (MAA) units and the number of graft chain units is defined as the 
number of ethylene glycol (EG) repeating units. By definition the value of β can 
be between 0 and 1. For the polymer containing 1:1 molar ratio of MAA:EG, the 
maximum possible value of β (βmax) is 1. By performing small deformation test 
measurements, Lowman and Peppas [19] experimentally determined the value of 
βmax to be 0.21 at pH 3.0. This means that in even at the low pH of the stomach, 
some of the PEG chains in the network are free to interact with the mucus and 
can potentially increase the mucoadhesiveness of the formulation.  
More importantly, the PEG chains increased the mucoadhesiveness of the 
microparticles at the near neutral pH of the small intestine. This is very important 
since it implies that the polymer carriers can increase the residence time of the 
loaded protein in the upper section of the intestine, which is the targeted site for 
absorption. The problem of mucoadhesiveness of the particles in the stomach 
can be addressed by placing the protein loaded particles inside a capsule 
covered with coatings that dissolve at the pH of the small intestine [20-22]. This 
would release the protein carriers directly into the upper small intestine where the 




 In this work, we demonstrated the ability of the PEG chains in the 
complexation hydrogels to enhance the retention of the particles in the GI tract. 
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The PEG chains were shown to affect the GI transit profiles of the hydrogels by 
improving their retention capacity. This property of the carriers is highly desired in 
the oral delivery applications, since increasing the residence time of therapeutic 
protein at the targeted site of absorption can significantly improve the fraction of 
orally administered protein that reaches the blood circulation. Further, if the 
carriers are able to interact with the intestinal mucosa, and provide a burst 
release of the protein, high local concentrations of the drug may be achieved in 
the microenvironment of the brush border. This can improve the protein 
bioavailability in two ways. First, the high concentration gradient across the 
epithelium can drive the protein across the cellular barrier. Secondly, the protein 
molecules released in the microenvironment of the brush border may be 
protected from degradation due to luminal enzymes such as trypsin and 
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Figure 6.1 9-anthracenylmethyl methacrylate (PolyFluor ® 407); a fluorescent 
monomer that was used to label the P(MAA-g-EG) microparticles. The monomer 
was added to the monomer mixture at 0.1 mol% and polymerized by UV free 


































Figure 6.2 Comparison of the fluorescently labeled microparticles with the control 
particles. P(MAA-g-EG) microparticles containing 1:1 MAA:EG microparticles were 
labeled with 9-anthracenylmethyl methacrylate (PolyFluor ® 407) and sieved to 
150-212 µm. (a) Labeled P(MAA-g-EG) microparticles: 150-212 µm, 5X, exposure 
time 100 ms; (b) Unlabeled P(MAA-g-EG) microparticles: 150-212 µm, 5 X, 
exposure time 1000 ms. The fluorescent images were obtained with a fluorescent 














































Figure 6.3 GI transit profile of the P(MAA-g-EG) 1:1 MAA:EG microparticles. The z-
axis shows microparticles remaining in the segments of GI tract (x-axis) as a 
percentage of microparticles administered orally. 50 mg of the fluorescently labeled 
microparticles (<53 µm) were administered orally via a sonde needle and the 
animals were sacrificed at different time intervals (y-axis). The small intestine was 
divided into 5 segments of equal length. The mucus was removed from the 
segments of the GI tract and dissolved in 0.1 wt% sodium deoxycholate solution in 
PBS. Fluorescence associated with the samples was measured by fluorescence 
spectrophotometer at excitation wavelength of 355 nm and emission wavelength of 
















































































































Figure 6.4 GI transit profile of the P(MAA-g-EG) 1:0 MAA:EG microparticles. The z-
axis shows microparticles remaining in the segments of GI tract (x-axis) as a 
percentage of microparticles administered orally. 50 mg of the fluorescently labeled 
microparticles (<53 µm) were administered orally via a sonde needle and the 
animals were sacrificed at different time intervals (y-axis). The mucus was removed 
from the segments of the GI tract and dissolved in 0.1 wt% sodium deoxycholate 
solution in PBS. Fluorescence associated with the samples was measured by 
fluorescence spectrophotometer at excitation wavelength of 355 nm and emission 
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Table 6.1 Gastrointestinal distribution of fluorescently labeled P(MAA-g-EG) (MAA :EG 
1:1, and 1:0) microparticles. Particles present in the stomach, small intestine and the 
colon are expressed as a percentage of total particles recovered in the GI tract. The rats 



























































Figure 6.5 Retention of the fluorescently labeled microparticles in the stomach and 
the duodenum. 50 mg of the fluorescently labeled microparticles (<53 µm) 
suspended in PBS were administered directly to the stomach or the duodenum and 
the non-adherent microparticles were washed after 5 min by perfusion HCl-KCl 
buffer or PBS buffer, respectively.  Fluorescence of the perfusate buffers was 
measured and retention of the particles was calculated (Eg 6.1). P(MAA-g-EG) 
microparticles with 1:1 MAA:EG (black) were compared with 1:0 (MAA:EG) (white) 
























One of the most desirable characteristics of the complexation hydrogels 
that make them excellent carriers for oral delivery of proteins is their ability to 
protect the protein drugs from proteolytic attack during their transit through the GI 
tract. In the absence of any mechanism to prevent protein digestion in the GI 
tract, the bioavailability of orally administered therapeutic proteins is typically low 
[1, 2]. It was the object of this study to evaluate the protection of insulin by the 
complexation hydrogels in the gastric and intestinal environment. 
The complexation hydrogels exhibit pH-dependent swelling behavior due 
to the formation/dissociation of interpolymer complexes [3-5]. The interpolymeric 
hydrogen-bonding complexes between etheric groups of the graft PEG chains 
and the acid protons of the PMAA network at low pH result in low mesh size of 
the network. The low mesh size severely limits the diffusion of drug into the 
gastric environment, and the drug is protected within the network structure. On 
exposure to the near-neutral pH environment of the intestine, the network swells 
to a high degree and results in burst release of the entrapped drug. In the neutral 
environment of the small intestine, ionized carboxylic acid groups of PMAA can 
bind free Ca2+. Therefore, the acidic groups in the polymeric network may 
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contribute to depletion of free calcium. Madsen and Peppas [6] showed that the 
complexation hydrogels can bind calcium at the pH of the small intestine and 
inhibit the activity of the calcium-dependent intestinal enzymes.  
In previous studies, the oral administration of insulin-loaded P(MAA-g-EG) 
hydrogels demonstrated significant insulin absorption and glucose reduction in 
healthy and diabetic rats [7-9]. This implies that P(MAA-g-EG) hydrogels have a 
direct mucosal absorption enhancing effect on insulin. However, the precise 
mechanisms behind the improvement in oral insulin bioavailability have not been 
fully elucidated. Therefore, the aim of this study was to evaluate the ability of 
P(MAA-g-EG) hydrogels to protect the incorporated insulin from proteolytic 
degradation in the gastric and intestinal enzyme fluids obtained from Wistar rats. 
Understanding the mechanisms by which the hydrogel carriers can prevent 
insulin from getting degraded in the GI tract can help in formulating strategies to 
improve the oral bioavailability of insulin using complexation hydrogels. Polymers 
networks with three different compositions were used in this study: polymers with 
the initial monomer feed ratio of 1:1 for MAA:EG (designated henceforth as 1:1 
MAA:EG polymer),  polymers with the initial monomer feed ratio of 4:1 for 
MAA:EG (designated henceforth as 4:1 MAA:EG polymer) and polymers with the 
initial monomer feed ratio of 1:0 for MAA:EG (designated as 1:0 MAA:EG 
polymer. This was done to understand the mechanisms by which the polymer 
networks protect insulin from gastric and intestinal degradation 
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7.2 Materials and Methods 
 
Preparation of Polymer Microparticles: P(MAA-g-EG) hydrogels prepared by free 
radical solution UV-polymerization of methacrylic acid (MAA) (Sigma, St. Louis, 
MO)and poly(ethylene glycol) ether monomethacrylate (PEGMA) with PEG 
molecular weight of 1000 (Polysciences, Warrington, PA). Tetra(ethylene glycol) 
dimethacrylate (TEGDMA) (Polysciences, Warrington, PA) was added at 1 mol% 
of the total monomer and 2 wt % of 2,2-dimethoxy-2-phenyl acetophenone 
(DMPA) was used as the initiator (Sigma-Aldrich, Chemie, Steinheim, Germany).  
 The copolymers were synthesized with the monomer feed ratio of 1:1, 4:1 
and 1:0 MAA:EG. Nitrogen was bubbled through the solution for 30 min to 
remove dissolved oxygen. The monomer mixture was pipetted between two 
glass plates separated by 0.9 mm Teflon spacers and the plates were exposed to 
UV light at 1mW/cm2 for 30 minutes. After the completion of the reaction, the 
polymer film was washed in deionized water for 7 days to remove unreacted 
monomer. All the copolymers were crushed and sieved to < 53 µm sizes after 
drying.    
Insulin Loading of Polymer Microparticles: Recombinant human insulin (26 IU/ 
mg) (Wako Pure Chemical, Osaka, Japan) was incorporated into the polymer 
particles by equilibrium partitioning. 140 mg of polymer microparticles (1:1, 4:1, 
and 1:0) were added to 20 ml of PBS containing specific amount of insulin. The 
mixture was stirred for 2 hours at 37 0C. The particles were then collapsed by 
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addition of 20 ml of 0.1N HCl and were allowed to equilibrate for 5 min. The 
loading mixture was then filtered through 1.0 µm pore size filter (47 mm; 
Advantec, Japan) and washed with 10 ml DI water. The particles were dried 
under vacuum and stored at 4 oC until further use. All the insulin loaded 
microparticles (ILPs) were loaded so as to contain 60 µg insulin in 1 mg ILP. The 
loading efficiency was determined by measuring the concentration of insulin 
before and after the loading procedure by HPLC. Each sample was directly 
injected into a HPLC system composed of a pump (LC-10AS, Shimadzu Co. Ltd., 
Kyoto, Japan), a UV detector (SPD-10AV, Shimadzu), an integrator (C-R3A, 
Shimadzu) and a GL-PACK Nucleosil 100-5C18 column (150 x4.6 mm i.d.). The 
mobile phase was acetonitrile-0.1% trifluoroacetic acid in deionized water–
sodium chloride (31:69:0.58, v/v/w). The flow rate was 1.2 ml/min and the peaks 




                             …(6.1) 
Here Ci was the concentration of insulin in solution before the loading study and 
Co was the concentration of insulin in solution after the loading study.   
Preparation of the gastric and intestinal fluids: Male Wistar rats weighing 200-
300g were fasted for 24 hours and anesthetized by intraperitoneal administration 







in a supine position and midline abdominal incision was performed. The pylorus 
and the cardia were clamped. The stomach was then excised and washed with 
saline water. A sonde needle was carefully inserted into the stomach from the 
pylorus and 2.5 ml HCl-KCl buffer (pH 1.2) was injected into the stomach. The 
contents of the stomach were mixed by shaking and the gastric fluid was 
withdrawn. This procedure was repeated two times so that 5 ml of the gastric 
fluid solution was obtained. The gastric fluid solution thus obtained was 
centrifuged at 3000 r.p.m. at 4 0C for 15 minutes. The total protein concentration 
of the purified gastric fluid was determined (Protein Quantification Kit, Dojindo 
Molecular Technologies, Inc. Gaithersburg, MD USA), since the enzyme 
concentration itself cannot be easily determined.  
To remove the intestinal fluid, a sonde needle was inserted into the upper 
portion of the small intestine and the intestine was cannulated on the lower side 
to remove the intestinal fluid. 20 ml PBS buffer (pH 7.4) was slowly injected 
through the sonde needle and the intestinal fluid solution was collected from the 
cannula. The collected fluid was centrifuged at 3000 r.p.m. at 4 0C for 15 
minutes. The intestinal fluid has high lipid contents which may interfere with the 
HPLC analysis of insulin. Hence this efflux was treated with two volumes of 
methylene chloride to remove the lipids. Two volumes of methylene chloride 
were mixed with the intestinal fluid and shaken vigorously for 1 minute. Following 
this, the mixture was centrifuged at 3000 r.p.m. for 5 minutes and the intestinal 
fluid was separated. The purification step was repeated 4 times [10]. In case of 
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the gastric fluid the lipid content is very low so this step was not necessary. The 
total protein concentration of the purified intestinal fluid was determined using the 
Protein Quantification Kit. To compare the results from different sets of insulin 
degradation studies, the concentration of the gastric or intestinal enzyme fluid 
was adjusted so that 50% of the initial insulin degraded in 30 min. For protein 
binding study and calcium deprivation study, the intestinal fluid was diluted with 
PBS to yield a protein concentration of 400-500 µg/ml as determined by the 
Protein Quantification. 
 
 7.2.1 Gastric Degradation of Insulin 
Two sets of studies were performed to analyze the effect of polymer 
particles on insulin degradation by the gastric fluid. The ability of the insulin-
loaded microparticles to protect the entrapped insulin was evaluated. In the 
second set of studies, the effect of polymer composition on the protease 
inhibition activity of the polymer particles was analyzed by studying the 
degradation of insulin in the presence of the microparticles.  
Protection of entrapped insulin in gastric fluid by the complexation hydrogels: 2 
ml of the gastric enzyme solution was incubated for 15 min at 37 0C. 10 mg of 
insulin-loaded polymer particles was added to the enzyme solution and the 
mixture was incubated for 1 h. Following incubation, the solution was centrifuged 
at 3000 r.p.m. for 5 min and the supernatant was removed to separate the 
particles. 40 ml PBS (pH 7.0) was then added to the particles and the total 
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amount of insulin released from the microparticles in 3 hours was measured by 
HPLC. For the control experiments, the amount of insulin equal to the amount 
incorporated in ILPs, was exposed to 2 ml of gastric fluid at 37 0C for 1 h.  
Protease inhibition by the complexation hydrogels: 1900 µL of the gastric solution 
was incubated for 37 0C for 15 minutes. P(MAA-g-EG) microparticles (MAA:EG = 
1:1, 4:1, 1:0) were added to the enzyme solution and immediately after the 
addition of microparticles, 100µl insulin solution (4 mg/ml) was added to this 
solution. Samples of 50 µl were withdrawn at predetermined time intervals after 
addition of the insulin solution. The enzyme activity in the withdrawn samples 
was completely inhibited by addition of 50µL of ice-cold acetonitrile solution 
(acetonitrile: 0.1 % trifluoroacetic acid (TFA): urea=31:69:0.16, v/v/w). The 
samples were then analyzed by HPLC to determine the amount of insulin 
remaining in the solution at different time intervals. Insulin remaining as a 
percentage of the initial insulin present in the solution was plotted against time 
and compared with the control (no polymer). The degradation rate was 
determined from the slope of the semi log plot of percentage insulin remaining 
plotted against time.  
 
7.2.2 Intestinal Degradation of Insulin 
In this study, insulin degradation in the intestinal fluid treated with polymer 
microparticles was evaluated. The ability of the insulin-loaded microparticles to 
protect the insulin released in the intestinal fluid solution was also analyzed. 
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Insulin-loaded polymer microparticles with 1:1, 4:1 and 1:0 MAA:EG, were used 
in these experiments. Further, the calcium binding and protein binding of the 
complexation hydrogels in the intestinal fluid solution was also studied.  
Insulin degradation by polymer-treated intestinal fluid: 2 ml of the intestinal fluid 
was incubated at 37 0C for 15 min. 10 mg of P(MAA-g-EG) microparticles (1:1, 
4:1, 1:0 MAA:EG) or Carbopol 934P were added to the fluid and incubated at 37 
0C for 1 h. Following incubation, the particles were separated by centrifugation at 
3000 rpm for 5 min and supernatant was collected. The pH of the fluid was 
adjusted to 7.4, and insulin solution was added, which contained 2 mg/ml insulin. 
At predetermined time points up to 30 min, 50 µl of samples were withdrawn from 
the incubation mixture. The samples were analyzed after adding 50 µl of ice-cold 
acetonitrile solutin (acetonitrile: 0.1 % TFA=31:69, v/v) to terminate the reaction.  
Protein binding by the hydrogels in the intestinal fluid: 2 ml of the intestinal fluid 
was incubated at 37 0C for 15 min. 10 mg of P(MAA-g-EG) microparticles (1:1, 
4:1, 1:0 MAA:EG) or Carbopol 934P were added to the fluid and incubated at 37 
0C for 1 h. The concentration of protein in the fluid was then determined by the 
Protein Quantification Kit. 
Calcium binding by the hydrogels in the intestinal fluid: 2 ml of the intestinal fluid 
was incubated at 37 0C for 15 min. 10 mg of P(MAA-g-EG) microparticles (1:1, 
4:1, 1:0 MAA:EG) or Carbopol 934P were added to the intestinal fluid and 
incubated at 37 0C for 1 h. The concentration of calcium in the fluid was 
determined using Calcium test kit (Wako, Japan).  
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Degradation of insulin released from the microparticles in the intestinal fluid: 
P(MAA-g-EG) microparticles with 1:1, 4:1 and 1:0 MAA:EG typically have 
different loading efficiencies. Hence, the loading efficiencies of the microparticles 
were adjusted by changing the initial insulin concentration of the loading solution 
such that all the compositions tested released the same amount of insulin under 
the experimental conditions. This step was necessary to compare the enzyme 
inhibitory effect of the three different polymer formulations studied.   
A sample of 20 ml of the intestinal enzyme solution was incubated for 15 
minutes at 37 0C.  Insulin-loaded particles (10 mg) were added to the enzyme 
solution and 50 µL samples were withdrawn at predetermined time intervals up to 
60 min. After adding 50 µl of ice-cold acetonitrile solutin (acetonitrile: 0.1 % 
TFA=31:69, v/v) to terminate the reaction, the samples were analyzed by HPLC. 
The fractional release of insulin from ILPs, defined as the ratio of the amount 
released at any time, Mt, to the total amount of insulin released after 1 h, M∞, was 
calculated.  
Additionally, 20 ml of the intestinal fluid containing 0.01 mmol Ca2+ was 
incubated at 37 0C for 15 min. 10 mg of ILPs (MAA:EG=1:1) were added to the 
fluid and incubated at 37 0C. At predetermined time points up to 60 min, 50 µl of 
samples were withdrawn from the incubation mixture. After adding 50 µl of ice-
cold acetonitrile solution (acetonitrile: 0.1 % TFA=31:69, v/v), the samples were 
then analyzed by HPLC. 
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Statistical analysis: Each value was expressed as the mean ± S.D. For group 
comparisons, the one-way layout ANOVA with duplication was applied. 
Significant differences in the mean values were evaluated by the Student’s 
unpaired t-test. A p value of less than 0.05 was considered significant. 
 
7.3 Results and Discussion 
 
7.3.1 Insulin protection in gastric fluid by the hydrogels 
By using the gastric and intestinal fluids directly extracted from rats, we 
were able to evaluate the ability of the polymeric carrier to protect insulin under 
conditions similar to those in the GI environment. To understand the mechanisms 
of insulin protection in the gastric fluid, and further the effect of polymer 
composition on the insulin protection ability of the network, we studied (i) the 
degradation of insulin entrapped inside the polymer particles by the gastric 
enzymes, and (ii) the direct inhibition of the proteolytic activity in the gastric fluid 
by the polymer carriers. 
 
7.3.1.1 Protection of the entrapped insulin by complexation hydrogels  
In order to examine the insulin protection ability of the complexation 
hydrogels in the harsh environment of the stomach, the native insulin and ILP 
were treated with the gastric fluid. After the treatment in gastric fluid, insulin 
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remaining inside the particles was measured. The results are shown in Figure 7.1 
for hydrogels with different molar ratios of MAA and EG repeating units. 
The unprotected insulin in the control experiment was rapidly degraded in 
the gastric fluid and only 20 % of the insulin remained after 1 h. In contrast, more 
than 80 % of the insulin remained undegraded in all the three ILPs. It is evident 
that all the three hydrogel compositions were effective in protecting the 
entrapped insulin from enzymatic degradation. Morishita et al. [11] reported that 
at pH 1.2, only 6 % of the insulin was released from the P(MAA-g-EG) hydrogels 
with 1:1 molar ratio of MAA:EG repeating units as the hydrogel was in a 
collapsed state [11], suggesting that the ability of the P(MAA-g-EG) hydrogel to 
protect the entrapped insulin can be chiefly attributed to the ineffective diffusion 
of insulin out of the hydrogels at low pH. On the other hand, it has been reported 
that the P(MAA-g-EG) hydrogels containing 4:1 or 1:0 molar ratio of MAA:EG 
released almost 30-40 % of the insulin in 1 h at pH 1.2 [11]. However in the 
present studies, even the crosslinked PMMA or 4:1 MAA:EG particles hydrogels 
effectively prevented the degradation of entrapped insulin. One of the reasons for 
this observation could be that the experimental conditions, such as the release 
volume, were different from that of Morishita’s study [11], these results imply that 




7.3.1.2 Insulin protection by direct inhibition of gastric enzymes by complexation 
hydrogels  
To further characterize the protection ability of the hydrogels, we 
investigated whether P(MAA-g-EG) microparticles could directly inhibit the gastric 
enzymes, thus preventing insulin degradation. Insulin was incubated in the 
gastric fluid in the presence or absence of P(MAA-g-EG) microparticles at 37 0C. 
The results are shown in Figure 7.2(a). The degradation rate constants were 
determined from the slopes. These results are shown in Figure 7.2(b). As 
expected, insulin was rapidly degraded in the absence of microparticles. 
Interestingly, even in the presence of P(MAA-g-EG) hydrogel with 1:1 molar ratio 
of MAA:EG repeating units the degradation rate constant did not change 
significantly and less than 20 % of insulin was present at 60 min. The calculated 
degradation rate constants for insulin with or without the 1:1 hydrogels were 1.45 
± 0.05 × 10-2 min-1 and 1.42 ± 0.17 × 10-2 min-1, respectively. On the other hand, 
in the presence of P(MAA-g-EG) microparticles with 4:1 and 1:0 molar ratio of 
MAA:EG repeating units, insulin remaining at 1 h increased significantly and the 
degradation rate constants were 0.64 ± 0.03 × 10-2 min-1  and 0.32 ± 0.06 × 10-2 
min-1, respectively.  
Figure 7.3 shows the effect of increasing amounts of the 1:1 P(MAA-g-EG) 
microparticles on the insulin degradation rate in the gastric fluid. The degradation 
rate constant was almost constant even at high concentration of the particles. 
This difference in the inhibitory characteristics of the polymer containing 1:1 
  124
MAA:EG and the polymer containing 4:1 or 1:0 seemed to be due to the 
difference in the amount of free MAA units in the polymer network. At low pH, 
most of the MAA units in the polymer with 1:1 MAA:EG are expected to be 
complexed with the EG units. However, the polymers with 4:1 or 1:0 MAA:EG 
contain significant number of free MAA units. The inhibitory behavior may thus be 
linked to the presence of free MAA units in the network. This hypothesis was 
further supported by results presented in Figure 7.4. It can be seen that the 
increase in the amount of PMAA polymer (containing 1:0 MAA:EG) resulted in a 
decrease in the degradation rate constant. Thus, inhibitory effect of the polymer 
reached a saturation value, such that at higher concentrations, no further 
decrease in the degradation rate constants was observed with increasing 
concentration of PMMA in the solution.  
The precise mechanism of this inhibition remains unclear but the observed 
inhibitory effect may be due to weak hydrophobic interactions of the polymer 
backbone with the active sites on the protein. Complexation between the MAA 
units and the pendant EG units reduces this interaction thus reducing inhibition of 
the enzymes. It is worth noting that the inability of the hydrogels containing 1:1 
molar ratio of MAA:EG repeating units to inhibit the gastric enzyme is a desirable 
feature because this means that the polymer carriers can protect the entrapped 
insulin without interfering with the digestion of nutrient proteins by the gastric 
enzymes. The polymer microparticles with 1:1 MAA:EG are indeed the preferred 
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carriers for insulin delivery as they typically exhibit better release behavior  
compared to the microparticles with 4:1 or 1:0 of MAA:EG repeating units [4].  
 
7.3.2 Enzyme inhibition by complexation hydrogels in intestinal fluid 
It is well known that several luminally secreted proteases such as trypsin, 
chymotrypsin, elastase, are present in the small intestine [12]. Insulin is very 
sensitive to these proteases and is easily inactivated.  
 
7.3.2.1 Insulin degradation in enzyme solution pre-treated with polymer 
microparticles 
To investigate whether P(MAA-g-EG) hydrogels could inhibit the insulin 
degradation in the intestinal fluid, insulin degradation in the intestinal fluid was 
studied. To avoid the interaction between the P(MAA-g-EG) hydrogels and 
insulin, the intestinal fluid was preincubated in the presence or absence of 
P(MAA-g-EG) microparticles at 37 0C for 1 h. After adjusting pH of the fluid to 7.4 
to avoid the effect of changes of pH, insulin was incubated with the fluid at 37 0C. 
The results are shown in Figure 7.5(a). The degradation rate constants were 
determined from the slopes (shown in Figure 7.5(b)).  
The results indicated that in the intestinal fluid containing no hydrogels, 
insulin was rapidly degraded and less than 50 % of insulin was detected at 30 
min. The degradation rate constant was 1.12 ± 0.03 × 10-2 min-1. On the other 
hand, in the intestinal fluid treated with P(MAA-g-EG) hydrogels with 1:1, 4:1, or 
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1:0 molar ratio of MAA:EG repeating units or Carbopol 934P, insulin remaining 
as significantly higher and the degradation rate constants were 0.76 ± 0.05 × 10-2 
min-1, 0.44 ± 0.06 × 10-2 min-1, 0.36 ± 0.03 × 10-2 min-1 and 0.02 ± 0.01 × 10-2 
min-1  
It is interesting to note that the enzyme inhibitory action of these hydrogels 
in the intestinal fluid was dependent on the density of the ionized carboxylic 
groups in the hydrogel structure. Carbopol 934P was previously reported to 
strongly inhibit the protease activities [6, 13]. The enzyme inhibition activities of 
P(MAA-g-EG) hydrogels were lower compared to that of Carbopol 934P. 
 
7.3.2.2 Calcium binding and protein binding by hydrogels in intestinal fluid 
It is thought that the main reason for the observed enzyme inhibitory effect 
is the Ca2+ deprivation of the enzyme structures. For instance, trypsin is a serine 
protease in the intestinal fluid, which has a binding site for calcium [14]. Calcium 
plays an important role in maintaining the thermodynamic stability of this enzyme. 
Therefore, if the calcium is removed from the enzyme structure, the activity is 
inhibited [13]. In addition, some direct interactions between the hydrogels and 
enzymes such as the incorporation of the enzymes into hydrogels may explain 
this inhibitory effect. Therefore, in order to investigate the exact mechanism of 
this inhibitory effect, protein binding studies and Ca2+ binding studies in the 
intestinal fluid were performed. The intestinal fluid was incubated in the presence 
or absence of P(MAA-g-EG) microparticles at 37 0C for 1 h. The changes in the 
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Ca2+ levels or the protein levels were then estimated. The results are shown in 
Figure 7.6, and Figure 7.7. No changes in the intestinal protein levels were 
detected in the presence of microparticles, suggesting that the direct interaction 
between the hydrogels and enzymes was negligible.  
On the other hand, in the intestinal fluid treated with all the three hydrogels 
and Carbopol 934P, significant reduction of Ca2+ levels was observed (Figure 
7.7). Moreover, the Ca2+ binding activity of these hydrogels was dependent on 
the amount of the carboxylic groups in the hydrogel structure. Madsen and 
Peppas [6] also reported that the affinity of the polymers toward calcium was 
dependent on the density of the ionized carboxylic groups. The amount of Ca2+ 
sequestered from the solution in the present study was lower but comparable. 
The results shown in Figure 7.5, 7.6, and Figure 7.7, establish that the 
insulin degradation inhibitory effect correlates with the Ca2+ binding activity in the 
intestinal fluid. These results are summarized in Figure 7.8. A linear relationship 
(r2 = 0.9931) was observed between the degradation rate and the reduction in 
the Ca2+ levels in the solution. It is evident that the decrease in the insulin 
degradation rate correlates well with the Ca2+ reduction, suggesting that higher 
the affinity toward Ca2+, stronger is the enzyme inhibition. Thus the Ca2+ binding 





7.3.3 Insulin release from the hydrogels in the intestinal fluid 
Insulin release from the ILPs in the intestinal fluid was investigated. The 
fractional release of insulin, defined here as the ratio of the amount of insulin 
released at any time, Mt, in the experimental solution to the total amount released 
in PBS after 1 h, M∞, is shown in Figure 7.9. It was observed that in all the three 
hydrogels, the particles rapidly reached the swollen state and burst release of 
insulin occurred. The released insulin was then gradually degraded in the 
intestinal fluid. In a preliminary experiment it was determined that insulin was 
rapidly degraded in the intestinal fluid in the absence of microparticles. The 
insulin remaining at 15 min, 30 min and 60 min was 70.3 ± 1.2 %, 47.8 ± 4.3 % 
and 23.3 ± 1.3 %, respectively.  
The release profiles in the intestinal fluid were compared to the release 
profiles in PBS. The observed burst release of insulin in the intestinal fluid implies 
that in the harsh environment of the intestinal fluid, a condition of ‘high insulin 
concentration’ could be maintained for a short time due to the burst release of 
insulin. Previously, Morishita et al. [8] reported that insulin released from ILPs 
was rapidly absorbed from the ileal membrane in rats. Therefore, it is believed 
that maintaining the condition of ‘high insulin concentration’ in the small intestine 
for even a short time can increase the oral insulin bioavailability. 
As can be seen from Figure 7.9, the enzyme inhibitory action of these 
hydrogels was also significant. Nevertheless, some amount of insulin released 
from ILPs was constantly degraded. All the three types of polymers were able to 
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protect insulin from degradation due to proteolytic attack in the intestinal 
environment. It was also shown that the degradation rate for the insulin released 
from the 1:1 MAA:EG formulation into the intestinal solution containing excess 
calcium was comparable to the degradation rate for control insulin (added to the 
intestinal solution) (Figure 7.10) . This confirmed the earlier observation that the 
inhibition of the enzyme activity is mediated through calcium binding by the 




It was shown in these studies that the complexation hydrogels were highly 
effective in protecting proteolytic degradation of insulin under conditions 
mimicking the gastric and intestinal lumen. Investigation of the mechanism of 
insulin protection in the gastric fluid led to the important conclusion that the 
P(MAA-g-EG) copolymers containing 1:1 molar ratio of MAA:EG repeating units 
had no direct inhibitory effect on the gastric enzymes. The polymer microparticles 
limit the degradation of the entrapped insulin primarily by limiting the diffusion of 
protein into the gastric fluid. This is important because it implies that the 1:1 
MAA:EG polymer, which is typically observed to result in higher bioavailabilities 
compared to other compositions, will not interfere with the gastric digestion of 
nutrient proteins.  
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Calcium binding was identified as the most important factor contributing to 
the observed inhibition of the intestinal enzymes by the hydrogels. Once again, 
all the polymer formulations stabilized insulin in the intestinal solution. However, 
some of the insulin released from all the formulations was degraded. This may be 
one of the factors that limit the bioavailability of insulin administered orally in the 
form of insulin-loaded polymer particles. Thus, any strategy that enhances the 
stability of insulin against proteolytic attack in the intestinal lumen may increase 
the oral bioavailability. Further, if such a strategy could be used in combination 
with the complexation hydrogels-based delivery system, it may significantly 
enhance the insulin bioavailability. One such approach based on conjugation of 
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Fig. 7.1 Insulin remaining in the insulin loaded polymer after 1 h exposure to 
gastric fluid at 37 oC. A sample of 2 ml of the gastric enzyme solution was 
incubated for 15 min at 37 0C. 10 mg of insulin-loaded polymer particles was 
added to the enzyme solution and incubated for 1 h. Following incubation, the 
particles were separated and the insulin remaining inside the particles was 
released in PBS for 3 hours and measured by HPLC. For the control experiments, 
the amount of insulin equal to the amount incorporated in ILPs, was exposed to 2 


























































































Fig. 7.2(a) Semi-log plot of % insulin remaining in the gastric fluid vs. time. 
P(MAA-g-EG) microparticles (MAA:EG = 1:1 (■), 4:1(▲), 1:0(◊)) were added to 
1.9 ml enzyme solution with100µl insulin solution. Samples were withdrawn at 
predetermined time intervals and the samples were analyzed with HPLC after 
stopping the enzyme activity. Control (□) indicates only insulin exposed to gastric 














































































Fig. 7.2(b) Comparison of the effects of hydrogel composition on insulin degradation 
rate constants. The degradation rate constants were determined from the slope of the 
semi log plot of the percentage insulin remaining plotted against time in figure 7.2(a). 
Control indicates only insulin was exposed to gastric fluid. Each value represents 








































































P(MAA-g-EG) microparticles with 1:1 MAA:EG 
(mg/ml) 
Fig. 7.3 Effect of MAA:EG 1:1 microparticles concentration on insulin degradation 
rate constant in the gastric fluid. The microparticles were added to 1.9 ml enzyme 
solution with100µl insulin solution. Samples were withdrawn at predetermined time 
intervals and the samples were analyzed with HPLC after stopping the enzyme 




































































Fig. 7.4 Effect of MAA:EG 1:0 microparticles concentration on insulin degradation 
rate constant in the gastric fluid. The microparticles were added to 1.9 ml enzyme 
solution with100µl insulin solution. Samples were withdrawn at predetermined 
time intervals and the samples were analyzed with HPLC after stopping the 
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Fig. 7.5(a) Semi-log plot of % insulin remaining in the intestinal fluid vs. time. 2 ml 
intestinal solution was incubated with 10 mg P(MAA-g-EG) microparticles 
(MAA:EG = 1:1 (■), 4:1(▲), 1:0(●)) and Carbopol 934P (◊)for 1 hr. The polymers 
were separated and insulin solution was added to the enzyme solution. Samples 
were withdrawn at predetermined time intervals and the samples were analyzed 
with HPLC after stopping the enzyme activity. Control (○) indicates only insulin 
exposed to intestinal. Each reading is average of three values. 
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Fig. 7.5(b) Inhibition of insulin degradation by hydrogels in the intestinal fluid; 
comparison of insulin degradation rate constants. The degradation rate constants 
were determined from the slope of the semi log plot of the % insulin remaining 
plotted against time in figure 7.5(a). Control indicates only insulin exposed to 
intestinal fluid. Each value represents average of three values. Statistically 
significant difference: p<0.01, **  







































































Fig. 7.6 Effect of microparticles on the protein levels in intestinal fluid. 2 ml of the 
intestinal fluid was incubated at 37 0C for 15 min. 10 mg of P(MAA-g-EG) 
microparticles (1:1, 4:1, 1:0 MAA:EG) or Carbopol 934P were added to the fluid and 
incubated at 37 0C for 1 h. The concentration of protein in the fluid was then 
determined by the Protein Quantification Kit. Each value represents average of 
























































Fig. 7.7 The effect of hydrogels on the Ca2+ levels in intestinal fluid. 2 ml of the 
intestinal fluid was incubated at 37 0C for 15 min. 10 mg of P(MAA-g-EG) 
microparticles (1:1, 4:1, 1:0 MAA:EG) or Carbopol 934P were added to the fluid 
and incubated at 37 0C for 1 h. The Ca2+ concentration was then determined. 
Each value represents average of three values. Statistically significant difference: 


























































































Fig. 7.8 Relationship between the insulin degradation rate constants and the 
decrease in Ca2+ concentration in the intestinal environment. Each value 





































































Fig. 7.9 Insulin release profiles from ILPs in the intestinal fluid or PBS. 10 mg of 
insulin-loaded polymer particles (MAA:EG = 1:1(a), 4:1 (b), and 1:0 (c)) was 
added to the 20 ml enzyme solution (▲)or PBS (■) and samples were withdrawn 
at predetermined time intervals up to 60 min. After stopping the enzyme activity, 
the samples were analyzed by HPLC. The fractional release of insulin from ILPs, 
defined as the ratio of the amount released at any time (Mt) to the total amount of 
















































Fig. 7.10 Effect of Ca2+ addition on the inhibition of insulin degradation in the 
intestinal environment by the complexation hydrogels containing 1:1 MAA:EG. 
ILPs, or only insulin were added to intestinal fluid or intestinal fluid containing 
Ca2+. The degradation rate constants were determined from the slope of the semi 
log plot of the percentage insulin remaining plotted against time. Each value 
represents average of three values. Statistically significant difference: p<0.01, *, 












































As described in Section 2.4.2, complexation hydrogels developed in our 
laboratory have emerged as one of the most promising methods for orally 
delivering therapeutic proteins [1-3]. Both in vitro and in vivo studies with insulin 
loaded microparticles have demonstrated the efficacy of these hydrogels as 
vehicles for peroral administration of insulin [1, 4, 5]. The data presented in 
Chapter 6 and Chapter 7 also indicate that the complexation hydrogels exhibit 
highly beneficial characteristics for protein oral delivery.   
One of the other effective strategies for enhancing bioavailability of 
proteins exploits the receptor-mediated endocytotic pathway used by the cells for 
the selective and efficient uptake of specific macromolecules required for various 
cell processes. By coupling proteins and peptides to ligands that can recognize 
specific receptors on the epithelial cells, transcellular delivery of these 
macromolecular biopharmaceuticals may be achieved. Since only those 
molecules that are conjugated to the ligands are transcytosed, this process 
eliminates the potential side effects associated with the unspecific transport via 
the paracellular pathway. Transferrin is one of the most widely investigated 
proteins for enhancing the cellular uptake of therapeutic agents. It is a naturally 
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occurring protein involved in iron transport. Absorptive uptake of the iron-bound 
transferrin is often used to enhance the transcytosis of therapeutic agents and 
drug carriers across polarized cells such as the epithelial cells and the 
endothelial cells. Transferrin-receptor (TfR) mediated delivery systems have 
been widely exploited for delivery of drug carriers [6, 7] neurotoxins, and trophic 
factors across the blood-brain-barrier for treatment of tumors and 
neurodegenerative diseases [8, 9].  
TfR-mediated cellular uptake has also been exploited for targeted delivery 
of anticancer drugs, proteins, and therapeutic genes into primary proliferating 
malignant cells that over express the transferrin receptors [10]. Covalent coupling 
of transferrin with therapeutic drugs, proteins, or genetic infusion of therapeutic 
peptides into the structure of transferrin results in complexes with improved 
specificity and cytotoxicity toward malignant cells and enhanced uptake 
characteristics [11]. 
Researchers recently demonstrated improved efficacy of orally 
administered insulin by conjugating insulin with transferrin through disulfide 
linkages [12]. Transferrin receptors are present in high density in human GI 
epithelium, and transferrin can resist tryptic and chymotryptic degradation  [12-
14]. Shah and Shen [15] showed that insulin conjugated to transferrin via 
disulfide linkages can be transported across enterocytes-like the Caco-2 cells. 
The disulfide bond can be cleaved after the conjugate is absorbed into the blood 
stream, giving rise to free insulin [16]. Xia et al. [12] showed that insulin-
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transferrin conjugate exhibited a slow but prolonged hypoglycemic effect 
compared to that of the native human insulin in streptozotocin-induced diabetic 
rats.  
The object of this study was to develop a delivery system consisting of the 
complexation hydrogels acting as delivery vehicles for insulin-transferrin 
conjugates. The use of P(MAA-g-EG)-based microparticles as delivery vehicles 
for the insulin-transferrin conjugates may constitute a superior transmucosal 
delivery system for insulin. The system may improve the efficacy of oral insulin 
administration since: (i) insulin in the conjugated form may be further protected 
from enzymatic degradation due to steric hindrance created by the conjugated 
transferrin; (ii) owing to the mucoadhesive nature of the delivery system, most of 
the conjugate will be released within the localized microenvironment of the small 
intestine’s filamentous brush border creating a high local concentration of the 
conjugate;  (iii) the conjugate will have larger residence time in the small 
intestine; and (iv) the insulin-transferrin conjugate can cross the intestinal barrier 
by TfR-mediated transcellular pathway, which may further increase the efficiency 
of insulin absorption. 
This is the first of three chapters that deal with the development of a 
delivery system based on complexation hydrogels used as carriers for oral 
delivery of insulin-transferrin conjugates. This chapter focuses on the synthesis 
of insulin-transferrin conjugates, analysis of the intermediate products, and 
characterization of the final reaction products. Loading and release of the 
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conjugates from the complexation hydrogels are given in Chapter 9 and cellular 
studies are discussed in Chapter 10. 
 
8.2 Materials and Methods 
 
8.2.1 Synthesis of Insulin-Transferrin Conjugates 
The protein conjugation method described here has been developed by 
Carlsson et al. [17] and was used for preparation of insulin-transferrin conjugates 
by Shah and Shen [15]. Insulin (Ins) was conjugated to transferrin (Tf) through 
disulfide linkages using a heterobifunctional crosslinker, succinimidyl 3-(2-
pyridyldithio)propionate abbreviated as SPDP (Pierce, Rockford, IL).  The 
structure of SPDP and the reaction scheme for conjugation are given in Figure 
8.1 and Figure 8.2 respectively.  
Insulin modification by DMMA (step I): Insulin was reacted with dimethylmaleic 
anhydride (DMMA) (Sigma-Aldrich Chemie, Steinheim, Germany) to block the 
primary amine groups at the n-terminals of insulin chains which can potentially 
react with SPDP. A sample of 25 mg of bovine insulin (Sigma, St. Louis, MO) 
was added to a solution containing 1.5 ml of 1N HCl and 3 ml PBS solution (pH 
6.9). After completely dissolving insulin, the pH of the solution was adjusted to 
6.9 by addition of 1.5 ml of 1N NaOH solution. Dissolved insulin was then reacted 
with 3.5 mg of DMMA under constant stirring for 0.5 h. The pH of the solution 
was maintained at 6.8 to 6.9 by addition of 1M Na2CO3 solution. Reaction with 
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DMMA was repeated two more times so that a total of 10.5 mg of DMMA was 
added to insulin at a controlled pH of 6.8-6.9. A micro-pH meter (IQ Scientific 
Instruments, San Diego, CA) was used to monitor the pH of the solution during 
the reaction. The reaction mixture was transferred to dialysis tubing (Float-a-
lyzer, MWCO 3500; Spectrum Laboratories, Rancho Dominguez, CA) and 
dialyzed against PBS buffer (pH 6.9) for 24 hours to remove unreacted DMMA.  
Insulin modification with SPDP (step II): Following dialysis, the DMMA-modified 
insulin was reacted with SPDP to introduce disulfide bonds at primary amine 
group of lysine at the B29 position of insulin. The pH of modified insulin solution 
was raised to 9.0 by addition of 1M Na2CO3 and 6.0 mg of SPDP dissolved in 
150 µl dimethyl formamide (DMF) was added to this solution. The reaction was 
constantly stirred at 4 0C for 2 hours. The pH of the reaction was maintained at 
8.8-9.0 during the course of the reaction.  
The modified insulin was then dialyzed against a PBS buffer (pH 8.0) for 
24 hours to remove unreacted SPDP reagent. To measure the average number 
of moles of 2-pyridyl disulfide groups attached per mole of insulin (PDP: Insulin 
ratio), 700 µl of Ins-PDP solution was reduced by 25mM dithiothreitol (DTT) 
(Pierce, Rockford, IL). PDP-modified protein on reduction with DTT releases of 2-
pyridinethione chromophore which can be quantitated by measuring the 
absorbance at 343 nm (A343). A molar extinction coefficient of 8.08 x 103 M-1cm-1 
at 343 nm (ε343,2-TP) and 5.10 x 103 M-1cm-1 at 280 nm (ε280,2-TP) was used for 
calculations [17, 18]. Protein concentration was determined by measuring the 
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absorbance at 280 nm (A280). The molar extinction coefficient of 5.8 x 103 M-1cm-1 
at 280 nm was used for insulin. A sample of 40 µl DTT reduced modified insulin 
solution was diluted to 700 µl and the absorbance was measured in triplicates at 
343 nm and 280 nm with a microplate reader (Synergy HT, Bio-Tech 
Instruments, Winooski, VT). The PDP: protein ratio was determined by the 





Transferrin modification with SPDP (step III): Transferrin was dissolved in 4 ml 
phosphate buffer (pH 7.0, 30mM) at a concentration of 20 mg/ml. Four-fold molar 
excess of SPDP dissolved in 100 µl DMF and added to the transferrin solution 
under constant stirring. The reaction mixture was stirred for 2 hours at 4 oC. The 
modified transferrin was then dialyzed against phosphate buffer (pH 8.0, 30mM, 
3mM EDTA) in Float-a-lyzer dialysis tubing (MWCO 50,000, Spectrum 
Laboratories, Rancho Dominguez, CA) for 24 hours to remove unreacted SPDP 
reagent. Following dialysis, entire transferrin solution was reduced by reacting 
with 25mM DTT for 1 h to generate thiol-containing transferrin (Tf-SH). The PDP: 
Tf modification ratio was determined by using molar extinction coefficient of 93.0 
x 103 M-1cm-1 at 280 nm (ε280,Tf) as described above.  
 
                                               A343 x ε280, protein 
PDP/protein =        




Conjugation of modified proteins (step IV): The reaction solution from step III 
containing Tf-SH was immediately purified by elution on D-Salt Dextran Desalting 
Columns (MWCO 5000, 10 ml, Pierce Biotechnology, Inc., Rockford, IL). Four 
columns were connected in series to achieve the desired purification. 1 ml 
fractions were collected using a fraction collector (Spectrum Chromatography 
Inc, Houston, TX). Phosphate buffer (pH 8.0, 30 mM, 3 mM EDTA) was used to 
elute the protein from the columns. Fractions with A280 values greater than 0.2 
were collected. It was important to use EDTA-containing buffer for elution to 
prevent metal-catalyzed oxidation of free –SH groups of transferrin into disulfide 
bonds, which may lead to formation of crosslinked transferrin complexes.  
 Purified Tf-SH was then reacted with Ins-PDP obtained from the reaction 
step II in a molar ratio of 1:2 of Tf-SH: Ins-PDP. To follow the progress of the 
reaction, 40 µl of the reaction samples were withdrawn at 0, 5, 10, 30, 60, 90, 
120, 150 min and diluted to 700 µl with phosphate buffer. Reaction of each mole 
of insulin with Tf-SH is accompanied by the release of one mole of 2-
pyridinethione. Hence, A343 values of the samples were measured with a 
microplate reader in triplicates to determine the concentration of 2-pyridinethione. 
To determine the average number of moles of insulin attached to one mole 
transferrin (Ins: Tf ratio), concentration of the 2-pyridinethione was divided by 
transferrin concentration in the samples. The A343 values used were corrected for 
the baseline absorbance at 343 nm due to transferrin and insulin. When 
approximately 2 moles of 2-pyridinethione were released per mole of transferrin, 
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the reaction was stopped by addition of 4 mg of n-ethylmaleimide (NEM) (MP 
Biomedicals, Aurora, OH). NEM reacts with free thiol groups [19] and prevents 
further crosslinking of transferrin molecules via oxidation of unreacted thiols. 
Following the reaction, the conjugate was purified by dialysis (MWCO 25,000) 
against phosphate buffer (pH 8.0, 30mM, 3mM EDTA) until no free insulin was 
detected in the solution by HPLC.  Total protein concentration of the final purified 
conjugate solution was determined by Quick Start™ Bradford assay (Bio-Rad 
Laboratories, Hercules, CA) using BSA or unmodified transferrin as a reference 
standard [20]. 20 µl of the protein samples were added to 1 ml of Bradford 
reagent and the absorbance was detected with a microplate reader at 595 nm. 
After concentration measurements the conjugate solution was divided into 
aliquots and stored at -80 oC until used.  
 
8.2.2 Analysis of the Insulin Modification Reaction  
 Modifications of the primary amines of insulin due to DMMA reaction (step 
I) and SPDP modification (step II) was studied here by quantitatively measuring 
the amount of free primary amine groups of the protein using fluorescamine 
assay and by identifying the sites of insulin modification by mass spectroscopy. 
This was important since improper modifications of the protein may lead to 
decrease n its bioactivity [21].  
Fluorescamine assay for measurement of free amine groups of insulin: A primary 
amine assay utilizing 4-phenylspiro[furan-2(3H),1'-phthalan]-3,3'-dione 
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(fluorescamine) (Sigma, St. Louis, MO) was performed to estimate insulin 
primary amine modification by DMMA and by SPDP. 1.08 mM fluorescamine 
stock solution was prepared by dissolving 0.9 mg fluorescamine in 3 ml acetone. 
Insulin standard solutions were prepared containing 0.05, 0.1, 0.25, 0.5, 1, and 2 
mg/ml native, unmodified insulin in PBS buffer. 50 µl of fluorescamine stock 
solution was added to 150 µl of insulin standard solutions in 96 well plates and 
the fluorescence measurements were performed a microplate reader [22]. The 
excitation wavelength for measurements was 390 nm and the emission 
wavelength was 470 nm. A standard curve of emission at 470 nm (Em470) vs. 
insulin concentration (mg/ml) was prepared (Figure 8.5).  
Samples were taken from the modification reaction before modification 
with DMMA (after step I), after purifying the DMMA-modified insulin and after 
purifying the SPDP-modified insulin intermediate (after step II). The 
concentrations of the samples were adjusted to account for the dilution caused 
by dialysis of the modified intermediate products, so that the final concentration 
in all the samples was 0.75 mg/ml. A plot of Em470 vs. concentration (mg/ml) was 
prepared for all the three samples. Concentrations of 0.75 mg/ml, 0.375 mg/ml 
and 0.1875 mg/ml were included in the plot of Em470 vs. concentration for all the 
three samples (Figure 8.5). The slopes of standard curve and plots for three 
samples were calculated and plotted against the expected number of moles of 
free amines present per mole of insulin samples (Figure 8.6).  
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Mass spectroscopy analysis of the insulin modification reaction: All chemicals 
were purchased from Sigma (St. Louis, Mo) without any further purification 
unless otherwise noted.  Sample aliquots were taken before and after the DMMA 
and SPDP modification steps.  Dialysis of each aliquot was performed by Slide-
A-Lyzer Mini Dialysis units, 3.5K MWCO (Pierce Biotchnology, Rockford, IL) 
against 0.5 L deionized H2O with Triethylamine (TEA) at pH 7.5 for 30 minutes. 
The dialysis was repeated before dilution for ESI-MS analysis.  Dialyzed SPDP 
modified insulin was digested with immobilized trypsin, TPCK (Pierce 
Biotechnology, Rockford, IL) treated in 0.1M NH4OAc buffered to pH 8.5 for 18 
hours at 37°C for identification of the SPDP modification sites.  The trypsin digest 
samples were desalted and concentrated with C18 ZipTips (Millipore, Billerica, 
MA).  ESI-MS and MSn experiments were performed on an LCQ Duo quadrupole 
ion trap mass spectrometer (ThermoFinnigan, San Jose, Ca).  All samples were 
diluted to 10uM and run at 3µl/min for ESI-MS analysis in 99/1/1 MeOH/H2O/TEA 
(negative mode) or 99/1/1 MeOH/H2O/HoAc (positive mode).   
 
8.2.3 Analysis of the Insulin-Transferrin Conjugates 
HPLC analysis: A Reversed Phase-HPLC method was established for analysis of 
the conjugates to be used in quantification of the conjugates in later studies.  The 
same method was used for measurement of insulin and transferrin 
concentrations. The HPLC system was a Waters 2695 Alliance Separation 
Module (Waters, Milford, MA) equipped with Waters 2487 Dual λ Absorbance 
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Detector (Waters, Milford, MA). All the data were collected utilizing Empower 
Applications version 5.00.00 software. A Symmetry300™ C4 column (particle 
size 5 µm, 3.9mm i.d. ×150mm length) (Milford, MA) was used for the 
separations. The solvents used for the analysis were: solvent A (water, 0.1% 
trifluoroacetic acid (TFA)) and solvent B (HPLC-grade acetonitrile, 0.08% TFA). 
The mobile phase for the analysis consisted of a linear gradient of 70% of solvent 
A to 40% of solvent A in 6 min. The gradient was controlled by the Empower 
software. The column temperature was set at 40 oC. The flow rate of the mobile 
phase was set at 0.6 ml/min and the peaks were detected at 215 nm.  
SDS-PAGE analysis: For SDS-PAGE, protein samples were diluted in NuPAGE® 
lithium dodecyl sulfate (LDS) sample buffer (Invitrogen Life Technologies, 
Carlsbad, CA). Samples were heated to 70 oC in Eppendorf Thermomixer 
(Brinkmann Instruments, Westbury, NY) for 10 min before being loaded into 
wells. Gel electrophoresis was conducted with NuPAGE® Novex 7% Tris-Acetate 
Gel (1.0 mm, 10 well; Invitrogen Life Technologies, Carlsbad, CA) in NuPAGE® 
Tris-Acetate SDS Running Buffer (Invitrogen Life Technologies, Carlsbad, CA). 
The electrophoresis was performed in a Novex X-Cell Surelock Mini-Cell 
apparatus (Invitrogen Life Technologies, Carlsbad, CA) at 150 V for 2 hours. 
Relative molecular weights were estimated by comparison with molecular weight 
standards. Following electrophoresis, the gel was rinsed three times for 5 
minutes with 100 ml deionized water (DI water) and stained with Coomassie G-
250 SimplyBlue™ SafeStain (Invitrogen Life Technologies, Carlsbad, CA) for 1 h. 
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The staining solution was then discarded and the gel was placed in DI water for 
1hr. At the end of 1 h, 20 ml of 20% NaCl (w/v) solution was added to the water 
and the gel was stored at room temperature until scanned. The gel was scanned 
using a digital scanner.  
 
8.2.4 Enzymatic Stability of Insulin-Transferrin Conjugates 
 The degradation profile of the conjugates was studied in comparison with 
insulin and transferrin in simulated intestinal fluid. The simulated intestinal fluid 
was prepared by dissolving trypsin (Sigma, St. Louis, MO) in 50 mM phosphate 
buffer solution with pH of 7.4 and ionic strength of 154 mM. Insulin and 
transferrin stock solutions were prepared in the reaction buffer. Conjugate 
solution was diluted with the reaction buffer to achieve desired concentration. All 
the solutions were pre-warmed at 37 oC for 15 minutes. The protein and the 
trypsin concentrations in the stock solutions were adjusted so that after adding 
trypsin solution to the insulin, transferrin and conjugate stock solutions, the initial 
protein concentration in the reaction mixture was 1 mg/ml and the trypsin 
concentration was 3.2 mg/ml. At time t=0, trypsin stock solution was added to 
insulin, transferrin and the conjugate solutions at 37 oC under continuous mixing. 
50 µl samples were withdrawn at 0, 5, 10, 15, 30 and 60 min and the enzyme 
activity in the samples was stopped by addition of 50 µl ice-cold acetic acid 
solution (50% (v/v) acetic acid in DI water). The samples were then analyzed by 
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HPLC as described previously. Degradation rate constants were determined from 
the slope of semi-log plot of the percentage of initial protein remaining vs. time.  
 
8.3 Results and Discussion 
 
8.3.1 Synthesis of Insulin-Transferrin Conjugates 
 Insulin was conjugated to transferrin using SPDP (Figure 8.1), a 
heterobifunctional, cleavable cross-linker that reacts with primary amines and 
sulfhydryl groups [23]. The reaction scheme for conjugation is shown in Figure 
8.2. The amine-reactive portion of SPDP reagents is the n-hydroxysuccinimide 
(NHS) ester. Upon SPDP reaction with the accessible primary amines of a 
protein, a mixed disulfide is formed which has free 2-pyridyldithio groups, that 
can react with free sulfhydryl groups from other proteins. This results in formation 
of conjugates of different proteins (heteroconjugates), without unwanted cross-
reaction products such as the homoconjugates of individual proteins. This 
crosslinker is especially applicable to this research since the disulfide linkages 
are inherently unstable in the plasma [24]. Hence disulfide linkages linking the 
two proteins may be cleaved once the conjugate reaches systemic circulation 
[16, 25, 26]. Xia et al. [12] showed that free insulin was released within 5 minutes 
of incubation of the insulin-transferrin conjugates with rat liver slices. Free insulin 
was also detected in the rat serum 4 hours after oral administration of the insulin-
transferrin conjugates.  
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 Step I of the conjugation involves modification of the n-terminal primary 
amines of insulin by reaction with DMMA. Insulin has three primary amine 
moieties: at A1-Glycine (A1Gly), B1- Phenylalanine (B1Phe) and at B29-Lysine 
(B29-Lys) (Figure 8.10). All the primary amines can potentially react with SPDP 
reagent at a pH where most of the amine groups are deprotonated so that the –
NH2 group can act as a nucleophile and react with the electron-deficient carbon 
atom of the succinimidyl group of SPDP (Figure 8.1). However, Lindsay and 
Shall [27] reported that acetylation of insulin at the A1Gly position resulted in 
decrease in the biological activity of insulin. Hence insulin modifications involving 
primary amines are usually directed at either B1Phe or B29Lys positions [28]. In 
this work SPDP modification was carrier out at the B29 lysine group of insulin. 
Hence it was necessary to block the n-terminal primary amines before reacting 
insulin with SPDP. This was done by reacting insulin with DMMA at a controlled 
pH of 6.8-6.9. The pKa of the n-terminal amine residues is around 7.5-8.0, 
whereas the pKa of the lysine group is around 10.5 [29]. Thus, at the reaction pH 
a significant number of terminal amine groups were in their deprotonated state, 
and were able to react with DMMA through nucleophilic attack (Figure 8.2, step 
I). However, since the pH was more 2 units below the pKa of the lysine residue, 
most of the lysine residues remained unreacted. The DMMA modification of 
insulin is acid-labile and the amino acid residues can be regenerated by making 
the solution slightly acidic.  
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 SPDP modification of the purified intermediate from step I was carrier out 
at the pH of 9.0 to generate the Ins-PDP intermediate. The modification was 
measured by UV spectroscopy after reducing a small aliquot of purified Ins-PDP 
by 25 mM DTT dissolved in pH 4.5 sodium-acetate buffer.  At this concentration, 
the DTT is able to selectively reduce the -S-S- bonds in the crosslinker without 
affecting the protein disulfide linkages. The modification ratio (PDP: Ins) 
calculated from equation 8.1 was (0.95 ± 0.05): 1. Modification ratio for 
transferrin (PDP: Tf) was approximately 4: 1.  
 After reducing the Tf-PDP intermediate to generate thiol containing 
transferrin (Tf-SH), the intermediate was purified by size exclusion. 2 moles of 
Ins-PDP was added per mole of Tf-SH. Figure 8.3 shows the progress of the 
reaction followed by measuring the A343 for determining 2-pyridinethio released. 
When added Ins-PDP was almost entirely reacted releasing 2 moles of 2-
pyridinethio, the reaction was stopped by addition of NEM to prevent crosslinking 
of the Ins-Tf conjugates due to oxidation of excess –SH on insulin-conjugated 
transferrin. The conjugation ratio of 2:1 Ins:Tf was chosen since excessive 
modification of transferrin by insulin attachment will result in a bulky complex 
which may adversely affect the diffusion characteristics of the conjugate in the 
polymer network reducing loading and release efficiencies of the conjugate.  
Little or no insulin was detected in the reaction mixture by HPLC at the 
end of the reaction. The conjugate was extensively dialyzed to remove unreacted 
residual insulin. The concentration of purified conjugate was determined using 
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Bradford assay [20]. In this assay, the negatively charged Coomassie blue 
reagent binds the positive charges on protein, which results in absorbance shift 
from 465 nm to 595 nm. The protein concentration can be determined by 
measuring the absorbance at 595 nm. Because many proteins have nearly 
identical response curve, the methods can be applied widely using a single set of 
standards [20]. BSA and transferrin were used as standards to calculate the 
concentration of conjugate in the purified conjugate solution. This was done to 
verify that BSA or transferrin could be used as a reference standard to measure 
concentration of the conjugate. As expected, both the proteins had approximately 
the same slopes for A595 vs. concentration plots. Figure 8.4 shows the standard 
curves of BSA and transferrin.  
 
 8.3.2 Analysis of the Insulin Modification Reaction  
 Cellular studies performed by Shah and Shen [15] showed that conjugate 
molecules containing up to 3 insulin molecules per molecule of transferrin were 
able to get transported across the Caco-2 cell monolayers by transcellular 
mechanism. This means that the modification of transferrin did not decrease its 
ability to bind the transferrin receptors on the cell surfaces and get transported 
across the cell monolayers by receptor-mediated transcytosis. Thus, SPDP 
modification of the surface exposed lysine residues of transferrin does not 
decrease its biological activity. However, improper modification of insulin by 
DMMA or SPDP may result inhibition of its physiological activity. Hence sites of 
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modification of insulin were verified here by fluorescamine assay and mass 
spectroscopy analysis of the insulin modified by step I (DMMA modification) and 
step II (SPDP modification).  
 
8.3.2.1 Fluorescamine assay for quantification of the primary amine groups 
 Fluorescamine, a non-fluorescent compound, rapidly reacts rapidly with 
primary amines in proteins, such as the terminal amino groups and the ε-amino 
groups of lysine residues, to form fluorophors which are excited at 390 nm and 
fluoresce at 475 nm [30]. The reaction is completed in 100-500 ms and excess 
reagent is quickly hydrolyzed to nonfluorescent products. The fluorescent product 
is stable for several hours.  
Figure 8.5 shows the plot of Em470 vs. concentration for insulin standards, 
unmodified insulin (before step I), DMMA-modified insulin (after step I), and 
SPDP-modified insulin (after stem II). As can be seen from the Figure, the 
calibration plots for standard curve and unmodified insulin overlap and have 
comparable slopes. The slopes of the calibration curves greatly reduced after 
DMMA modification, indicating that the number of free amino groups per mole of 
insulin has reduced. Fluorescence values for corresponding concentrations of the 
SPDP-modified insulin are even lower indicating that the SPDP-modified 
derivative of insulin has fewer amino groups that are free to react with 
fluorescamine than the DMMA-modified insulin.  
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Ideally, PDP-insulin should not react with fluorescamine since a 
successfully modified insulin molecule should not have any free amino groups. 
But in actual reaction, some unreacted amino groups are to be expected that can 
react with fluorescamine to form the fluorophors. In Figure 8.6 the slopes of the 
calibration plots from Figure 8.5 are plotted against the expected number of free 
amino groups per mole of insulin for various samples. A linear correlation (r2 = 
0.9808) was observed indicating that the fluorescence drop correlated well with 
the conversion of free amino groups into intermediates that were unreactive 
towards fluorescamine.  
 This was an important finding since it established that the primary amines 
were indeed getting converted into intermediates owing to DMMA and SPDP 
modifications. However this assay did not provide much information about the 
reaction site specificity of the modification agents. Hence, mass spectroscopy 
analysis was performed on the insulin intermediates to confirm the modifications 
and to evaluate the specificity of the reagents for reaction with the primary 
amines.  
 
8.3.2.1 Mass spectroscopy analysis of the insulin modifications 
 Figure 8.7 shows the mass spectra of unmodified bovine insulin in the 
negative mode. The mass to charge ratio (m/z) for the 4- state was 1432 
corresponding to the molecular weight of 5728 Da.  
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Mass spectra of the DMMA-modified insulin: Figure 8.8 shows the close up of  
the 4- state MS spectra for DMMA-modified insulin in 50/50/1 H2O/MeOH/TEA. 
As can be seen from the spectra, most of the insulin was in 2:1 DMMA: insulin 
form indicated by the peak at 1495.3 m/z. Importantly, no peak was identified for 
3:1 derivative of insulin indicating that the n-terminal amines were the main 
modification sites of DMMA at the pH of 6.8-6.9. Satellite peaks from the water 
loss from the original molecule can also be identified in the spectra.  
Mass spectra of the SPDP-modified insulin: Figure 8.9 shows the SPDP-modified 
insulin intermediate. The 2:1:1 DMMA: Insulin: PDP peak can be identified at 
1544.3 m/z ratio. It is interesting to note that a peak for 3:1 DMMA: insulin can be 
identified in the spectra. This could be due to the reaction of the residual DMMA 
at pH 9.0 with the lysine group. This samples analyzed by mass spectroscopy 
was not subjected to dialysis step for removal of unreacted DMMA before 
reacting the insulin with SPDP. This may explain the appearance of the 3:1 
DMMA: insulin peak in the spectra.  
Mass spectra of the trypsin digest of PDP-insulin intermediate: To further identify 
the sites of modification more accurately, mass spectra of the trypsin-digested 
modified insulin intermediate was studied. Figure 8.10 shows the sites of DMMA 
and SPDP modifications and the amide bonds digested by trypsin. As shown in 
the Figure, trypsin can digest the insulin molecule at the amide bond between 
B23Arg and B24Gly groups forming a 43 amino acid long peptide (Ins-43) 
containing the n-terminals and a smaller 8 amino acid peptide (Ins-8) containing 
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the B chain c-terminal of the original molecule. These peptide fragments were 
then individually analyzed. Figure 8.11 shows the mass spectra of the Ins-43 
peptide fragment (3- state). As expected peaks corresponding to both 1:1 and 2:1 
DMMA: Ins were identified in the spectra, but no peak was identified for PDP 
attached to Ins-43. This indicates that the PDP did not attach at the n-terminal 
primary amines.  
The mass spectra for Ins-8 is shown in Figure 8.12.  The 8 amino acid 
peptides (G-F-F-Y-T-P-K-A) were further fragmented into smaller peptides by 
collision induced dissociation. From the fragments generated, two peptide 
fragments were analyzed; Y4 (T-P-K-A) and B7 (G- F- F-Y-T-P-K), such that both 
the peptides contained the lysine residue. The table inserted in Figure 8.12 
shows the expected m/z ratio for the PDP attached states of Ins-8, (GFFYTPKA)-
PDP; Y4, (TPKA)-PDP and B7, (GFFYTPK)-PDP. As seen in the spectra, PDP 
attachment was identified to all the peptide fragments. This indicated that the 
PDP was attached to amino acid residues common to Y4 and B7 (T, P,K).  
Further analysis of a smaller peptide segment containing only the two 
terminal amino acids (Y2, K-A) indicates that the PDP was attached to the lysine 
residue of the insulin molecule (Figure 8.13). This is a very important result since 
the site of PDP modification site is verified as the B29 lysine group by isolating 
only the two terminal amine groups from the insulin macromolecular structure.  
The data from mass spectroscopy and fluorescamine assay together 
provide evidence that the SPDP modification is primarily at B29Lys and the 
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DMMA modification sites are A1Gly and B1Phe. These are very important results 
since improper modification may result in reduction or complete loss of insulin 
activity. Further evidence of the biological activity of insulin in the conjugated 
form is given in chapter 11.  
 
8.3.3 Analysis of the Insulin-Transferrin Conjugates 
 
8.3.3.1 HPLC analysis the Insulin-Transferrin Conjugates 
 It was important to develop a HPLC method for quantitative determination 
of the conjugate for subsequent studies. Figure 8.14 shows the HPLC 
chromatogram for insulin, transferrin and the purified conjugate. The insulin 
eluted from the C4 column due to the applied gradient with a retention time of 
approximately 3.4 min, where as the transferrin and the conjugates eluted at 
around 4.5 and 7.5 min respectively. More importantly, the chromatogram of the 
purified conjugate did not show any peak for transferrin or insulin, indicating that 
the conjugate was essentially pure and did not contain either of the unmodified 
proteins. Based on these results, a standard curve for conjugate was prepared.  
 
8.3.3.2 SDS-PAGE analysis of the In-Tf conjugate 
 SDS-PAGE analysis of the conjugate revealed a single band for the 
conjugate at around 90 kDa (Figure 8.15). This was close to the expected 
molecular weight of about 91.6 kDa for the conjugate which contains two 
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molecules of 5.73 kDa insulin attached to one molecule transferrin (80 kDa). No 
peak for the unmodified transferrin was observed in the lane for the conjugate.  
Bovine serum albumin (BSA) was run along with the conjugate and transferrin for 
comparison.  
 
8.3.4 Enzymatic Stability of Insulin-Transferrin Conjugates 
 Intact insulin-transferrin conjugate has been shown to reach systemic 
circulation in diabetic rats [12]. In these studies insulin and insulin transferrin 
conjugates were orally administered in diabetic rats in a 30 mg/ml NaHCO3 
solution to neutralize the gastric acidity and to protect digestion of proteins in the 
stomach. However there was no mechanism to reduce the degradation of insulin 
or the conjugate in the intestinal milieu. Even in the absence of such a 
mechanism, the conjugate was able to reach the systemic circulation without 
getting completely degraded. This provides an indirect evidence of increased 
stability of the conjugated insulin against tryptic and chymotryptic attack. 
However this improvement in the stability of the conjugate in enzymatic solution 
has not been demonstrated experimentally. Hence in this study, the degradation 
profiles of insulin, transferrin and the conjugate were evaluated in a solution 
containing trypsin. As can be seen from Figure 8.16, Most of the insulin degraded 
due to tryptic attack within 15 minutes of incubation, whereas transferrin was 
significantly more stable at the same enzyme concentrations. The conjugate 
degraded at a faster rate as compared to transferrin, but was more stable than 
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the unmodified insulin. The degradation rate constants were calculated from the 
slope of the semi-log plot of the percentage of initial protein remaining vs. time 
(Figure 8.17 and Table 8.1). The degradation rate constant calculated was 21.1 x 
10-3 min-1 for insulin and 0.73 x 10-3 min-1 and 6.17 x 10-3 min-1 for the transferrin 
and the conjugate, respectively. These data indicated that the stability of insulin 
was significantly increased due to its conjugation with transferrin. This may be 
one of the important factors contributing to the observed hypoglycemic effect of 
the orally administered conjugates. Although the reasons behind the observed 
increase in stability of the conjugate are not clearly understood, this may be due 
to the shielding effect of the transferrin which limits enzymatic degradation of 
insulin. Transferrin has been shown to be resistant to tryptic and chymotryptic 
digestion [13]. Thus the large transferrin molecule may stabilize the conjugated 
insulin against enzymes by creating a hindrance for the enzymatic attack.  
As shown in chapter 8, the complexation hydrogels are able to protect 
protein degradation in both gastric and intestinal environments. Orally 
administered conjugate in the form of conjugate-loaded polymer microparticles 
may have even higher stability from proteolytic attack, due to limited diffusion of 
the conjugate out of the microparticles into the stomach and inhibition of the 






Insulin-transferrin conjugate was synthesized by site-specific modification 
of insulin and modification of transferrin by a heterobifunctional crosslinker. 
Proper modification of the insulin molecule, which is critical to its physiological 
function, was verified through fluorescence photometry and mass spectroscopy. 
The conjugation resulted in a macromolecular heteroconjugate of controlled 
stoichiometry consisting of two insulin molecules and one transferrin molecule. A 
HPLC-based method was established to be used in quantitative determination of 
conjugate in subsequent studies. Insulin in the conjugated form also exhibited 
enhanced stability against proteolytic attack. This, combined with ability of 
complexation hydrogels to prevent protein degradation in gastric and intestinal 
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Figure 8.1 Succinimidyl 3-(2-pyridyldithio)propionate (SPDP), a 
heterobifunctional, cleavable crosslinker for protein crosslinking. 
Contains amine-reactive N-hydroxysuccinimide (NHS) ester, and 
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Figure 8.2A Conjugation reaction, step I (DMMA blocking of the n-terminal amine 
groups). DMMA reaction with insulin at pH of 6.8-6.9. Only the primary amines at n-
terminal are deprotonated and are able to react with DMMA. Primary amine at B29 

































































Figure 8.2B Conjugation reaction, step II (SPDP reaction with DMMA-modified 


































































































Figure 8.2C Conjugation reaction, step III (SPDP modification of transferrin). SPDP 
reacts with transferrin at pH 7.0 to form Tf-PDP. The modification ratio can be 
controlled by altering the amount of SPDP reacted with transferrin.  Purified Tf-PDP is 





































































Figure 8.2D Conjugation reaction, step IV (Ins-PDP reaction with Tf-SH). Purified Tf-


























Figure 8.3 Conjugation reaction progress monitored by release of 2-pyridinethio (2-TP) 
released per mole of transferrin. 40 µl samples were withdrawn at predetermined time 
intervals and diluted with 660 µl phosphate buffer. Absorbance of the samples was 
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Figure 8.4 Bradford assay standard curves for measurement of conjugate 
concentration. 20 µl of the protein samples (BSA standard ∆ or transferrin standard ■) 
were added to 1 ml of bradford reagent and the absorbance was detected with a 
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Figure 8.5 Fluorescamine assay for determination of free amine groups of insulin. 50 
µl of 1.08 mM fluorescamine in acetone was added to 150 µl protein samples (insulin 
standard, unmodified insulin, DMMA-modified insulin, or SPDP-modified insulin) in a 
microplate reader. The fluorescence associated with the samples was measured with 
a microplate reader (Excitation at 390 nm and emission at 470 nm) (Error bars smaller 
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Figure 8.6 Fluorescamine assay for determination of free amine groups of insulin. 
Slopes of the linear relationship between emission at 470 nm vs. concentration for 
various insulin samples (insulin standard, unmodified insulin, DMMA-modified insulin, 
or SPDP-modified insulin) plotted against the expected number of moles of free amine 

































Figure 8.7 Mass spectra of unmodified bovine insulin showing various charged state. 
The 4- state with a mass to charge ratio of 1432 corresponds to 5728 Da 
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Figure 8.8 Mass spectra of the DMMA-modified bovine insulin (4- state) in 50/50/1 
H2O/MeOH/TEA. Peak for the 2:1 DMMA: insulin is identified at 1495.3 m/z ratio.  
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Figure 8.9 Mass spectra of the SPDP-modified bovine insulin (4- state) in 50/50/1 
H2O/MeOH/TEA. Peak for the 2:1:1 DMMA: insulin: PDP is identified at 1544.3 m/z 
ratio. No peak for 2:1 PDP is seen in the spectra 
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Figure 8.10 Insulin primary structure showing modification sites of DMMA, SPDP and 
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Figure 8.11 Mass spectra of the trypsin digest of the larger peptide formed after trypsin 
digestion (Ins-43). The spectra was obtained in 50/50/1 H2O/MeOH/TEA and the charge state 
was 3-. No peak for PDP derivative of Ins-43 was identified in the mass spectra  
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  M.W +2 State +1 State
GFFYTPKA-
PDP 1128.7 564.38   
B7-PDP 1040.68 520.34   
Y4-PDP 614.13   614.13















Figure 8.12 Mass spectra of the trypsin digest of the smaller peptide formed after trypsin 
digestion (Ins-8). The inserted table shows the estimated molecular weights of the PDP-
attached peptide fragments in +2 or +1 states. The molecular weights are estimate based on 



































Figure 8.13 Mass spectra of the n-terminal peptide fragments of insulin obtained by collision 
induced dissociation of the trypsin digest. +1 charge states of Y2-PDP, (KA)-PDP; and Y4-
PDP, (TPKA)-PDP are identified.  
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Figure 8.14 HPLC chromatograms of insulin, transferrin and insulin-transferrin 
conjugate. The mobile phase for the analysis consisted of a linear gradient of 70% of 
solvent A to 40% of solvent A in 6 min. A Symmetry300™ C4 column (particle size 5 































































Figure 8.15 SDS-PAGE analysis of the insulin-transferrin conjugate. 5 µl of 1mg/ml 
protein solutions mixed with 10 µl sample buffer and 25 µl DI water and heated at 70 
oC for 10 minutes. 25 µl of each solution was then loaded into the wells. The gel was 
run at 150 V for 2 hours and then stained with Coomassie G-250 after washing the 



































Figure 8.16 Protein degradation profiles in the simulated intestinal fluid. Initial 
protein concentrations in the reaction was 1 mg/ml and the trypsin 
concentration was 3.2 mg/ml. The total reaction volume was 5 ml and the pH 
was 7.4. 50 µl samples were withdrawn at different time intervals and the 
trypsin activity in the samples was stopped by addition of equal volumes of 







































Figure 8.17 Log of %protein remaining vs. time (min). Initial protein concentrations 
in the reaction was 1 mg/ml and the trypsin concentration was 3.2 mg/ml. The 
total reaction volume was 5 ml and the pH was 7.4. 50 µl samples were withdrawn 
at different time intervals and the trypsin activity in the samples was stopped by 























































Protein Slope (min-1) 
Degradation rate constant (K) 
(min-1) x 103 
Insulin -0.0486 21.10 
Transferrin -0.0017 0.73 
Conjugate -0.0142 6.17 
Table 8.1 Degradation rate constants for insulin, transferrin and conjugate in the 
presence of trypsin. Rate constants were calculated from the slope of semi-log 











 The loading and release of Ins-Tf conjugate from the complexation 
hydrogels is described in this chapter. The P(MAA-g-EG) complexation hydrogels 
have been specifically designed for optimized oral delivery of small molecular 
weight drugs and therapeutic proteins. The complexation/decomplexation 
phenomenon in these polymer networks renders them pH responsive. The pH 
increase upon transit from the gastric environment into the upper small intestine 
causes the network to swell, resulting in an increase in the mesh size of the 
network. The entrapped molecules can be released from the networks at the 
increased pH.  
 Thus, optimizing the delivery systems for the specific drug molecule of 
interest is an important step in developing oral delivery formulations. The 
complexation hydrogels can be tailored for optimized delivery of both small 
molecular weight drugs and large molecular weight proteins and peptides. In our 
laboratory, polymeric carrier systems have been developed for oral delivery of 
both small molecules, such as theophylline (MW 180.17 Da) and bleomycin (MW 
1400 Da), and large molecular weight peptides and proteins such as salmon 
calcitonin (MW 3500 Da), and insulin [1-8]. The process of loading of a molecule 
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into the polymer particles and subsequent release of the loaded molecules is 
limited by the diffusion of the molecule in the polymeric microparticles. Thus, by 
controlling the mesh size of the polymer network, desired release profiles may be 
obtained for a drug molecule. The mesh size of the network is greatly influenced 
by the density and the nature of the crosslinker added to the monomer mixture 
during the synthesis step. For instance, changing the crosslinker from ethylene 
glycol dimethacrylate (EGDMA) to poly(ethylene glycol)600 dimethacrylate 
(PEG600DMA, where 600 represents the molecular weight of the PEG chain in 
the monomer), while maintaining the same crosslinking density, should increase 
the mesh size of the resulting network in the swollen state. Thus, the crosslinker 
EGDMA could be used at high crosslinking density for release of small molecular 
weight drugs, whereas PEG600DMA used at low crosslinking density will result 
in a network that is more suited for delivery of high molecular weight compounds.  
 One important problem in using the P(MAA-g-EG) microparticles 
developed in our laboratory for insulin delivery, for the present application of Ins-
Tf conjugate delivery was the size of the conjugate. The hydrodynamic radius of 
insulin is ~20 Å whereas the transferrin molecule has hydrodynamic radius of 
~40 Å. Thus the diffusion coefficient of the conjugate molecules, containing two 
molecules of insulin attached to a transferrin molecule, may be significantly lower 
compared to the native insulin. Thus, one of the objectives of this work was to 
optimize the polymeric carrier system for delivery of the conjugates.  
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9.2 Materials and Methods 
 
Synthesis of P(MAA-g-EG) microparticles: Microparticles were synthesized with 
three different crosslinkers added to the monomer mixture at the same 
crosslinking density. The crosslinkers used in this work were: Tetra(ethylene 
glycol) dimethacrylate (TEGDMA), poly(ethylene glycol)400 dimethacrylate 
(PEG400DMA) and poly(ethylene glycol)600 dimethacrylate (PEG600DMA). All 
the crosslinkers were purchased from Polysciences, Inc. (Warrington, PA). The 
monomers used in this reaction are shown in Figure 9.5. 
Polymer films were prepared by UV-initiated free radical solution 
polymerization of methacrylic acid (MAA) (Aldrich Chemical Company, 
Milwaukee, WI) and poly(ethylene glycol) ether monomethacrylate (PEGMA) 
(Polysciences, Inc. Warrington, PA). PEGMA was used as received whereas 
MAA was vacuum distilled at 47°C/25 mmHg to remove the inhibitor 
hydroquinone monomethyl ether.  
 MAA and PEGMA were mixed in the molar ratio of 1:1. PEGMA with PEG 
molecular weight of 1000 was used in this synthesis.  The crosslinkers were 
added at a concentration of 0.80 mol% of the total monomers. The photoinitiator, 
1-hydroxy-cyclohexl-phenylketone, (Irgacure-184) (Ciba-Geigy Co. Hawthorne, 
NY), was added in the amount of 0.1wt % of the total amount of monomers.  To 
inhibit auto acceleration in the polymerization reaction, monomer mixture was 
diluted with a mixture of 50 % v/v ethanol and deionized water (Milli-Q Plus 
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system, Millipore). Oxygen dissolved in the monomer mixture, which acts as free 
radical scavenger, was removed by bubbling the monomer solution with nitrogen 
for 25 minutes. The mixture was then pipetted into glass plates separated by 
Teflon spacers with a thickness of 0.9 mm. The polymerization was carried out 
by exposing the glass plates containing the monomer mixture to a UV light (16 
mW/cm2 at 365 nm) under nitrogen environment for 35 minutes.  After the 
completion of the reaction, the polymer films were washed in deionized water for 
approximately 7 days in order to remove unreacted monomers, crosslinking 
agent, initiator and sol fraction. After washing the polymer films were dried at 
room temperature for a day and then placed in a vacuum oven at 27 °C for 2 
days.  The dry polymer films were then crushed by using a mortar and pestle and 
then sieved to 150-212 µm. All the particles were stored in a desiccator until 
further use. 
Transferrin loading into the polymer microparticles: Transferrin loading and 
release studies were performed to evaluate if a large molecular weight protein 
could be loaded and release from the P(MAA-g-EG) microparticles. Transferrin 
loading into the microparticles was achieved by equilibrium partitioning from a 
concentrated protein solution.  
 Transferrin (Sigma Chemical Co., St. Louis, MO) stock solution was 
prepared by dissolving the protein in PBS buffer at pH 7.4 at a concentration of 1 
mg/ml. The loading was performed in glass beakers that were previously 
siliconized with Sigmacote (Sigma Chemical Co., St. Louis, MO) to minimize the 
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adhesion of protein to the glass surface during the experiment. Polymer 
microparticles were added to 20 ml of the transferrin stock solution at a 
concentration of 7 mg/ml and the solution was stirred overnight on a plate 
shaker. At the end of this period, the particles were collapsed by addition of 20 ml 
0.1 N HCl solution to reduce the pH. The particles were then filtered with a 0.45 
(m filter paper (Millipore, Billerica, MA) and washed with 10 ml deionized water to 
remove the surface attached protein. The loading efficiency was calculated 
based on the transferrin concentration before and after the loading. The protein 
concentrations were determined by HPLC.  
The HPLC system was a Waters 2695 Alliance Separation Module 
(Waters, Milford, MA) equipped with Waters 2487 Dual λ Absorbance Detector 
(Waters, Milford, MA). All the data were collected utilizing Empower Applications 
version 5.00.00 software. A Symmetry300™ C4 column (particle size 5 µm, 
3.9mm i.d. ×150mm length) (Milford, MA) was used for the separations. The 
solvents used for the analysis were: solvent A (water, 0.1% trifluoroacetic acid 
(TFA)) and solvent B (HPLC-grade acetonitrile, 0.08% TFA). The mobile phase 
for the analysis consisted of a linear gradient of 70% of solvent A to 40% of 
solvent A in 6 min. The gradient was controlled by the Empower software. The 
column temperature was set at 40 oC. The flow rate of the mobile phase was set 
at 0.6 ml/min and the peaks were detected at 215 nm.  
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 The microparticles were stored overnight at -4 oC and freeze dried to 
obtain dry, transferrin loaded microparticles. The microparticles were stored 
inside a desiccator at -4 oC until used.  
Transferrin release from the polymeric carriers at pH 7.4: Transferrin release 
studies were performed in a dissolution apparatus (Distek model 2100B, Distek 
Inc., North Brunswick, NJ) by using the paddle method.  10 mg of the transferrin-
loaded microparticles were placed in 50 ml dimethyl glutaric acid (DMGA) 
(Sigma, St. Louis, MO) buffer at pH 7.0. The ionic strength of the solution was 
0.1M.  200 µl samples were withdrawn at predetermined time intervals up to 2 
hours and analyzed with HPLC as described above. After each sample 200 µl 
buffer was added to maintain a constant volume. The temperature of the solution 
was maintained at 37 oC and the solutions were stirred at 100 r.p.m.  
Ins-Tf conjugate loading into the polymer microparticles: Ins-Tf conjugate was 
loaded into the microparticles similar to transferrin loading. In this experiment, 70 
mg of the polymer microparticles were added to 10 ml of 1 mg/ml solution of 
conjugate in PBS. The conjugate solution for loading (1 mg/ml conjugate in PBS) 
was prepared by the dilution of the conjugate stock solution which was stored at  
-4 oC after the synthesis of the conjugate (Chapter 8). After loading the conjugate 
for 12 hours, the pH was dropped by addition of 10 ml of 1N HCl. The particles 
were then filtered and washed with 1 ml deionized water. The particles were 
stored in a desiccator at -4 oC until used.  
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Release of the Ins-Tf conjugates from the polymeric carriers under dynamic pH 
conditions: The release of the conjugate from the microparticles was performed 
under dynamic pH conditions to mimic the transit of the polymer particles through 
the GI tract. Conjugate release studies were performed in the dissolution 
apparatus using the paddle method. 10 mg of the conjugate-loaded 
microparticles were placed in 50 ml DMGA buffer at pH 3.2. The ionic strength of 
the solution was 0.1 M.  Samples of 200 µl were withdrawn at predetermined 
time intervals up to 1 h. The pH of the solution was increased to 7.0 by addition 
of 1N NaOH to the solution. 200 µl samples were withdrawn at predetermined 
time intervals up to 3 hours and analyzed with HPLC as described above. After 
each sample 200 µl buffer of corresponding pH was added to maintain a constant 
volume. The temperature of the solution was maintained at 37 oC and the 
solutions were stirred at 100 r.p.m.  
Mesh size measurements for the polymer networks: The mesh size 
measurements for the polymers containing TEGDMA, PEG400DMA and 
PEG600DMA crosslinkers were performed according to the method described by 
Hassan et al. [14] Polymer films were prepared by the method described above. 
Immediately after the synthesis of the polymer films, 12 mm discs were cut and 
weighed in air and in n-heptane. The weight in heptane was obtained by 
weighing the discs in a stainless steel mesh basket suspended in heptane. The 
sample discs were then washed in deionized water for 5 days and transferred 
into pH 7.0 DMGA buffer used for the release studies and allowed to swell for 4 
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days. The weight measurements were performed in air and in heptane. The 
weights of the dried disks were measured after drying the polymer disks under 
vacuum for 2 days.  
 
9.3 Results and Discussion 
 
9.3.1 Transferrin Loading and Release from the Microparticles 
This study was performed to verify that a large molecular weight protein can 
be successfully loaded and release from the polymer microparticles. This was 
necessary since insulin was thus far the largest protein that we have successfully 
loaded and released from the polymer microparticles. Since the conjugate 
formed after crosslinking of insulin to transferrin was significantly bigger than the 
native, unmodified insulin, its diffusion into and out of the polymer network could 
be significantly hindered. Thus, the loading and release study using transferrin 
served as step to verify that proteins that are much larger than insulin can be 
delivered by the complexation hydrogels.  
When insulin is loaded into the polymer microparticles, loading efficiencies 
as high as 90% are achieved [9, 10]. In the present study, the loading efficiency 
for the microparticles containing TEGDMA, PEG400DMA, and PEG600DMA 
were 61.9 ±1.2 %, 52.9 ±4.3 %, and 51.9 ± 3.2 %, respectively. The 
concentration of transferrin in the loading solution decreased by approximately 
90% of its initial value for all the three polymers in the 12 hours of experiment. 
However, after HCl addition and the wash step to remove any protein attached to 
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the surface, the efficiencies reduced. This is probably because the protein that 
was either attached to the surface of the polymer or was near the surface of the 
polymer inside the microparticles was washed out during the wash step.  
The release profiles of transferrin from the three polymers tested is shown in 
Figure 9.2. In all the three polymers, most of the protein was released in the first 
hour of the experiment. The release efficiencies, defined here as the percentage 
of the loaded amount that is released into the buffer, increased with the 
increasing length of the cross linker. The microparticles containing PEG600DMA 
had the highest release efficiency of about 60%.  
This study confirmed that the microparticles could be used for releasing 
large molecular weight proteins. While successful release of transferrin in this 
study did not necessarily mean that the conjugate could be delivered using the 
complexation hydrogels, but it did imply that the polymeric carriers could be 
tailored to release proteins with much higher molecular weight than insulin. The 
loading and release studies for the conjugate are discussed below.   
 
9.3.2 Ins-Tf Conjugate Loading and Release from the Microparticles 
Figure 9.3 shows the loading efficiencies of the conjugate before and after 
the HCl wash step. In comparison with the loading efficiencies of unmodified 
transferrin (Figure 9.1), two important differences can be noted. Firstly, the 
percentage decrease in the protein concentration after 12 hours of the 
experiment was lower for the conjugate compared to the transferrin. In addition, 
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the efficiencies did not drop significantly after the addition of HCl and the wash 
step. This data indicated that the native transferrin molecule partitioned better in 
the polymer microparticles compared to the conjugate, but once the conjugate 
entered the polymer network, it could not diffuse out easily during the wash step. 
Interestingly, the overall loading efficiency was higher for the conjugate 
compared to transferrin.  
The release profiles for the conjugate are shown in Figure 9.4. It should be 
noted that the release of the conjugate was performed under dynamic pH 
conditions. The pH of the release buffer was changed from 3.2 to 7.0 after 1 h 
incubation at pH 3.2. This was done to mimic the transition of the polymer 
formulations from the gastric environment to the upper small intestine. However, 
in all the three polymers tested, no conjugate was detected by the HPLC 
measurements in the release buffer at pH 3.2. Hence, only the profile for release 
at the neutral pH is shown in Figure 9.4. This is significant since it implies that 
most of the protein will be released in the upper small intestine which is the 
targeted site for absorption. This will minimize any possible degradation of the 
conjugated insulin in the stomach.  
For the microparticles loaded with insulin, a small portion of the loaded 
insulin is typically released at low pH [10]. The mesh size of the network at the 
gastric pH is approximately 70 Å [11]. Thus, the insulin molecule with a 
hydrodynamic radius of about 20 Å, may get released at the low pH. However, in 
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case of the conjugate, the large size of the molecule may not allow any diffusion 
into the low pH environment.  
Once again, the release efficiencies of the conjugate increased with the 
increase in the length of the crosslinker from TEGDMA to PEG600DMA. The 
overall release efficiencies were significantly lower than for transferrin in the 
corresponding polymers. The maximum release efficiency was approximately 
36%. 
 
9.3.3 Mesh size measurements for the polymer networks 
Measurements of the mesh sizes in the three polymers tested at the pH of 
the release experiment were performed using the Peppas-Merrill equation [12-
14]. The polymer volume fraction in the gel immediately after preparation 
(relaxed state), v2,r and the polymer volume fraction of the swollen gels (swollen 
state), v2,s, were determined as follows: 
 
                                                   

















Vg,r  and Vg,s were the volumes of the gel in the relaxed state and the 
swollen state, respectively and Vp  was the volume of the polymer in dry state. 






where, Wa and Wh were the weights of the gel in air and in heptane, and ρh 
was the density of heptane. The number average molecular weight between 






In this equation, nM is the number average molecular weight of the linear 
polymer produced without crosslinking agent under the same conditions of 
polymerization. V1 is the molar volume of water (18.1 cm3/mol); υ  is the specific 































































Wa,r, in air before swelling and the volume, Vp. The Flory polymer-solvent 
interaction parameter, χ, was calculated as a weighted average of the values for 
PMAA (χ  = 0.5987) and PEG (χ  = 0.55) in water [14]. 
 The correlation length or the mesh size of the polymer network (ξ), was 
calculated as:  
 






2( )1 2  is the root-mean-square, unperturbed, end-to-end distance of the 
polymer chains between two neighboring crosslinks. The unperturbed end-to-end 
distance of the polymer chain between two adjacent crosslinks can be calculated 
using Equation 9.5  
 
         
   (9.5a) 
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where Cn is the Flory characteristic ratio (PMAA= 14.6 and PEG = 3.8), l is the 
length of the bond along the polymer backbone (1.54 Å) and N is the number of 
links per chain. Mr is the molecular weight of the repeating units.     
 The results of this analysis are given in Table 9.1. The polymer films 
containing TEGDMA crosslinker had and average mesh size of 209 Å where as 
the films containing PEG400DMA and PEG600DMA crosslinkers had almost the 
same mesh size (226 Å and 227  Å, respectively). Experimental errors may be 
one of the reasons why the polymers containing PEG400DMA and PEG600DMA 
crosslinkers had so similar mesh sizes. However, the difference in the mesh size 
of films containing TEGDMA and PEG600DMA was significant. Whether this 
difference in the calculated mesh sizes was the only reason behind the observed 
differences in the release profiles is not known. One other possible explanation 
for this observed difference in release efficiencies is that the hydrophilicity of the 
crosslinkers increases from TEGDMA to PEG600DMA. The PEG600DMA has 
approximately 13 ethylene glycol units where as PEG400DMA and PEG600DMA 
have ~9, and 4 ethylene glycol units, respectively. Incorporating crosslinkers with 
higher hydrophilicity may help the network swell to a greater extent in the 
aqueous medium thus releasing the more of the entrapped protein.  
 
9.4 Conclusions 
 In this study, the polymeric carriers were optimized for delivery of large 
molecular weight proteins. The insulin-transferrin conjugate was successfully 
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loaded and released from the polymer microparticles. Both loading and release 
efficiencies were lower in comparison to the typical efficiencies for insulin [10]. 
However, since the conjugate released from the microparticles in the upper small 
intestine will have better stability and permeability characteristics, as will be 
shown in the next chapter, overall efficacy of this formulation should be higher. 
Based on the analysis presented in this chapter, the polymer carriers containing 
PEG600DMA crosslinker were chosen for the cellular evaluation of the conjugate 
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Figure 9.1 The effect of crosslinker in the polymer on the loading efficiencies of transferrin. 
Transferrin was loaded into the polymer particles by equilibrium partitioning. 140mg 
microparticles were placed in 20 ml PBS solution containing 1 mg/ml transferrin. The 
particles were collapsed by addition of 1N HCl after 12 hours. The particles were filtered and 
washed with deionized water. The percentage of transferrin loaded after incubation for 12 
hours (black) and after the wash step (white) was measured. Concentrations were measured 














































Figure 9.2 Percentage of the loaded transferrin released at pH 7.4. The effect of crosslinker 
used on the release profile of the transferrin. 10 mg conjugate loaded microparticles 
containing TEGDMA (●) PEG400DMA (▲) and PEG600DMA (■) were placed in pH 7.0 
buffer and 0.2 ml samples were withdrawn at different time intervals. The protein released 
































































































Figure 9.3 The effect of crosslinker used on the loading efficiencies of the Ins-Tf conjugate. 
Conjugate was loaded into the polymer particles by equilibrium partitioning. 70 mg 
microparticles were placed in 10 ml PBS solution containing 1 mg/ml transferrin. The 
particles were collapsed by addition of 1NHCl after 12 hours. The particles were filtered and 
washed with deionized water. The percentage of conjugate loaded after incubation for 12 
hours (black) and after the wash step (white) was measured. Concentrations were measured 









































































Figure 9.4 Percentage of the loaded conjugate released at pH 7.4. The effect of crosslinker 
used on the release profile of the Ins-Tf conjugate. 10 mg conjugate loaded microparticles 
containing TEGDMA (●) PEG400DMA (▲) and PEG600DMA (■) were placed in pH 3.2 
buffer and 0.2 ml samples were withdrawn at 20, 30, 60 min. The pH of the buffer was then 
increased 7.0 buffer and 0.2 ml samples were withdrawn at different time intervals. The 







































Crosslinker in the polymer Mesh size (Å) 
TEGDMA 209.2 ± 6.3 
PEG400DMA 226.1± 2.4 
PEG600DMA 227.0 ±1.4 
Table 9.1 Mesh size of the polymer films containing TEGDMA, PEG400DMA and 
PEG600DMA crosslinkers. Polymer films were swollen in pH 7.0 for 4 days and the mesh 











































Figure 9.5 Monomers for synthesis of the complexation hydrogels. Irgacure 184 acts as an 
initiator, MAA and PEGMA are added in 1:1 molar ratio of MAA:EG units. The crosslinkers 
































Methacrylic Acid Poly(ethylene glycol) (n) monomethylether monomethacrylate (PEGMA)
1-hydroxycyclohexyl phenyl ketone 
  
           (Irgacure-184) 
n = 4; Tetraethylene glycol dimethacrylate (TEGDMA) 
n ~ 9; Poly(ethylene glycol) 400 dimethacrylate (PEG400DMA)




CELLULAR EVALUATION OF FORMULATIONS BASED ON 
COMPLEXATION HYDROGELS FOR ORAL DELIVERY OF INSULIN-






 In vitro evaluation of the cellular permeability of the insulin-transferrin 
conjugates in the presence of the complexation hydrogels was an important goal 
of this work. As described in Chapter 8, the conjugates were synthesized through 
disulfide crosslinking [1, 2]. Further, the conjugates were successfully loaded and 
released from the complexation hydrogels optimized for delivery of large 
molecular weight proteins. In this chapter the cellular studies for in vitro 
evaluation of the transport of the conjugates across cellular barrier in presence or 
in absence of the polymer microparticles is presented. Establishing the 
effectiveness of a formulation by performing in vitro permeability studies is an 
important step in the development of oral delivery formulations.  
 The in vitro model used for these studies was Caco-2 cells grown on 
permeable supports. Caco-2 cell line, which originates from a human colonic 
adenocarcinoma, is the most widely used cell culture model for in vitro 
permeability studies [3-6]. These cell lines are used as rapid screening tools for 
comparing different strategies for enhancing drug permeability [7]. By placing the 
drug formulation on the apical side of the cell monolayers and measuring the 
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cumulative fraction of the drug transported across the barrier, the permeability of 
the drug can be estimated (Fig. 10.1).  
Caco-2 cells have morphological and functional characteristics similar to 
the absorptive enterocytes of the intestinal epithelium [6]. One of the main 
disadvantages of these cells is that they lack heterogeneity of the intestinal 
epithelium. The small intestinal epithelium consists of six distinct cell types: the 
enterocytes or absorptive cells, mucin producing goblet cells, endocrine cells, 
paneth cells, M cells, tuft and cup cells [8], whereas the Caco-2 cells consist of 
the enterocytes cells. Since they lack the goblet cells, the mucus layer that 
covers the intestinal epithelial cells is absent in the monolayers of the Caco-2 
cells. This is sometimes seen as a major disadvantage of this model since the 
presence of mucus can greatly affect the diffusion of some molecules across the 
cell barrier [9, 10]. To address this issue, cocultures consisting of Caco-2 cells 
and HT29-MTX cells (mucus producing goblet cell clone consisting of large 
population of mature goblet cells), have been developed [11]. Even though this 
coculture provides an alternative to the Caco-2 cells, it has not been fully 
characterized to compare the in vitro permeability data with the in vivo 
permeability of drugs. Hence, Caco-2 cell line remains the most applicable cell 
line for permeability studies.   
 The transport of therapeutic agents or proteins across the intestinal gut 
wall may take place via various pathways (Figure 10.2) [12]. The molecules can 
cross the cellular barrier through the cell membrane of the enterocytes 
  219
(transcellular transport), or via the tight junctions between the cells (paracellular 
transport). The transcellular pathway can be further classified into carrier-
mediated transport, passive diffusion and receptor-mediated transcytosis. 
Confocal microscopy evidence presented in Chapter 5 showed that the 
predominant mechanism of transport for native insulin across the Caco-2 cell 
monolayer was the paracellular pathway. The complexation hydrogels are known 
to induce reversible increase in the permeability of the tight junctions between 
the Caco-2 cells. P(MAA-g-EG) microparticles placed with insulin on the apical 
side of the cell monolayers increased the permeability of insulin across the 
barrier approximately two-folds [13]. The insulin permeability enhancement was 
attributed to the ability of the hydrogels to reversibly increase the tight junctional 
permeability. Furthermore, as discussed in Section 2.4.4 and Chapter 8, the 
insulin-transferrin (Ins-Tf) conjugate has been shown to increase the insulin 
permeability across the epithelial barrier through the transferrin receptor (TfR)-
mediated transcellular pathway [1]. Thus, in the formulations developed in this 
work, consisting of hydrogels loaded with the Ins-Tf conjugates, the changes in 
the insulin permeability may be due to both the transcellular and the paracellular 
pathways.  
 Hence, the specific objectives of this study were to evaluate the changes 
in the permeability of insulin due to its conjugation to transferrin, and to measure 
the changes in the Ins-Tf conjugate permeability due to the presence of the 
microparticles. Upon oral administration of the conjugate-loaded microparticles, 
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the overall increase in the permeability of the conjugated insulin across the 
intestinal epithelium may be due to (i) the transcellular component of the 
transport because of the conjugated transferrin, and (ii) the paracellular 
component of transport due to the reversible increase in tight junctional 
permeability caused by the microparticles. Hence it was important to evaluate the 
improvement in insulin transport due to conjugation and due to the presence of 
the microparticles.    
 
10.2 Materials and Methods 
 
Development of the Caco-2 cell monolayers: The cells were cultured in 75 cm2 
culturing flasks (VWR Scientific, West Chester, PAs ) with 10 mL of Dulbecco’s 
Modified MEM, culture media, DMEM (Bio Fluids, Biosource International). The 
seeding density for cultivation was 2.5x105 cells/flask. The cells were maintained 
in an incubator at 37 °C temperature, 95 % relative humidity, and 5 % CO2. The 
culture medium was replaced with fresh medium every other day for about 6 or 7 
days, until the cells reached 70-80% confluency. A passage operation was 
performed after the cells reached 60-80% confluency. In the passage operation, 
the cells were detached from the culturing flask by trypsinization, counted and 
transferred at the desired seeding density to a new culturing flask or 
experimental wells. In these cells studies, cells with passage numbers between 
60 and 65 were used. 
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 For transport studies, Caco-2 cells were grown in 6-well Transwell® plates 
(4.71 cm2/well) (Costar, Corning Incorp., Corning NY).  The culturing cell density 
was 2.35 x 105 cells/well. The cells were grown in a DMEM culture medium 
containing fetal bovine serum (FBS) for 21 to 24 days until they achieved a 
constant transepithelial electrical resistance, which indicated that the tight 
junctions had formed in the monolayer [14, 15]. The medium was changed every 
other day and the electrical resistance was monitored using a voltmeter with a 
chopstick electrode (World Precision Instrument, Sarasota, FL). The 
experimental setup is shown in Figure 10.1. Each well consisted of two 
chambers:  the apical (top) and the basolateral (bottom), which were separated 
by a membrane with 3.0 µm pore size.  
On the day of the experiment, the cell membranes were allowed to 
equilibrate for one hour with the experimental medium, Hanks’ balanced salt 
solution (HBSS), with Ca2+. 2.0 ml of the HBSS was placed in the apical chamber 
and 2.5 ml was placed in the basolateral chamber. It was important to use 
medium containing Ca2+ since decrease in the extracellular Ca2+ concentrations 
can deplete the intracellular Ca2+ which can induce dilations of the tight junctions. 
After one hour of incubation, the cell monolayer achieved a constant electrical 
resistance after the change of the medium.  
Conjugate transport across the Caco-2 cell monolayer: Insulin was dissolved in 
pre-warmed HBSS solution at a concentration of 0.2 mg/ml. The conjugate stock 
solution was diluted by addition of pre-warmed HBSS to yield a final 
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concentration of 0.2 mg/ml. To establish the mechanism of conjugate transport 
across the cell barrier, a solution containing the Ins-Tf conjugate at the final 
concentration of 0.2 mg/ml and unmodified transferrin at the final concentration of 
2 mg/ml in HBSS was prepared. Since the conjugate is believed to be 
transported across the cell monolayer by TfR-mediated transcytosis, excess 
unmodified transferrin present in the apical side should compete with the 
conjugate for the receptors on the cell surface. This should reduce the 
permeability of the conjugate across the cell monolayer.  
 After equilibrating the cell monolayers with HBSS for one hour as 
described above, the HBSS from both the apical and the basolateral sides was 
removed. 2.5 ml of fresh, pre-warmed HBSS was placed in the basolateral 
chamber of each cell monolayer. 2.0 ml of solutions prepared above containing 
either insulin (control), Ins-Tf conjugate, or Ins-Tf conjugate with transferrin in 
HBSS were placed in the apical sides of monolayers. The Transwell® plates were 
then placed in the incubator at 37 oC. At 0.5, 1, 2, and 3 hours, the cells were 
removed from the incubator and 100 µl samples were withdrawn from the 
basolateral chambers. 100 µl samples were also withdrawn at 0 h and 3 hours to 
measure the changes in the apical concentrations during the course of the 
experiment. The transepithelial electrical resistance (TEER), which depends on 
the permeability of the tight junctions, was measured after each sample 
measurement. During the measurements, the plates were laced on a heating mat 
at 37 oC. This was important because changes in the temperature can induce 
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changes in the tight junctional permeability. Changes in temperature can also 
affect the energy-dependent transcellular transport of the conjugate. The 
samples were placed in vials and stored at -4 oC until analyzed. The 
concentration measurements were performed using ELISA assay. 
Protein transport across the Caco-2 cell monolayer in the presence of P(MAA-g-
EG) microparticles: Protein transport in the presence of microparticles was 
studied to evaluate the effect of microparticles on the permeability of insulin or 
the Ins-Tf conjugate. The polymer microparticles used in this study were 
prepared as described in Chapter 9 and contained PEG600DMA as the 
crosslinker. This polymer formulation was used since it was shown in Chapter 9 
to be optimal for the release of the large molecular weight conjugates.  
 For the transport studies, insulin and the conjugate solutions (0.2 mg/ml) 
in HBSS were prepared as described above. After removing the HBSS from the 
apical and the basolateral chambers, 2.0 ml of the protein solutions and 2.5 ml 
HBSS were added to the apical and the basolateral chambers, respectively. 
Immediately after addition of the protein-containing HBSS, 10 mg dry polymer 
microparticles were added to the apical side. 100 µl samples were withdrawn at 
0.5, 1, 2, and 3 h as described above and analyzed by ELISA assay as described 
below.    
Transport of the conjugate loaded in the microparticles across the cell 
monolayer: This study was performed to establish that the conjugate released 
from the microparticles into the apical HBSS medium could cross the Caco-2 cell 
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monolayer. The monolayers were incubated with HBSS for 1 h at 37 oC as 
described previously and the HBSS medium was then replaced with fresh HBSS. 
10 mg of the conjugate loaded microparticles were placed in the apical side of 
the cell monolayers. 100 µl samples were withdrawn at 0.5, 1, 2, 3, and 4 h and 
analyzed with ELISA.  
ELISA assay measurements of the transported insulin and Ins-Tf conjugate: 
Measurements of free and transferrin-bound insulin transported across the cell 
monolayers were performed using a sandwiched enzyme-linked immunosorbent 
assay (ELISA) for bovine insulin (Alpco Diagnostics, Windham, NH). This assay 
allows accurate determination of insulin concentrations in 0.25-6 ng/ml range. 
ELISA standard curves were prepared for both free insulin and the Ins-Tf 
conjugate. 
Preliminary experiments were carried out to determine the dilution factors 
required to adjust the concentrations in the ng/ml range. The samples obtained 
from the basolateral sides containing free insulin were diluted 10 times whereas 
the samples containing the transferrin-bound insulin (Ins-Tf conjugate) were used 
without any dilutions. This was done because 1.0 mg/ml concentration of the 
conjugate is equivalent to approximately 0.125 mg/ml of the bond insulin. Thus a 
1 mg/ml conjugate solution contains same free insulin as a 10 times diluted 1 
mg/ml insulin sample.  
 The ELISA assay measurements were performed according to the 
protocol provided by Alpco Diagnostics. A sample of 25 µl of standards and 
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samples was pipetted into the microplate wells coated with mouse monoclonal 
antibody for bovine insulin. A sample of 50 µl of the conjugate working solution 
containing peroxidase conjugated mouse monoclonal anti-insulin was added to 
each well. The plate was incubated at room temperature for 2 hours at under 
constant shaking. The wells were washed 6 times to remove the unreacted 
peroxidase-conjugated anti-insulin antibody by filling all the wells with wash 
solution and discarding the solution after each washing step. A sample of 200 µl 
of 3,3',5,5'-tetramethylbenzidine substrate (TMB) solution was added to each well 
and allowed to react for 15 min. 50 µl of stop solution containing sulfuric acid was 
pipetted into each well and allowed to react for 10 seconds. The optical density 
was measured at 450 nm using a microplate reader (Synergy HT; Bio-Tech 
Instruments, Winooski, VT).   
 
10.3 Results and Discussion 
 
 Evaluation of the transport characteristics of the insulin in the free and the 
transferrin-conjugated form was performed here. The efficacy of the Ins-Tf 
conjugate and polymeric microparticles to transport the bound and free insulin, 
respectively, was compared. The measurements of the apparent permeability 
(Papp) were performed according to the following standard analysis.  
 In this analysis, the cellular monolayer barrier is approximated to a 
chemically homogeneous slab. By applying Fick’s first law to the diffusion 
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process across the monolayers, following relationship between the rate of protein 
transported from the donor (apical) and receiver (basolateral) compartments and 
the concentration gradient is obtained:  
 
 (10.1) 
where, Q(t) is the cumulative amount of protein transported to the receiver 
compartment (mg); K is the distribution coefficient between the medium in the 
barrier and the aqueous donor and receiver solutions; D is the diffusion 
coefficient (cm2/s); h is the thickness of the barrier to diffusion (cm); A is the area 
of the cell monolayer (cm2); and CD and CR are the concentrations of protein in 
the apical and the basolateral compartments (mg/ml). The apparent permeability 
(Papp) was defined as:  
 
(10.2) 
 Further simplification of the equation is achieved by approximating the 
receiver compartment to a ‘perfect sink’. Ideally this would mean that the 
concentration in the basolateral compartment is always zero (which can be 
achieved by constantly removing the basolateral solution and replacing it with a 
fresh medium). However, conventionally a condition where the value of CR 
remains below 10% of the CD is acceptable. With these further simplifications, 















   
(10.3) 
 
where, CD0 is the initial concentration in the donor compartment. The term dQ/dt 
is the slope of the linear relationship between the cumulative amount of protein 
transported (mg) vs. time (s).  
 
10.3.1 Enhancement of Insulin Transport across the Cell barrier due to the 
Complexation Hydrogels 
 Previous studies performed in our lab have demonstrated that the 
complexation hydrogels placed in the apical compartment of monolayers with 
insulin caused 4-20 fold increase in the permeability of insulin [13, 16]. Foss et al. 
[13] reported 2-fold increase in permeability of insulin whereas Ichikwa and 
Peppas [16] reported about 20-fold increase in the permeability due to the 
presence of microparticles. Significant variability is typically observed in the 
results obtained from in vitro transport experiments because of differences in 
experimental conditions, passage numbers, and other factors. Hence the data 
presented here is not compared with the earlier results obtained in our 
laboratory. However, reliable comparisons can be made within the same 
experimental set while comparing different formulations.  
Figure 10.3 shows the cumulative amount of insulin transported across the 









was 1.08 ± 0.15 x 10-9 cm/s as calculated from Eq. 10.3 using the slope the plot 
in Figure 10.3. Figure 10.4 shows the cumulative amount of insulin transported 
across the cell barrier in the presence of the P(MAA-g-EG) microparticles. The 
Papp value for insulin in this case was 6.44 ± 1.3 x 10-9 cm/s. The permeability 
values of various formulations are given in Table 10.1. Thus, as expected, the 
microparticles caused increase in the permeability of insulin. Approximately 6-
fold increase in insulin Papp was observed.  
It can be observed from Figure 10.4 that there was an initial lag in the 
transport of insulin across the cellular barrier (0.5 and 1 h readings). This can be 
explained by changes in the TEER values of the cell monolayer due to the 
presence microparticles (Figure 10.5). As mentioned previously, the TEER value 
is a measure of the permeability of the tight junctions. Higher the permeability, 
lower is the TEER value of a monolayer. The reduction in TEER values has been 
shown to correlate with the increase in Papp values of insulin across the 
monolayers [13, 17, 18]. In Figure 10.5 the reduction in the TEER values is 
noticed to start after around 1 h after the start of the experiment. This correlates 
with the observed lag in insulin transport in Figure 10.4 implying that the 
permeability increase is primarily due to the opening of the tight junctions.  
10.3.2 Enhancement of Insulin Transport across the Cell barrier due to 
Conjugation with Transferrin 
 Shah and Shen [19] reported a15-fold increase insulin permeability due to 
its conjugation to transferrin. It was also shown that the primary mechanism of 
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transport of the conjugates is the TfR-mediated transcytosis of the conjugated 
insulin. Hence one of the important goals of this study was to assess the 
transport characteristics of the Tf-bound insulin. The concentration 
measurements were performed using ELISA for bovine insulin. This was possible 
because insulin in the conjugated configuration was still able to bind the 
antibodies targeted at two different antigenic determinants on the insulin 
molecule. Figure 10.6 shows the cumulative Ins-Tf conjugate transported (ng) 
across the monolayers as a function of time (h). Ins-Tf conjugation caused a 15-
fold increase in the insulin permeability. The overall permeability of the conjugate 
across the monolayer was calculated to be 16.3 ± 2 x 10-9 cm/s.  
As seen from the plot, unlike for the transport process in the presence of 
the microparticles (Figure 10.4), there is no lag time in the transport process of 
the conjugate. This was expected since the transport of the conjugate is a 
receptor-mediated process, compared to the transport process in due to the 
polymer. 
 
10.3.3 Enhancement of Insulin Transport across the Cell barrier due to 
Conjugation with Transferrin and the Complexation hydrogels 
 Figure 10.7 shows the combined effect of conjugation and the 
microparticles on the transport of insulin across the cellular barrier. The changes 
in the TEER values as a percentage of the initial TEER are plotted against time 
in Figure 10.8. The Papp value calculated from the slope of the plot in Figure 10.7 
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was 24 ± 0.05 x 10-9 cm/s. Thus the permeability of the conjugate increased due 
to the presence of the microparticles (approximately 1.5-fold increase in the 
permeability of the conjugate due to the microparticles). However, the enhancing 
effect of the hydrogels on the conjugation permeability was less pronounced than 
seen for unmodified insulin, where a 6-fold permeability enhancement was 
observed. One of the reasons for this behavior is that the paracellular pathway is 
size-dependent. Smaller molecules may diffuse easily across this pathway 
compared to large proteins such as the Ins-Tf conjugate. In the absence of any 
enhancing agents, only molecules with radius less than 11 Å are effectively 
transported via the paracellular pathway [20]. Thus the transport of the 
conjugated protein consisting insulin (~ 20 Å hydrodynamic radius) and 
transferrin (~ 40 Å hydrodynamic radius) may be limited by this route, even if the 
permeability of the tight junctions is increased due to the microparticles.  
More importantly, a 22-fold increase in the transport of insulin was 
observed due to the combined effect of conjugation and the presence of the 
microparticles (Table 10.1). This is a very important result since it demonstrates 
the effectiveness of combining the two strategies based on utilization of TfR-
mediated transcytosis and the use of complexation hydrogels for improved oral 
delivery.  
 The ability of the Ins-Tf conjugate released from P(MA-g-EG) 
microparticles to traverse the Caco-2 cell barrier was also tested in this work. 
This was done to show that the process of loading the conjugate into the 
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microparticles did not adversely affect the conjugate’s ability to get transported 
across the cellular barrier. However, permeability measurements were not 
performed for this set, since due to the experimental conditions in this study, the 
standard method for Papp measurements did not apply. For instance, the 
assumption of constant concentration in the apical side (CD(t) = CD0) was not 
valid here. This is because at initial time, when the conjugate-loaded 
microparticles were added to the donor compartment, the concentration of the 
conjugate in this compartment is zero. The conjugate is released over time and 
hence the concentration changes with time. Figure 10.9 shows the total 
conjugate released in the apical side and the conjugate transported across the 
barrier as a function of time. These results indicate that the polymer slowly 
released the protein conjugate into the apical side. This was followed by uptake 
and transport of the released conjugate across the cell monolayer. Thus, the 
process of loading the conjugate, drying the loaded microparticles and 
subsequent release of the protein did not adversely affect its ability to get 
transported across the cellular barrier.  
 
10.3.4 Competitive Transport of Ins-Tf Conjugate and Unmodified Transferrin 
across the Cell Barrier 
 To establish that the transport of the Ins-Tf conjugate molecules across 
the cells is mediated by the TfR receptors, transport of the conjugate was 
evaluated in the presence of 20-fold excess transferrin by weight in the donor 
  232
compartment. HBSS solution containing 0.2 mg/ml conjugate with 2 mg/ml Tf 
was placed on the apical side and the permeability of the conjugate was 
measured (Figure 10.10). The addition of Tf to the apical side reduced the 
permeability of the conjugate from 16.3 ± 2 x 10-9 cm/s to 0.97 ± 0.18 x 10-9 cm/s. 
The significant decrease in the conjugate permeability was attributed to the 
competitive binding of the excess Tf to its receptors thus reducing the 
permeability of the conjugate across the cells. Thus, it was established that the 
transport of the conjugate across the barrier was primarily mediated via the 
transferrin receptors.  
 
10.3.5 Indirect Evidence of Insulin Stability in the Conjugated form by ELISA 
Analysis  
 An indirect evidence of intact secondary structure of insulin in the 
transferrin-bound state was provided in this work through successful quantitative 
determination of the conjugate concentration by ELISA assay. The ELISA assay 
used here was based on the direct sandwich technique in which two monoclonal 
antibodies are directed against separate antigenic determinants (or epitopes) on 
the bovine insulin molecule. In the assay, insulin in the sample reacts with 
peroxidase-conjugated anti-insulin and the anti-insulin immobilized on the well 
surfaces. Thus for successful determination of insulin, either in free or Tf-
conjugated form would require that both the antibodies, bind to their respective 
epitopes on the insulin molecule. Further, disruption of the secondary structure of 
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the protein may adversely affect its ability to bind to the antibodies via the 
antigenic determinants. Since we were able to use the ELISA assay for 
quantitative determination of the Ins-Tf conjugate, this means that the insulin in 
the conjugated form has secondary structure similar to the native, unmodified 
insulin. Even though this can not be accepted as a conclusive evidence of the 
biological activity of insulin, it does indicate that the secondary structure of insulin 




 The in vitro evaluation of the formulation consisting of polymer 
microparticles as carriers for the Ins-Tf conjugates was performed using Caco-2 
cell model. The effect of conjugation and the presence of microparticles on 
insulin permeability were separately studied. Transferrin receptor-mediated 
transcytosis was identified as the primary mechanism of transport of the 
conjugate across the cell barrier. The microparticles increased the permeability of 
both insulin and the conjugate, most probably through enhancement in the 
paracellular transport induced by dilations of the tight junctions. The observed 
22-fold net increase in insulin permeability due to the combined effect of 
transferrin conjugation and the presence of the microparticles implies that this 
formulation can result in significant increase in the oral bioavailability of insulin. 
This permeation enhancing effect, combined with the increased stability of the 
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conjugate against proteolytic degradation, should enhance the overall efficacy of 
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Figure 10.1 Experimental setup for the permeability studies using Caco-2 cells. The 
cells were grown on Transwell® porous supports in DMEM medium for 21 days. The 
experiments were performed in HBSS. The particles and the protein solution were 
placed on the apical side and the samples were withdrawn from the basolateral side. 
The TEER values of the monolayer were measured using a chopstick electrode. The 
cell monolayers were incubated at a constant temperature of 37 oC during the 






























(1) (2a) (2b) (2c)
Epithelium
Figure 10.2 Mechanisms of transport across the intestinal epithelium. The epithelial cells 
separating the luminal side from the systemic circulation are held together by tight 
junctions. The two main mechanisms of transport are (1) paracellular transport, and (2) 
transcellular transport. The transcellular transport can be further divided into (2a) carrier-
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Figure 10.3 The cumulative amount of insulin transported across Caco-2 cell 
monolayers grown on porous Transwell® filters without microparticles (control 
experiment). A 0.2 mg/ml insulin solution in HBSS was placed in the apical chamber
and 100 µl samples were withdrawn from the basolateral chamber at different time
intervals. The samples were analyzed by bovine insulin ELISA. The cell monolayers
were incubated at a constant temperature of 37 oC during the experiment.  Each 
value is average of two cell monolayers, with a deviation that is either indicated as a
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Figure 10.4 The cumulative amount of insulin transported across Caco-2 cell 
monolayers grown on porous Transwell® filters with microparticles. A 0.2 mg/ml 
insulin solution in HBSS was placed in the apical chamber with 10 mg P(MAA-g-
EG) microparticles containing PEG600DMA crosslinker. 100 µl samples were 
withdrawn from the basolateral chamber at different time intervals. The samples 
were analyzed by bovine insulin ELISA. The cell monolayers were incubated at a 
constant temperature of 37 oC during the experiment.  Each value is average of two 
cell monolayers, with a deviation that is either indicated as a bar or is smaller than 
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Figure 10.5 Effect of polymer microparticles on the transepithelial electrical 
resistance of Caco-2 cell monolayers grown on porous Transwell®. A 0.2 mg/ml 
insulin solution in HBSS was placed in the apical chamber with (triangles) or 
without (squares) 10 mg P(MAA-g-EG) microparticles containing PEG600DMA 
crosslinker. The TEER of the cell monolayers was measured immediately after 
taking samples for permeability measurements. The cell monolayers were 
incubated at a constant temperature of 37 oC during the experiment. Each value is 
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Figure 10.6 The cumulative amount of insulin-transferrin conjugate transported 
across Caco-2 cell monolayers grown on porous Transwell® filters without the 
microparticles. A 0.2 mg/ml conjugate solution in HBSS was placed in the apical 
chamber. 100 µl samples were withdrawn from the basolateral chamber at different 
time intervals. The samples were analyzed by bovine insulin ELISA. The cell 
monolayers were incubated at a constant temperature of 37 oC during the 
experiment.  Each value is average of two cell monolayers, with a deviation that is 
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Figure 10.7 The cumulative amount of insulin-transferrin conjugate transported 
across Caco-2 cell monolayers grown on porous Transwell® filters in the presence 
of microparticles. A 0.2 mg/ml conjugate solution in HBSS was placed in the apical 
chamber with 10 mg P(MAA-g-EG) microparticles containing PEG600DMA 
crosslinker. 100 µl samples were withdrawn from the basolateral chamber at 
different time intervals. The samples were analyzed by bovine insulin ELISA. The 
cell monolayers were incubated at a constant temperature of 37 oC during the 
experiment.  Each value is average of two cell monolayers, with a deviation that is 
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Figure 10.8 Effect of polymer microparticles on the transepithelial electrical 
resistance of Caco-2 cell monolayers grown on porous Transwell®. A 0.2 mg/ml 
insulin-transferrin conjugte solution in HBSS was placed in the apical chamber with 
(triangles) or without (squares) 10 mg P(MAA-g-EG) microparticles containing 
PEG600DMA crosslinker. The TEER of the cell monolayers was measured 
immediately after taking samples for permeability measurements. The cell 
monolayers were incubated at a constant temperature of 37 oC during the 
experiment. Each value is average of two cell monolayers, with a deviation that is 
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Figure 10.9 Total amount of conjugate in the apical and basolateral chambers. 10 
mg conjugate loaded microparticles were added to the apical side and the samples 
were taken from the apical and basolateral sides at different time points and 
analyzed with ELISA. The experiment was carried out at a constant temperature of 
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Figure 10.10 The cumulative amount of insulin-transferrin conjugate transported 
across Caco-2 cell monolayers grown on porous Transwell® filters in the presence 
of excess unmodified transferrin. A 0.2 mg/ml conjugate solution in HBSS 
containing 2.0 mg/ml transferrin was placed in the apical chamber of the 
monolayers. 100 µl samples were withdrawn from the basolateral chamber at 
different time intervals. The samples were analyzed by bovine insulin ELISA. The 
cell monolayers were incubated at a constant temperature of 37 oC during the 
experiment.  Each value is average of two cell monolayers, with a deviation that is 


























































Formulation Permeability (Papp)  (cm/s) x 109 
Control (insulin) 1.08 ± 0.15 
Polymer + insulin 6.44 ± 1.3 
Ins-Tf conjugate 16.3 ± 2 
Polymer + conjugate 24 ± 0.05 
Conjugate + excess Tf 0.97 ± 0.18 
Table 10.1 Insulin permeability across Caco-2 cell monolayers grown on porous 
Transwell® filters. Insulin formulations in HBSS were placed on the apical side of the cell 
monolayers and samples were withdrawn at different time points from the basolateral sides 
at different time points. The samples were analyzed with ELISA. Apparent permeability 
was determined from the slopes of linear relationship between amount of protein 
transported and the time. The experiment was carried out at a constant temperature of 37 








 Oral delivery of proteins has been dubbed the “holy grail of drug delivery” 
[1, 2]. Oral insulin delivery systems are at the heart of research efforts in the field 
of oral protein delivery. Development of oral insulin formulations would 
significantly improve the quality of life of patients suffering from diabetes. The 
limited bioavailability of therapeutic proteins administered orally is primarily 
because of their low enzymatic stability and low permeability across the cellular 
barrier of the intestinal epithelium [3, 4]. Many different approaches, coming from 
such diverse disciplines as biomaterials, conjugation chemistry, biochemistry, 
have provided approaches to solve some of the problems associated with oral 
delivery of proteins.  
 The complexation hydrogels developed in our laboratory, are one of the 
most promising classes of materials for use in targeted oral delivery of proteins 
[4-6]. They exhibit many characteristics that make them ideal candidates for oral 
delivery applications. Hence, in vivo and in vitro understanding of the functioning 
of these hydrogels was an important goal since this understanding may lead to 
newer approaches that may provide even better bioavailability of the orally 
administered protein. One of the important goals of this work was to carry out in 
vivo and in vitro studies that could provide valuable information about oral protein 
delivery using complexation hydrogels.  
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 The two main characteristics of the hydrogels studied in this work were (i) 
the ability of the PEG chains in the network to increase the gastrointestinal 
retention of the polymeric carriers (ii) ability of the orally administered hydrogels 
to protect the degradation of insulin in the gastrointestinal tract.  
 Evaluation of effect of PEG chains in the P(MAA-g-EG) microparticles on 
the GI distribution and retention of polymer particles showed that the both the 
distribution and retention characteristics of the particles were significantly 
affected due to the presence of PEG chains. The PEG chains increased the 
retention of the microparticles in both gastric and intestinal environment. Increase 
in the intestinal retention is a desirable feature since it can potentially improve 
protein absorption by delaying the clearance of the protein from the GI tract.  
 Another important goal of this work was to analyze and understand the 
mechanism behind the ability of polymeric carriers to protect insulin degradation 
during transit in the GI tract. Our results showed that the hydrogels were very 
effective in protecting the entrapped insulin in the gastric environment and could 
also inhibit the intestinal enzymes to certain extent by binding free Ca2+ in the 
intestinal fluid solution.  
 Results from confocal microscopy analysis of insulin transport in Caco-2 
cells indicated that the primary route of transport was the paracellular pathway 
and that the transcellular component of the transport was insignificant. In 
addition, studies with sodium caprate, a model permeation enhancer, showed 
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that using a permeation enhancer with complexation hydrogels may cause 
permanent damage to the cell monolayer.  
 Hence, it was proposed that any further enhancement in the overall 
efficacy of our oral formulations would require  
(i) Improved stability of insulin against proteolytic attack in the intestinal 
environment.  This could significantly improve the bioavailability since 
the enzyme inhibition by complexation hydrogels can also protect the 
insulin 
(ii) Improvement in the permeability characteristics of insulin across the 
intestinal epithelium, preferably through the specific transcellular 
pathway 
Based on these observation, a strategy was formulated that could further 
enhance the bioavailability of insulin when administered using complexation 
hydrogels.  Insulin was conjugated to transferrin, which can get transcytosed 
across the intestinal epithelium by receptor-mediated transcytotis. Work of Shen 
and coworkers has shown that orally administered insulin-transferrin conjugate 
(Ins-Tf conjugate) was able to reach the systemic circulation in intact form [7, 8]. 
We developed a formulation consisting of the complexation hydrogels for 
delivery of Ins-Tf conjugates. The conjugates were successful synthesized and 
the polymer microparticles were optimized for the delivery of Ins-Tf conjugates.  
Finally, cellular evaluation of the formulation consisting of complexation 
hydrogels and the Ins-Tf conjugates was carried out. Overall, approximately 24 
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fold increase in the insulin permeability was demonstrated due to the combined 
effect of the conjugation and the presence of the complexation hydrogels.  
Thus in this work, we have developed a formulation that combines the 
beneficial characteristics of the Ins-Tf conjugates and the complexation 
hydrogels. The formulation was demonstrated to have characteristics that make it 
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